[{"OPOM": ["Invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01272037"], "CPOM": ["RS, as measured by Oncotype DX [\u00a0Time\u00a0Frame:\u00a0Up to 15 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 6, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01272037?rank=1&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0The time from the second registration (randomization) to death due to any cause, assessed up to 15 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">DDFS [\u00a0Time\u00a0Frame:\u00a0The time from second registration to distant recurrence, new invasive primary, or death due to any cause, assessed up to 15 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local disease-free interval [\u00a0Time\u00a0Frame:\u00a0The time from second registration to local/regional recurrence, assessed up to 15 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicities using standard National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared between the two arms using logistic regression.</div></li>\n</ul></td>"], "BT": ["Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast "], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Distant DFS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local disease-free interval [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicities using standard NCI-CTCAE version 4.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01272037"], "EPCD": ["February 2022 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast ", " With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast "], "COOM": ["Not Provided"], "SD": ["January 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01997333"], "CPOM": [], "FRD": ["November 18, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01997333?rank=7&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of Response  (DOR) [\u00a0Time\u00a0Frame:\u00a0At least 18 months following treatment initiation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0During treatment and 3 months from end of treatment through end of study or approximately up to 5 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Adverse Events (AE) [\u00a0Time\u00a0Frame:\u00a0Usually following at least 1 cycle of study treatment (1 dose of CDX-011 or capecitabine and until discontinuation of follow-up)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The percentage of patients experiencing one or more adverse events will be summarized by treatment arm, relationship to study drug, and severity.</div></li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetic (PK) [\u00a0Time\u00a0Frame:\u00a0Following 1 dose of CDX-011.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Concentration of the antibody-drug conjugate, total antibody and free MMAE will be determined.</div></li>\n</ul></td>"], "BT": ["Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast "], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01997333"], "EPCD": ["September 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast ", " (The METRIC Study)"], "COOM": ["Not Provided"], "SD": ["November 2013"]},
{"OPOM": ["CR rate in the brain at 12-weeks post-WBRT measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on MRI scan of the brain [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01622868"], "CPOM": ["CR rate in the brain measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on MRI scan of the brain [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 15, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01622868?rank=3&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">CR rate in the brain measured using revise RECIST version 1.1 based on MRI scan of the brain [\u00a0Time\u00a0Frame:\u00a04 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Response in the brain also will be measured using bidimensional measurements (WHO/modified McDonald's criteria).</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) (CR + PR) measured using RECIST version 1.1 based on MRI scan of the brain [\u00a0Time\u00a0Frame:\u00a0At 4 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">ORR (CR + PR) measured using RECIST version 1.1 based on MRI scan of the brain [\u00a0Time\u00a0Frame:\u00a0At 12 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-specific ORR (CR + PR) [\u00a0Time\u00a0Frame:\u00a0At 4 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-specific ORR (CR + PR) [\u00a0Time\u00a0Frame:\u00a0At 12 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall response (CR, PR, or stable disease [SD]) [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Treatment-related toxicity as measured by Common Terminology Criterial for Adverse Events version 4 [\u00a0Time\u00a0Frame:\u00a0Up to 12 weeks post WBRT\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">CNS PFS [\u00a0Time\u00a0Frame:\u00a0From the time of randomization to the date of first failure (CNS progression or death due to any cause), assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated by the Kaplan-Meier method. Compared between arms using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with PFS.</div></li>\n<li style=\"margin:1ex 0.5ex\">PFS [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first failure or last follow-up, assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated by the Kaplan-Meier method. Compared between arms using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with PFS.</div></li>\n<li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first failure, assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated by the Kaplan-Meier method. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with OS.</div></li>\n</ul></td>"], "BT": ["Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast "], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">CR rate in the brain at 4-weeks post WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) (CR + PR) at 4 weeks post-WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">ORR at 12 weeks post-WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-specific ORR at 4 weeks post-WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-specific ORR at 12 weeks post-WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall response (CR, PR, or stable disease [SD]), assessed up to 12 weeks post-WBRT and then every 12 weeks thereafter [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Treatment-related toxicity as measured by Common Terminology Criterial for Adverse Events (CTCAE) version 4, assessed up to 12 weeks post-WBRT and then every 12 weeks thereafter [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">CNS PFS from the time of randomization to the date of first failure (CNS progression or death due to any cause) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">OS from the date of randomization to the date of first failure [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01622868"], "EPCD": ["February 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast ", ": A Collaborative Study of RTOG and KROG"], "COOM": ["Not Provided"], "SD": ["July 2012"]},
{"OPOM": ["Progression-Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a036 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01925274"], "CPOM": ["Progression-Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a036 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 15, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01925274?rank=8&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Number of participants with Dose-limiting toxicities (DLT) [\u00a0Time\u00a0Frame:\u00a028 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Determination of unacceptable toxicity in patients enrolled at sites in Japan.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants With Objective Response [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as \u226530% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study \u22654 weeks after initial documentation of response.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (DR) [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants Using Healthcare Resources [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">FACT-C</div></li>\n<li style=\"margin:1ex 0.5ex\">Area under the Concentration-Time Curve (AUC) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.</div></li>\n<li style=\"margin:1ex 0.5ex\">Maximum Observed Plasma Concentration (Cmax) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to Reach Maximum Observed Plasma Concentration (Tmax) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Levels of signaling proteins in paired and single tumor biopsies [\u00a0Time\u00a0Frame:\u00a00, 36, 37\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Gene sequences and/or gene copy numbers in paired tumor biopsies [\u00a0Time\u00a0Frame:\u00a00, 36, 37\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal "], "OOOM": ["Not Provided"], "LUD": ["July 11, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Number of participants with Dose-limiting toxicities (DLT) [\u00a0Time\u00a0Frame:\u00a028 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants With Objective Response [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (DR) [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants Using Healthcare Resources [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the Concentration-Time Curve (AUC) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Maximum Observed Plasma Concentration (Cmax) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to Reach Maximum Observed Plasma Concentration (Tmax) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01925274"], "EPCD": ["January 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase 2 Study Of PF-05212384 Plus Irinotecan Versus Cetuximab Plus Irinotecan In Patients With KRAS and NRAS Wild Type Metastatic Colorectal "], "COOM": ["Not Provided"], "SD": ["April 2014"]},
{"OPOM": ["Overall survival time between 3 treatment arms [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00632853"], "CPOM": ["Overall survival time between 3 treatment arms [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 8, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00632853?rank=4&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Time\u00a0Frame:\u00a0Up to Interim Analysis\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Complete and partial response rates [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Failure-free survival [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local tumor progression according to RECIST criteria [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates of distant metastases and intracranial metastases [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung ", " Receiving Cisplatin and Etoposide"], "OOOM": ["Not Provided"], "LUD": ["June 14, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Complete and partial response rates [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Failure-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local tumor progression according to RECIST criteria [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates of distant metastases and intracranial metastases [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00632853"], "EPCD": ["June 2023 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung ", " Also Receiving Cisplatin and Etoposide"], "COOM": ["Not Provided"], "SD": ["March 2008"]},
{"OPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00588770"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0Time from randomization to date of death from any cause, censored at date of last contact, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 28, 2007"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00588770?rank=5&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">One-sided Fisher's exact tests with alpha of 0.05 will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response rates [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The sum of the longest diameters of all target lesions will be calculated at baseline and reported as the baseline sum longest diameter. The sum longest diameter will be used to characterize the objective tumor response.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Time\u00a0Frame:\u00a0From the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Comorbidities [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The impact of comorbidities on endpoints will be assessed.</div></li>\n</ul></td>"], "BT": ["Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck "], "OOOM": ["Not Provided"], "LUD": ["July 18, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Impact of comorbidity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00588770"], "EPCD": ["December 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck "], "COOM": ["Not Provided"], "SD": ["August 2008"]},
{"OPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01546987"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death due to any cause.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 3, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01546987?rank=9&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of unexpected grade \u2265 3 adverse events and/or clinically significant decrement in patient-reported quality of life (PR-QOL) among patients treated with TAK-700 [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented AE \u2265 grade 3 and/or to the date of first clinically significant decrement in patient-reported quality of life (PR-QOL) among patients treated with TAK-700.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates and cumulative incidence of biochemical control - freedom from PSA failure [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented biochemical failure by the Phoenix definition (PSA \u2265 2 ng/ml over the nadir PSA) or the initiation of salvage androgen deprivation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">General clinical treatment failure-free interval [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented general clinical treatment failure defined as: PSA &gt; 25 ng/ml or documented local disease progression or regional or distant metastasis or initiation of androgen deprivation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prostate cancer-specific survival and other-cause survival [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death due to prostate cancer for prostate cancer-specific survival and to the date of death due to other causes for other-cause survival.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in fatigue from baseline to 1 year, as measured by PROMIS [\u00a0Time\u00a0Frame:\u00a0One year from the date of randomization.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in PR-QOL as measured by EPIC [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the week prior to RT start, to the last week of RT and 1 year and 2.5 years after the initiation of therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Assessment of quality-adjusted survival using the EQ-5D [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the week prior to RT start, to the last week of RT and 1 year and 2.5 years after the initiation of therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Nadir and average serum testosterone at 12 and 24 months during treatment [\u00a0Time\u00a0Frame:\u00a0From baseline to 12 months and 24 months of treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lipid profiles at 12 and 24 months [\u00a0Time\u00a0Frame:\u00a0From baseline to 12 months and 24 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Fasting plasma glucose, fasting plasma insulin, and hemoglobin A1c at 12 and 24 months [\u00a0Time\u00a0Frame:\u00a0From baseline to 12 months and 24 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in body mass index (BMI) during 24 months of treatment and during the first three years of follow-up [\u00a0Time\u00a0Frame:\u00a0From baseline to 2 years from the start of treatment and after that every year for 3 more years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events ascertained via Common Toxicity Criteria for Adverse Effects (CTCAE) version 4 [\u00a0Time\u00a0Frame:\u00a0From the start of therapy to 6 months of follow-up.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of recovery of testosterone to &gt; 230 ng/dL (accepted threshold for supplementation) after 12 and 24 months of follow-up [\u00a0Time\u00a0Frame:\u00a0From the treatment end date to the date when testosterone levels first recovered to &gt; 230 ng/dl within 12 months and 24 months of treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Median time to recovery of testosterone to &gt; 230 ng/dL during the first five years of follow-up [\u00a0Time\u00a0Frame:\u00a0From the date of ranomization to the post-treatment end date when testosterone levels first recovered to &gt; 230 ng/dl within 5 years after treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidence of relevant clinical survivorship endpoints including new diagnosis of type 2 diabetes, coronary artery disease, myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, or osteoporotic fracture [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first reported new incidence of any of the above mentioned clinical endpoints.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates and cumulative incidence of local/regional progression [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of the documented presence of local/regional recurrence.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates and cumulative incidence of distant metastases [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of documented distant recurrence.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate "], "OOOM": ["Not Provided"], "LUD": ["July 9, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of unexpected grade \u2265 3 adverse events and/or clinically significant decrement in patient-reported quality of life (PR-QOL) among patients treated with TAK-700 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates and cumulative incidence of biochemical control (freedom from PSA failure), local/regional progression, and distant metastases [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">General clinical treatment failure-free interval [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prostate cancer-specific survival and other-cause survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in fatigue from baseline to 1 year, as measured by PROMIS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in PR-QOL as measured by EPIC [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Assessment of quality-adjusted survival using the EQ-5D [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Nadir and average serum testosterone at 12 and 24 months during treatment [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lipid profiles at 12 and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Fasting plasma glucose, fasting plasma insulin, and hemoglobin A1c at 12 and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in body mass index (BMI) during 24 months of treatment and during the first three years of follow-up [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events ascertained via CTCAE version 4 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of recovery of testosterone to &gt; 230 ng/dL (accepted threshold for supplementation) after 12 and 24 months of follow-up [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Median time to recovery of testosterone to &gt; 230 ng/dL during the first five years of follow-up [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidence of relevant clinical survivorship endpoints including new diagnosis of type 2 diabetes, coronary artery disease, myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, or osteoporotic fracture [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01546987"], "EPCD": ["October 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate "], "COOM": ["Not Provided"], "SD": ["May 2012"]},
{"OPOM": ["Invasive disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01275677"], "CPOM": ["IDFS [\u00a0Time\u00a0Frame:\u00a0Time to local, regional, or distant recurrence, second non-breast primary breast cancer, or death from any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 11, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01275677?rank=2&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">DFS-DCIS [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">BCFS [\u00a0Time\u00a0Frame:\u00a0From randomization until local recurrence, or death from any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">RFI [\u00a0Time\u00a0Frame:\u00a0From randomization until invasive local, regional, or distant recurrence, or death from breast cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">DRFI [\u00a0Time\u00a0Frame:\u00a0From randomization until the first diagnosis of distant metastasis or death from breast cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0From randomization to death from any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events using the National Cancer Institute CTCAE v4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 30 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The frequency and severity of adverse events will be graded.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in HER2 mRNA level [\u00a0Time\u00a0Frame:\u00a0From baseline to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The interaction between treatment effect and HER2 mRNA level will be evaluated in the proportional hazards model, which would include an indicator for treatment group and the HER2 mRNA level as a continuous variable, and the corresponding interaction term. The log-hazard ratio plot for the interaction term with 95% confidence intervals will be used to determine the cut-off of the HER2 mRNA level that would determine a subset of the patients who would benefit from the adjuvant trastuzumab therapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Fcgamma receptor polymorphism [\u00a0Time\u00a0Frame:\u00a0From baseline to up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The polymorphism of the Fcgamma 158 receptor gene will be dichotomized as V/V (valine) vs. other genotypes and the polymorphism of the Fcgamma 131 receptor gene will be dichotomized as H/H (histidine) vs. other genotypes to evaluate an interaction between treatment group and Fcgamma polymorphism. The Kaplan-Meier method105 will be used to estimate the distribution of the primary endpoints stratified by the dichotomized subgroups, and the log-rank test106 will be used to statistically compare the time-to-event distributions.</div></li>\n</ul></td>"], "BT": ["Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast "], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Breast cancer-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Recurrence-free interval [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Distant recurrence-free interval [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequencies of adverse events using the NCI CTCAE v4.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01275677"], "EPCD": ["January 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast "], "COOM": ["Not Provided"], "SD": ["January 2011"]},
{"OPOM": ["Repository of malignant, borderline malignant neoplasms,  and related biological specimens [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00898079"], "CPOM": ["Repository of malignant, borderline malignant neoplasms, and related biological specimens [\u00a0Time\u00a0Frame:\u00a0Baseline\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00898079?rank=10&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Malignant, Borderline ", ", and Related Samples From Young Patients With "], "OOOM": ["Not Provided"], "LUD": ["February 13, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00898079"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric "], "COOM": ["Not Provided"], "SD": ["March 2003"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00946712"], "CPOM": [], "FRD": ["July 24, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00946712?rank=11&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS and PFS of EGFR FISH-positive patients by centralized review [\u00a0Time\u00a0Frame:\u00a0From date of registration to 3 years or death, whichever comes first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">PFS of the entire study population by centralized review and by institutional review [\u00a0Time\u00a0Frame:\u00a0From date of registration to 3 years or death, whichever comes first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response [\u00a0Time\u00a0Frame:\u00a0From date of registration to 3 years or death, whichever comes first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity as assessed by NCI CTCAE version 4.0 [\u00a0Time\u00a0Frame:\u00a0From date of registration to 3 years or death, whichever comes first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Comparison of other purported EGFR-related biomarkers with EGFR IHC, EGFR FISH,  and patient outcomes [\u00a0Time\u00a0Frame:\u00a0From date of registration to 3 years or death, whichever comes first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of KRAS mutations with response and outcome [\u00a0Time\u00a0Frame:\u00a0From date of registration to 3 years or death, whichever comes first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["S0819: Carboplatin/Paclitaxel With or Without Bevacizumab and/or Cetuximab in Stage IV or Recurrent Non-Small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["September 30, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS and PFS of EGFR FISH-positive patients by centralized review [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">PFS of the entire study population by centralized review and by institutional review [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity as assessed by NCI CTCAE version 3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Comparison of other purported EGFR-related biomarkers with EGFR IHC, EGFR FISH,  and patient outcomes [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of KRAS mutations with response and outcome [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00946712"], "EPCD": ["December 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-Small Cell Lung ", " (NSCLC)"], "COOM": ["Not Provided"], "SD": ["July 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01124695"], "CPOM": ["Correlation between CYP2D6 score (0 vs 1-2) and progression-free survival (PFS) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 14, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01124695?rank=12&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Correlation of CYP2D6 score (0 vs 1 vs 2) with PFS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of CYP2D6 score (0 vs 1-2) with PFS at 6 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of endoxifen concentration with  response [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of CYP2D6 with  response [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast "], "OOOM": ["Not Provided"], "LUD": ["December 6, 2012"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01124695"], "EPCD": ["July 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Prospective Trial Correlating Progression Free Survival With CYP2D6 Activity in Patients With Metastatic Breast ", " Treated With Single Agent Tamoxifen"], "COOM": ["Not Provided"], "SD": ["September 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00945009"], "CPOM": [], "FRD": ["July 22, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00945009?rank=13&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Combination Chemotherapy and Surgery in Treating Young Patients With Wilms "], "OOOM": ["Not Provided"], "LUD": ["April 1, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00945009"], "EPCD": ["July 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms "], "COOM": ["Not Provided"], "SD": ["July 2009"]},
{"OPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0three years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01226004"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 20, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01226004?rank=16&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Treatment Outcomes [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Measurement of surrogate outcomes including IPSS and SHIM scores</div></li>\n<li style=\"margin:1ex 0.5ex\">Treatment toxicity [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">urinary and rectal complications as well as sexual health</div></li>\n<li style=\"margin:1ex 0.5ex\">Assess biochemical disease free survival using PSA [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Multi-Institutional Registry for Prostate ", " Radiosurgery"], "OOOM": ["Not Provided"], "LUD": ["December 13, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Treatment Outcomes [\u00a0Time\u00a0Frame:\u00a0Three years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Measurement of surrogate outcomes including IPSS and SHIM scores</div></li>\n<li style=\"margin:1ex 0.5ex\">Treatment toxicity [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">urinary and rectal complications as well as sexual health</div></li>\n<li style=\"margin:1ex 0.5ex\">Assess biochemical disease free survival using PSA [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01226004"], "EPCD": ["July 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Multi-Institutional Registry for Prostate ", " Radiosurgery. An IRB Approved Observational Trial"], "COOM": ["Not Provided"], "SD": ["July 2010"]},
{"OPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00942331"], "CPOM": ["Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0From date of randomization to date of death due to any cause, assessed up to 7 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 17, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00942331?rank=15&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to date of progression or death due to any cause, whichever occurs first, assessed up to 7 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The primary analysis of PFS will be a two-sided stratified log-rank test comparing arm A and arm B. The stratification factors will consist of the two stratification factors used for patient randomization: prior nephrectomy (yes vs. no) and Motzer score (0 vs. 1\u22122 vs. 3+). Results from unstratified log-rank tests will also be provided. Kaplan-Meier methodology will be used to estimate median PFS for each treatment arm.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate (defined as confirmed complete and partial responses) using RECIST criteria [\u00a0Time\u00a0Frame:\u00a0Up to 7 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Cochran-Mantel-Haenszel test will be used to compare the two arms on the proportion of patients who experience an objective response adjusting on the stratification factors (presence of visceral disease [no, yes] and prior chemotherapy [no, yes]).</div></li>\n<li style=\"margin:1ex 0.5ex\">Grade 3 or greater treatment-related toxicity using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 7 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Fisher exact test will be used to compare the two treatment arms on the proportion of patients with unacceptable treatment related grade 3 or higher toxicity.</div></li>\n</ul></td>"], "BT": ["Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract "], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate (complete and partial response) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00942331"], "EPCD": ["June 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma"], "COOM": ["Not Provided"], "SD": ["July 2009"]},
{"OPOM": ["Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00719303"], "CPOM": ["Progression-free survival [\u00a0Time\u00a0Frame:\u00a0From entry onto the protocol to the date of first clinical, biochemical, or radiological evidence of progression or death due to any cause, up to 9 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 18, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00719303?rank=18&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Change in self-reported quality of life measured using RAND-36 [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Linear mixed effects models for repeated measures will be fitted to general health subscale score, physical functioning subscale score of RAND-36, and to GSRS-IBS overall score respectively.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in irritable bowel syndrome-specific symptoms measured using GSRS-IBS [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Linear mixed effects models for repeated measures will be fitted to general health subscale score, physical functioning subscale score of RAND-36, and to GSRS-IBS overall score respectively.</div></li>\n</ul></td>"], "BT": ["Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal "], "OOOM": ["Not Provided"], "LUD": ["February 26, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Quality of life and physical function [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Blood markers in predicting progression or death [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Blood markers in predicting recurrence or survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Plasma carotenoid levels [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patient compliance [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Impact on other aspects of quality of life [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Impact on bowel function [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00719303"], "EPCD": ["December 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal ", " Progression-Free Survival?"], "COOM": [], "SD": ["June 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00858364"], "CPOM": ["Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0from randomization until death or end of study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["March 5, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00858364?rank=17&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of neutralizing antibody formation to darbepoetin alfa [\u00a0Time\u00a0Frame:\u00a0first dose of investigative product to the end of treatment period\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of at least 1 Red Blood Cell (RBC) transfusion or hemoglobin less than or equal to 8.0 g/dL from study day 1 to end of efficacy treatment period [\u00a0Time\u00a0Frame:\u00a0study day 1 until end of efficacy treatment period\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of at least 1 Red Blood Cell (RBC) transfusion or hemoglobin less than or equal to 8.0 g/dL from week 5 (day 29) to end of efficacy treatment period [\u00a0Time\u00a0Frame:\u00a0Study day 29 to end of efficacy treatment period\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events (AEs) such as thrombovascular events (TVE), venous thromboembolic events (VTE), and AEs associated with Red Blood Cell (RBC) transfusions [\u00a0Time\u00a0Frame:\u00a0Randomization to 30 days after last dose of darbepoetin alfa\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in hemoglobin from baseline to end of efficacy treatment period [\u00a0Time\u00a0Frame:\u00a0screening until end of efficacy treatment period\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective tumor response [\u00a0Time\u00a0Frame:\u00a0randomization to subjects developing tumor progression\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0from randomization until disease progression\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Anemia Treatment for Advanced Non-Small Cell Lung ", " (NSCLC) Patients Receiving Chemotherapy"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0from randomization until disease progression\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of at least 1 RBC transfusion or hemoglobin less than or equal to 8.0 g/dL from week 5 (day 29) to end of efficacy treatment period [\u00a0Time\u00a0Frame:\u00a0Study day 29 to end of efficacy treatment period\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events (AEs) such as thrombovascular events (TVE), venous thromboembolic events (VTE), and AEs associated with RBC transfusions [\u00a0Time\u00a0Frame:\u00a0Randomization to 30 days after last dose of darbepoetin alfa\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective tumor response [\u00a0Time\u00a0Frame:\u00a0randomization to subjects developing tumor progression\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of at least 1 RBC transfusion or hemoglobin less than or equal to 8.0 g/dL from study day 1 to end of treatment period [\u00a0Time\u00a0Frame:\u00a0study day 1 until end of efficacy treatment period\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in hemoglobin from baseline to end of efficacy treatment period [\u00a0Time\u00a0Frame:\u00a0screening until end of efficacy treatment period\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of neutralizing antibody formation to darbepoetin alfa [\u00a0Time\u00a0Frame:\u00a0first dose of investigative product to the end of treatment period\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00858364"], "EPCD": ["February 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 \u00b5g Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung ", " Receiving Multi-cycle Chemotherapy"], "COOM": ["Not Provided"], "SD": ["June 2009"]},
{"OPOM": ["Change in mammographic density at 12 months compared to baseline [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01097278"], "CPOM": ["Change in mammographic density at 12 months compared to baseline [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 31, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01097278?rank=14&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Ki-67 as assessed in tissue obtained in breast biopsies at baseline and at 12 months [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast "], "OOOM": ["Not Provided"], "LUD": ["April 4, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Ki-67 as assessed in tissue obtained in breast biopsies at baseline and at 12 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "record_id": ["NCT01097278"], "EPCD": ["May 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast "], "COOM": ["Not Provided"], "SD": ["November 2011"]},
{"OPOM": ["Overall survival rate at 5 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01414608"], "CPOM": ["Overall survival rate [\u00a0Time\u00a0Frame:\u00a0At 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 10, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01414608?rank=19&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival rate [\u00a0Time\u00a0Frame:\u00a0At 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival rate [\u00a0Time\u00a0Frame:\u00a0At 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of acute and long-term toxicities [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patterns of disease recurrence [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Radiation protocol compliance [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life including psychosexual health [\u00a0Time\u00a0Frame:\u00a0Up to 36 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical "], "OOOM": ["Not Provided"], "LUD": ["June 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival rate at 3 and 5 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of acute and long-term toxicities [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patterns of disease recurrence [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Radiation protocol compliance [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life including psychosexual health [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of complete and partial metabolic response on a PET scan performed 4 - 6 months after completion of chemoradiation treatment [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01414608"], "EPCD": ["July 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical ", " Compared to Chemoradiation Alone: The OUTBACK Trial"], "COOM": ["Not Provided"], "SD": ["January 2012"]},
{"OPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01015833"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 17, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01015833?rank=20&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of adverse events, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Incidence of other adverse events (proteinuria, hypertension, and other common side effects of study drugs) will be assessed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The stratified log-rank test will be used.</div></li>\n</ul></td>"], "BT": ["Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver "], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity as assessed by NCI CTC v3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to progression [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01015833"], "EPCD": ["June 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)"], "COOM": ["Not Provided"], "SD": ["February 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00898365"], "CPOM": [], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00898365?rank=6&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Loss of heterozygosity [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["Study of Kidney ", " in Young Patients"], "OOOM": ["Not Provided"], "LUD": ["February 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Loss of heterozygosity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "record_id": ["NCT00898365"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Renal ", " Classification, Biology, and Banking Study"], "COOM": ["Not Provided"], "SD": ["February 2006"]},
{"OPOM": ["The number and type of adverse events reported by the investigator or the patient. [\u00a0Time\u00a0Frame:\u00a0From the time of signing the informed consent to the time of the End-of-Study Visit (ie, 30 days after discontinuation of study drug).\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT01217697"], "CPOM": ["The number and type of adverse events reported by the investigator or the patient. [\u00a0Time\u00a0Frame:\u00a0From the time of signing the informed consent to the time of the End-of-Study Visit (ie, 30 days after discontinuation of study drug).\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["October 7, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01217697?rank=21&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Study of Abiraterone Acetate in Patients With Advanced Prostate "], "OOOM": ["Not Provided"], "LUD": ["July 17, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01217697"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate ", " Who Have Progressed After Taxane-Based Chemotherapy"], "COOM": ["Not Provided"], "SD": ["November 2010"]},
{"OPOM": ["Duration of overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00954174"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 6, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00954174?rank=22&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed using a stratified Cox proportional hazards model.</div></li>\n<li style=\"margin:1ex 0.5ex\">Toxicity as assessed by CTCAE version 3.0 [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kruskal-Wallis test corrected for ties will be used to compare the maximum grade of acute adverse effects of therapy by treatment arm.</div></li>\n<li style=\"margin:1ex 0.5ex\">Quality of life measured using the FACT-G Physical Well-being and Functional Well-being subscales, FACT-En, and FACT/GOG-NTtx subscale [\u00a0Time\u00a0Frame:\u00a0Up to 30 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity "], "OOOM": ["Not Provided"], "LUD": ["March 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity as assessed by CTCAE version 3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00954174"], "EPCD": ["November 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal ", ") of the Uterus, Fallopian Tube, Peritoneum or Ovary"], "COOM": ["Not Provided"], "SD": ["August 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01942135"], "CPOM": ["Progression-Free Survival [\u00a0Time\u00a0Frame:\u00a0Baseline up to approximately 10 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["September 10, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01942135?rank=24&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a0Baseline until death (up to approximately 28 months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from randomization to date of death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective Response [\u00a0Time\u00a0Frame:\u00a0Baseline until approximately 10 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Complete or partial response recorded from randomization until disease progression or death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response [\u00a0Time\u00a0Frame:\u00a0Baseline up to approximately 10 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from the first documentation of objective tumor response to objective tumor progression or death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical Benefit Response (CBR) [\u00a0Time\u00a0Frame:\u00a0Baseline up to approximately 10 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">CBR is defined as complete response or partial response or stable disease equal to or greater than 24 weeks  according to RECIST version 1.1 recorded in the time period between randomization and disease progression or death of any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">1 Year Probability of Participant Survival [\u00a0Time\u00a0Frame:\u00a0From baseline through 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Probability of survival one year after randomization.</div></li>\n<li style=\"margin:1ex 0.5ex\">2 Year Probability of Participant Survival [\u00a0Time\u00a0Frame:\u00a0From baseline through 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Probability of survival 2 years after randomization</div></li>\n<li style=\"margin:1ex 0.5ex\">3 Year Probability of Participant Survival [\u00a0Time\u00a0Frame:\u00a0From baseline through 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Probability of survival 3 years after randomization.</div></li>\n<li style=\"margin:1ex 0.5ex\">Minimum Observed Plasma Trough Concentration (Cmin) [\u00a0Time\u00a0Frame:\u00a0Cycles 1 and 2\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cmin for palbociclib, fulvestrant and goserelin (if applicable)</div></li>\n<li style=\"margin:1ex 0.5ex\">Alterations in genes, proteins, and ribonucleic acids relevant to the cell cycle, drug targets, tumor sensitivity and/or resistance [\u00a0Time\u00a0Frame:\u00a0From baseline until approximately 10 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Biomarkers from tissue including genes, proteins, and RNA expression</div></li>\n<li style=\"margin:1ex 0.5ex\">Euro Quality of Life (EQ-5D)- Health State Profile Utility Score [\u00a0Time\u00a0Frame:\u00a0From baseline through approximately month 10\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">EQ 5D (version 3L) is a 6 item instrument designed to assess health status in terms of a single index value or utility score.</div></li>\n<li style=\"margin:1ex 0.5ex\">European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) [\u00a0Time\u00a0Frame:\u00a0From baseline through approximately month 10\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The EORTC QLQ C30 is a 30 item questionnaire composed of functional subscales; symptom scales; and other cancer related symptoms.</div></li>\n<li style=\"margin:1ex 0.5ex\">European Organization for Research and Treatment of Cancer breast cancer  module (EORTC QLQ BR23) [\u00a0Time\u00a0Frame:\u00a0From baseline through approximately month 10\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">EORTC QLQ BR23 is a 23 item breast cancer specific companion module to the EORTC QLQ C30.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to Deterioration (TTD) [\u00a0Time\u00a0Frame:\u00a0From baseline through approximately month 10\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from randomization to the first documentation of objective tumor progression, death due to any cause, and/or reduction in quality of life</div></li>\n<li style=\"margin:1ex 0.5ex\">Minimally Important Difference Cut-Off [\u00a0Time\u00a0Frame:\u00a0From baseline through approximately month 10\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Number of time points where the minimally importance difference in QoL is achieved</div></li>\n</ul></td>"], "BT": ["Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast ", " After Endocrine Failure (PALOMA-3)"], "OOOM": ["Not Provided"], "LUD": ["July 17, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01942135"], "EPCD": ["July 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Of Fulvestrant (Faslodex\u00ae) With Or Without PD-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast ", " Whose Disease Progressed After Prior Endocrine Therapy"], "COOM": ["Not Provided"], "SD": ["September 2013"]},
{"OPOM": ["Disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01196390"], "CPOM": ["Disease-free survival (DFS) [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first failure or last follow-up, assessed up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["September 4, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01196390?rank=25&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Pathologic complete response [\u00a0Time\u00a0Frame:\u00a0Within 4 weeks after surgical resection\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Pathologic complete response is defined as no viable residual tumor cells.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first failure or last follow-up, assessed up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS will be estimated by the Kaplan-Meier method. The distribution of OS estimates between the 2 arms will be compared using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with OS.</div></li>\n<li style=\"margin:1ex 0.5ex\">Adverse events [\u00a0Time\u00a0Frame:\u00a0From the start of chemoradiation up to the earlier date of surgery or 6 weeks after completion of chemoradiation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</div></li>\n<li style=\"margin:1ex 0.5ex\">Health-related quality of life (QOL) as measured by FACT-E [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Distributions of QOL data collection patterns over all collection points in each treatment arm will be described. To inspect the missing data mechanism for each tool, at least a graphical method will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Quality-adjusted survival [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The EQ-5D will be used to assess quality-adjusted survival. Quality-adjusted survival is calculated as the weighted sum of different time in different health states added up to a total quality-adjusted survival time [U=sum of quality (qi) of health states K times the duration (si) spent in each health state].</div></li>\n<li style=\"margin:1ex 0.5ex\">Molecular correlates of efficacy [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Predictors of cardiotoxicity [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal "], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Pathologic complete response [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Adverse events [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Health-related quality of life as measured by FACT-E [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality-adjusted survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Molecular correlates of efficacy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Predictors of cardiotoxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01196390"], "EPCD": ["August 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma"], "COOM": ["Not Provided"], "SD": ["December 2010"]},
{"OPOM": ["Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01004978"], "CPOM": ["Progression-free survival [\u00a0Time\u00a0Frame:\u00a0Time from randomization to progression or death without evidence of progression, assessed up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 29, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01004978?rank=23&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Time from randomization to death from any cause, or last known date of survival, assessed up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver ", " That Cannot Be Removed By Surgery"], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01004978"], "EPCD": ["February 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion"], "COOM": ["Not Provided"], "SD": ["October 2009"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT01450553"], "CPOM": ["Not Provided"], "FRD": ["October 7, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01450553?rank=29&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Tissue Collection Study for Patients With Non-Small Cell Lung ", " With Resectable Disease"], "OOOM": ["Not Provided"], "LUD": ["January 9, 2012"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01450553"], "EPCD": ["Not Provided"], "OT": ["Research and Development Study: Tissue Collection From Patients Who Are Undergoing Surgery for Non-Small Cell Lung "], "COOM": ["Not Provided"], "SD": ["October 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00772200"], "CPOM": [], "FRD": ["October 14, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00772200?rank=30&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Neuropsychological and Behavioral Testing in Young Patients With "], "OOOM": ["Not Provided"], "LUD": ["February 24, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00772200"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With "], "COOM": ["Not Provided"], "SD": ["September 2008"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT00082745"], "CPOM": [], "FRD": ["May 14, 2004"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00082745?rank=26&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Study of Late-Occurring Complications in Childhood ", " Survivors"], "OOOM": ["Not Provided"], "LUD": ["February 17, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00082745"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Key Adverse Events After Childhood "], "COOM": ["Not Provided"], "SD": ["March 2004"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00980460"], "CPOM": [], "FRD": ["September 18, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00980460?rank=28&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Feasibility of referral for liver transplantation [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A patient for whom referral is considered appropriate who receives a consultation after enrollment will be considered a success with respect to feasibility.</div></td>"], "BT": ["Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver "], "OOOM": ["Not Provided"], "LUD": ["February 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Feasibility of referral for liver transplantation [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "record_id": ["NCT00980460"], "EPCD": ["June 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Treatment of Children With All Stages of Hepatoblastoma"], "COOM": ["Not Provided"], "SD": ["September 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01231906"], "CPOM": [], "FRD": ["October 29, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01231906?rank=31&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Relative risk for death [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using the stratified partial likelihood for the relative risk regression model accounting for the factors used to stratify randomization at the time full information is obtained for the event-free survival (EFS) comparison. Methods for censored survival data, including but not limited to log-rank comparisons and proportional hazards regression modeling will be used to assess prognostic significance.</div></li>\n<li style=\"margin:1ex 0.5ex\">Histological response, in terms of event free survival after local control in patients who received local control therapy [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Methods for censored survival data, including but not limited to log-rank comparisons and proportional hazards regression modeling will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Positron emission tomography (PET)-determined response, in terms of event free survival after local control [\u00a0Time\u00a0Frame:\u00a0Up to week 13\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Methods for censored survival data, including but not limited to log-rank comparisons and proportional hazards regression modeling will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Probabilities of identifying tumors of at least 200 ml [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A two sided log-rank test of size 0.05 as a function of the percent of patients for whom measurements can be obtained will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Extent of tumor necrosis according to the necrosis grading criteria in patients who have surgical resection of tumor [\u00a0Time\u00a0Frame:\u00a0Week 13\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The probabilities of identifying patients with 'standard' necrosis grading as associated with increased risk using a two sided log-rank test of size 0.05 as a function of the percent of patients with 'standard' necrosis grading and its associated relative risk will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Radiological response of soft tissue component of mass by PET [\u00a0Time\u00a0Frame:\u00a0Up to week 13\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The probabilities of identifying patients with complete response (CR) as associated with decreased risk for EFS-event when compared with patients with less-than-CR using a two sided log-rank test of size 0.05 as a function of the percent of patients with standard response and its associated relative risk will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Differences associated with local control modality on risk for EFS event, according to surgery only v. radiation therapy only v. surgery and radiation therapy [\u00a0Time\u00a0Frame:\u00a0Up to week 13\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Stratified according to primary site of tumor as pelvis v. bone but not pelvis v. extra-osseous site. An omnibus log-rank test of size 0.05 will be used to assess whether there are differences associated with local control modality.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number and proportion of patients who experience any grade 2 or higher musculoskeletal event (ME), or surgery required to treat a complication of local therapy based on the NCI CTCAE v4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 3 months post-local control therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The proportion of patients who experience any ME will be compared across the three regimens using an exact test of proportions of size 0.05.</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients who have tumor present at the margin of resection on risk for EFS event in patients undergoing surgery [\u00a0Time\u00a0Frame:\u00a0Week 13\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma"], "OOOM": ["Not Provided"], "LUD": ["February 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Histologic response [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Initial volumetric tumor size as a prognostic factor for EFS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prognostic significance of imaging response by FDG-positron emission tomography (PET)  and EFS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Effect of local surgical margins in conjunction with histologic response on EFS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Effect of local therapy modality (surgery, radiotherapy or a combination) as well as the type of surgical reconstruction on musculoskeletal complications [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01231906"], "EPCD": ["September 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma"], "COOM": ["Not Provided"], "SD": ["November 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01615068"], "CPOM": ["Distribution of patients receiving unique treatment regimen/sequence of treatment regimens [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 6, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01615068?rank=32&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Post-progression survival (PPS) [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time-to-treatment failure (TTF) [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response rate (RR) [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety: Incidence of adverse events [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patient-reported outcome assessment (PRO) [\u00a0Time\u00a0Frame:\u00a0Up to 8 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["An Observational Study in Patients With HER2 Positive Metastatic Breast ", " (SystHERs Registry)"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01615068"], "EPCD": ["June 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast ", " (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast ", " Study))."], "COOM": ["Not Provided"], "SD": ["June 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01958021"], "CPOM": ["Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Up to approximatly 25 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 4, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01958021?rank=33&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0Up to approximately 69 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from date of randomization to the date of death from any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall response rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Up to approximately 25 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Overall response rate (ORR) is defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1.</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical benefit rate (CBR) [\u00a0Time\u00a0Frame:\u00a0Up to approximately 25 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Clinical Benefit Rate (CBR) is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) lasting more than 24 weeks as defined in RECIST 1.1.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive deterioration of ECOG performance status in one category of the score [\u00a0Time\u00a0Frame:\u00a0Up to approximately 25.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive deterioration of ECOG performance status in one category of score is defined as the time from the date of randomization to the date of event, which is defined as at least one score lower than the baseline.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and Tolerability of LEE011 [\u00a0Time\u00a0Frame:\u00a0Up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety will be determined by type, frequency and severity of adverse events per CTCAE version 4.03 and type, frequency and severity of laboratory toxicities per CTCAE version 4.03.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 10% deterioration in the global health status/quality of life (QOL) scale score of the EORTC QLQ-C30 [\u00a0Time\u00a0Frame:\u00a0Up to approximately 25 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time to definitive 10% deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10% relative to baseline worsening of the corresponding scale score (without further improvement above the threshold) or death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">QTc interval [\u00a0Time\u00a0Frame:\u00a0Baseline, cycle 1 day 15, cycle 2 day 1 and cycle 3 day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time between the start of the Q wave and the end of the T wave corrected for heart rate</div></li>\n</ul></td>"], "BT": ["Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast ", ".(MONALEESA-2)"], "OOOM": ["Not Provided"], "LUD": ["July 16, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01958021"], "EPCD": ["January 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast ", " Who Received no Prior Therapy for Advanced Disease"], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00807768"], "CPOM": ["Duration of recurrence-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 11, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00807768?rank=27&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidences of  vaginal recurrence, pelvic recurrence, distant (extra-pelvic) recurrence, and death from endometrial cancer [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity as assessed by NCI CTCAE v3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life as assessed by the FACT-G Physical and Functional Well-Being, FACT-En, FACT/GOG-Ntx, FACIT-F, PROMIS Fatigue-SF1, and FACT-Cx questionnaires [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial "], "OOOM": ["Not Provided"], "LUD": ["February 3, 2012"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT00807768"], "EPCD": ["March 2013 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma"], "COOM": ["Not Provided"], "SD": ["March 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01989676"], "CPOM": ["Percentage of Participants With Objective Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Week 25\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 28, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01989676?rank=34&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of Response (DOR) [\u00a0Time\u00a0Frame:\u00a0up to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The percent of patients The time from date of the first documentation of objective tumor response to the first documentation of PD or to death due to any cause in the absence of documented PD.</div></li>\n<li style=\"margin:1ex 0.5ex\">1-year Progression-Free Survival (PFS) Rate [\u00a0Time\u00a0Frame:\u00a0up to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time from date of randomization to first progression of disease (PD) or death due to any cause in the absence of documented PD.</div></li>\n<li style=\"margin:1ex 0.5ex\">1-year Survival Rate [\u00a0Time\u00a0Frame:\u00a0up to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Duration from enrollment to death. For participants who are alive, overall survival will be censored at the last contact.</div></li>\n<li style=\"margin:1ex 0.5ex\">Maximum Observed Plasma Concentration (Cmax) [\u00a0Time\u00a0Frame:\u00a0up to 4 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Peak PF-05280014 and trastuzumab-EU concentrations at selected cycles.</div></li>\n<li style=\"margin:1ex 0.5ex\">Minimum Observed Plasma Trough Concentration (Cmin) [\u00a0Time\u00a0Frame:\u00a0up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Trough PF-05280014 and trastuzumab-EU concentrations at selected cycles.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of ADA [\u00a0Time\u00a0Frame:\u00a0up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The percentage of patients with positive ADA and neutralizing antibodies will be summarized for each treatment arm.</div></li>\n</ul></td>"], "BT": ["A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin\u00ae [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast ", " Treatment (REFLECTIONS B327-02)"], "OOOM": ["Not Provided"], "LUD": ["July 18, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01989676"], "EPCD": ["May 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 3 Randomized, Double-Blind Study Of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-Line Treatment Of Patients With HER2-Positive Metastatic Breast "], "COOM": ["Not Provided"], "SD": ["February 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00904241"], "CPOM": [], "FRD": ["May 16, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00904241?rank=35&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">MYCN status per tumor [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cross tabulations of MYCN status per tumor versus MYCN status per blood will be generated, the percentage concordant and the percentage discordant will be calculated, and receiver operating characteristic (ROC) analyses will be performed. Kaplan-Meier curves of MYCN status per blood will be generated, and a logrank test comparison performed. The prognostic ability of MYCN status per tumor versus MYCN status per blood will be tested in a multivariable Cox model.</div></li>\n<li style=\"margin:1ex 0.5ex\">MYCN status per blood [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cross tabulations of MYCN status per tumor versus MYCN status per blood will be generated, the percentage concordant and the percentage discordant will be calculated, and ROC analyses will be performed. Kaplan-Meier curves of MYCN status per blood will be generated, and a logrank test comparison performed. The prognostic ability of MYCN status per tumor versus MYCN status per blood will be tested in a multivariable Cox model.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of OMA [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive analysis will be performed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of spinal cord compression [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive analysis will be performed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Presentation with multifocal primary tumors [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive analysis will be performed.</div></li>\n</ul></td>"], "BT": ["Biomarkers in ", " Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma"], "OOOM": ["Not Provided"], "LUD": ["July 23, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00904241"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Neuroblastoma Biology Studies"], "COOM": ["Not Provided"], "SD": ["November 2000"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00919269"], "CPOM": [], "FRD": ["June 11, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00919269?rank=37&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma"], "OOOM": ["Not Provided"], "LUD": ["February 12, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00919269"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol"], "COOM": ["Not Provided"], "SD": ["March 1999"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00932451"], "CPOM": [], "FRD": ["June 30, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00932451?rank=39&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of Response [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease Control Rate [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patient reported symptoms of lung cancer and health-related quality of life [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentrations of PF-02341066 [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Types of EML4-ALK fusion variants and ALK gene expression [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Protein expression of identified biomarkers in serial tumor samples (when available) [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to Tumor Response [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">QTc [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">genotypes of alleles possibly associated with adverse hepatic or renal drug reactions [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung ", " With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene"], "OOOM": ["Not Provided"], "LUD": ["July 10, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of Response [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease Control Rate [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patient reported symptoms of lung cancer and health-related quality of life [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Type, incidence, severity, seriousness and relationship to study medication of adverse events and laboratory test abnormalities [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentrations of PF-02341066 [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Types of EML4-ALK fusion variants and ALK gene expression [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Protein expression of identified biomarkers in serial tumor samples (when available) [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00932451"], "EPCD": ["July 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Non-Small Cell Lung ", " Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene"], "COOM": ["Not Provided"], "SD": ["January 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01602666"], "CPOM": [], "FRD": ["May 18, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01602666?rank=36&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Estimation of the PFS distribution of patients with NGGCT treated with IFR [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier estimates will be provided.</div></li>\n<li style=\"margin:1ex 0.5ex\">Estimation of the OS distribution of patients with NGGCT treated with IFR assessed [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier estimates will be provided.</div></li>\n<li style=\"margin:1ex 0.5ex\">Estimation of the PFS distribution of patients with localized germinoma patients and CSF serum hCG\u03b2 of 50 mIU/mL or less or CSF serum hCG\u03b2 greater than 50 mIU/mL and less than or equal to 100 mIU/mL [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier estimates will be provided.</div></li>\n<li style=\"margin:1ex 0.5ex\">Estimation of the OS distribution of patients with localized germinoma patients and CSF serum hCG\u03b2 of 50 mIU/mL or less or CSF serum hCG\u03b2 greater than 50 mIU/mL and less than or equal to 100 mIU/mL [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier estimates will be provided.</div></li>\n</ul></td>"], "BT": ["Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell "], "OOOM": ["Not Provided"], "LUD": ["March 31, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Estimation of the PFS distribution of patients with NGGCT treated with IFR assessed up to 5 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Estimation of the OS distribution of patients with NGGCT treated with IFR assessed up to 5 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Estimation of the PFS distribution of patients with localized germinoma patients  and CSF serum hCG\u03b2 \u2264 50 mIU/mL or CSF serum hCG\u03b2 &gt; 50 mIU/mL and \u2264 100 mIU/mL assessed up to 5 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Estimation of the OS distribution of patients with localized germinoma patients  and CSF serum hCG\u03b2 \u2264 50 mIU/mL or CSF serum hCG\u03b2 &gt; 50 mIU/mL and \u2264 100 mIU/mL assessed up to 5 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01602666"], "EPCD": ["January 2024 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell ", " (CNS GCT)"], "COOM": ["Not Provided"], "SD": ["May 2012"]},
{"OPOM": ["Banking of biological specimens, including associated demographic and clinical data [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00899990"], "CPOM": ["Banking of biological specimens, including associated demographic and clinical data [\u00a0Time\u00a0Frame:\u00a0Not Provided\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00899990?rank=38&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Biological Samples From Patients With Ewing Sarcoma"], "OOOM": ["Not Provided"], "LUD": ["February 18, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00899990"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A COG Study for Collecting and Banking Ewing Sarcoma Specimens"], "COOM": ["Not Provided"], "SD": ["February 2008"]},
{"OPOM": ["Recurrence-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00942357"], "CPOM": ["Recurrence-free survival [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 17, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00942357?rank=40&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Independence between the two endpoints, RFS and survival, and randomized treatment will be assessed with a stratified logrank test for an intent-to-treat analysis of eligible patients.</div></li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidence of local recurrence [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidence of distant metastases [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Acute and late adverse effects as measured by NCI CTCAE v3.0 [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The maximum grade over the entire course of therapy for any individual effect will be used as a summary of acute toxicity.  The Kruskal-Wallis test corrected for ties will be used to compare the maximum grade of acute adverse effects of therapy by treatment arm. A significance level of 0.01 will be used for each tested AE term or category.  No correction for multiple testing will be employed, since it is very important to identify moderate increases in the severity of toxicity at the risk of increasing the Type I error.</div></li>\n<li style=\"margin:1ex 0.5ex\">Patient-reported quality of life measured using FACT-G Physical Well-being (PWB) and Functional Well-being (FWB) subscales, FACT-En additional concerns subscale, FACT/GOG-NTX-4 subscale, and items C3 and C5 from the FACT-C [\u00a0Time\u00a0Frame:\u00a0Up to 1 year after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Linear mixed models adjusted for baseline score, age, and performance status at enrollment will be used to test the hypothesis of no difference in PWB+FWB scores and FACT-GOG/NTX-4 scores between assigned treatment arms in an intent-to-treat analysis of eligible patients.  These models will account for the correlation among scores measured over time.  The interaction between treatment and assessment time on QOL scores will be tested initially in each model.</div></li>\n</ul></td>"], "BT": ["Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial "], "OOOM": ["Not Provided"], "LUD": ["March 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidence of local recurrence [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidence of distant metastases [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Acute and late adverse effects as measured by NCI CTCAE v3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patient-reported quality of life [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00942357"], "EPCD": ["February 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Trial of Cisplatin and ", " Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma"], "COOM": ["Not Provided"], "SD": ["June 2009"]},
{"OPOM": ["Time from randomization to ipsilateral invasive breast cancer, ipsilateral skin cancer recurrence, or ipsilateral ductal carcinoma in situ (DCIS) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00769379"], "CPOM": ["Time from randomization to ipsilateral invasive breast cancer, ipsilateral skin cancer recurrence, or ipsilateral DCIS [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 8, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00769379?rank=41&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Invasive or DCIS disease-free survival [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Events for analysis of IDFS-DCIS include: local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer (other than squamous and basal cell carcinoma of the skin, melanoma in situ, and carcinoma in situ of the colon and cervix), or death from any cause prior to recurrence or second primary cancer. Invasive breast cancer, ipsilateral recurrence, and contralateral breast cancer will be compared across treatment arms using cumulative incidence functions.</div></li>\n<li style=\"margin:1ex 0.5ex\">Invasive or DCIS recurrence-free interval [\u00a0Time\u00a0Frame:\u00a0Time from randomization to first diagnosis of a local, regional or distant recurrence regardless of any intervening contralateral or other second primary cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cox proportional hazards models will be used to evaluate the effect of treatment on time to event. The distributions of time to event will be estimated by the Kaplan-Meier method for each treatment group and will be compared between treatments by simple and stratified log-rank tests. Compared across treatment arms using cumulative incidence functions.</div></li>\n<li style=\"margin:1ex 0.5ex\">Invasive regional or distant recurrence [\u00a0Time\u00a0Frame:\u00a0Time from randomization to first diagnosis of regional or distant recurrence, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cox proportional hazards models will be used to evaluate the effect of treatment on time to event. The distributions of time to event will be estimated by the Kaplan-Meier method for each treatment group and will be compared between treatments by simple and stratified log-rank tests. Compared across treatment arms using cumulative incidence functions.</div></li>\n<li style=\"margin:1ex 0.5ex\">Contralateral breast cancer (invasive or DCIS) [\u00a0Time\u00a0Frame:\u00a0Time from randomization to first diagnosis of contralateral invasive or DCIS breast cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cox proportional hazards models will be used to evaluate the effect of treatment on time to event. The distributions of time to event will be estimated by the Kaplan-Meier method for each treatment group and will be compared between treatments by simple and stratified log-rank tests. Compared across treatment arms using cumulative incidence functions.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Time from randomization to death from any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cox proportional hazards models will be used to evaluate the effect of treatment on time to event. The distributions of time to event will be estimated by the Kaplan-Meier method for each treatment group and will be compared between treatments by simple and stratified log-rank tests. Compared across treatment arms using cumulative incidence functions.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of post-treatment amenorrhea (absence of menstrual period for at least 12 months) in women who were premenopausal at the time of study entry [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Amenorrhea will be summarized by treatment arm in terms of incidence rates and the ranges, medians, and quantiles of duration.</div></li>\n</ul></td>"], "BT": ["Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Invasive or DCIS disease-free survival as assessed by time to local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer (other than squamous cell and b ... [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time from randomization to first diagnosis of a local, regional or distant recurrence regardless of any intervening contralateral or other second primary cancer [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time from randomization to first diagnosis of regional or distant recurrence [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time from randomization to first diagnosis of contralateral invasive or DCIS breast cancer [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time from randomization to death from any cause [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of post-treatment amenorrhea (absence of menstrual period for at least 12 months) at 18 months in women who were premenopausal at the time of study entry [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of cMYC-amplification status with trastuzumab (Herceptin\u00ae) in addition to radiotherapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of PI3 kinase gene mutation status with trastuzumab in addition to radiotherapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00769379"], "EPCD": ["March 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy"], "COOM": ["Not Provided"], "SD": ["November 2008"]},
{"OPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01217437"], "CPOM": ["Overall survival for each treatment arm [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 7, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01217437?rank=42&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Response rate for each treatment arm [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared by means of the exact conditional test of proportions.</div></li>\n<li style=\"margin:1ex 0.5ex\">Event-free survival [\u00a0Time\u00a0Frame:\u00a0From enrollment to disease progression, second malignant neoplasm, death regardless of cause, or date of last contact, whichever comes first, up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated by Kaplan-Meier method. Determined for each patient and compared across regimens using the log-rank test.</div></li>\n</ul></td>"], "BT": ["Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal "], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Response rate for each treatment arm [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Event-free survival (time from enrollment to disease progression, second malignant neoplasm, death regardless of cause, or date of last contact) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01217437"], "EPCD": ["September 2021 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial"], "COOM": ["Not Provided"], "SD": ["November 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00736749"], "CPOM": [], "FRD": ["August 15, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00736749?rank=43&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies"], "OOOM": ["Not Provided"], "LUD": ["February 5, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00736749"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Umbrella Long-Term Follow-Up Protocol"], "COOM": ["Not Provided"], "SD": ["May 2008"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01480479"], "CPOM": ["Overall Survival [\u00a0Time\u00a0Frame:\u00a0During treatment and every three months from end of treatment through end of study or approximately up to 5 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 21, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01480479?rank=45&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Time\u00a0Frame:\u00a0Every 12 weeks from Day 1 through progression or initiation of other anti-cancer therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compare progression-free survival between the two treatment arms</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and Tolerability [\u00a0Time\u00a0Frame:\u00a0Until day 28 of follow up\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety and tolerability will be measured by comparing the two arms in regards to vital sign measurement, physical and neurological examination, adverse events reporting, ECOG performance status, and EORTC core Quality of Life Questionnaire</div></li>\n</ul></td>"], "BT": ["Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma"], "OOOM": ["Not Provided"], "LUD": ["July 22, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01480479"], "EPCD": ["November 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma"], "COOM": ["Not Provided"], "SD": ["November 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00956670"], "CPOM": [], "FRD": ["August 8, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00956670?rank=48&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Lymphedema After Surgery in Patients With Endometrial ", ", Cervical ", ", or Vulvar "], "OOOM": ["Not Provided"], "LUD": ["March 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Patient characteristics: age, height, weight, body mass index, performance status, race [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Surgical characteristics: number of lymph nodes removed, laterality of nodes removed (bilateral vs. unilateral), lymph node status (presence/absence of metastases) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Post-surgical characteristics: development of infection, type of closed suction drain used, lymphocyst formation, use of radiation, and use of chemotherapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequency and severity of adverse events  as assessed by CTCAE v3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00956670"], "EPCD": ["July 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["The Lymphedema and Gynecologic ", " (LEG) Study: Incidence, Risk Factors, and Impact in Newly Diagnosed Patients"], "COOM": ["Not Provided"], "SD": ["June 2012"]},
{"OPOM": ["NCF as measured by each of the 4 neurocognitive tests periodically for 5 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01417507"], "CPOM": ["NCF as measured by each of the 4 neurocognitive tests (DET, IDN, OCLT, GMLT) [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 13, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01417507?rank=44&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to neurocognitive decline in patients who progress and who do not progress radiologically, as defined by the RCI-WSD [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The cumulative incidence approach will be used to estimate the median time to neurocognitive impairment to account for the competing risk of death and to determine if there is a clinically meaningful difference in the time to neurocognitive decline, as defined by the RCI-WSD (reliable change index\u2014within-subjects standard deviation), between radiologically progressed and non-progressed patients.</div></li>\n<li style=\"margin:1ex 0.5ex\">PFS [\u00a0Time\u00a0Frame:\u00a0The interval from registration to progression or death, whichever occurs first, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using the Kaplan-Meier method, and difference between the activation of different signaling pathways will be tested using the log rank test. Multivariate analyses with the Cox proportional hazards model for PFS will be performed to assess the activation of the signaling pathway effect adjusting for patient-specific risk factors. The covariates to be evaluated for the multivariate models are: activation of signaling pathway status, age, tumor size, and other prognostic factors.</div></li>\n<li style=\"margin:1ex 0.5ex\">Radiological progression [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine if the NCF decline is an earlier warning biomarker to radiologic progression, we will use NCF change as a time-dependent covariate in a Cox proportional hazards (PH) regression model with radiological progression as the endpoint. The Cox model estimates the ratio of hazard rate of radiographic failure with and without neurocognitive decline. Anticonvulsant use, tumor size, tumor histology, and further treatment received if recurrence is discovered, which may also have impact on the radiological progression, will also be considered in this Cox PH regression analysis.</div></li>\n<li style=\"margin:1ex 0.5ex\">Effect of salvage therapy on cognitive outcomes in patients who progress [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">QOL as measured by the EORTC QOL-30, EORTC QOL-BCN20, and EQ-5D [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The general linear mixed-effects model will be used to evaluate the changes of QOL and health utilities over time.</div></li>\n<li style=\"margin:1ex 0.5ex\">Frequency of seizures, evaluated using patient seizure diary [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Marginal models will be used to evaluate the change of frequencies of seizures over time for up to 5 years. Anticonvulsant use, tumor size, tumor histology, further treatment received if recurrence is discovered, and other prognostic factors will also be included in the covariates sets. The available molecular marker information will also be included as a covariate to evaluate the molecular correlates of seizure frequency.</div></li>\n<li style=\"margin:1ex 0.5ex\">Molecular correlates of QOL, NCF, seizure control, and PFS [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using the Kaplan-Meier method, and difference between the activation of different signaling pathways will be tested using the log rank test. Multivariate analyses with the Cox proportional hazards model for OS will be performed to assess the activation of the signaling pathway effect adjusting for patient-specific risk factors. The covariates to be evaluated for the multivariate models are: activation of signaling pathway status, age, tumor size, and other prognostic factors.</div></li>\n<li style=\"margin:1ex 0.5ex\">Symptomatic or clinical progression [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Symptomatic and clinical progression will be explored for the correlation with cognitive changes in addition to radiological progression.</div></li>\n</ul></td>"], "BT": ["Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain ", " Who Have Undergone Surgery"], "OOOM": ["Not Provided"], "LUD": ["December 20, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to neurocognitive decline as defined by the RCI-WSD [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">PFS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Association of cognitive function and radiological progression [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Effect of salvage therapy on cognitive outcomes in patients who progress [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">QOL as measured by the EORTC QLQ-C30,  EORTC QLQ-BCN20, and  EQ-5D [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequency of seizures [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Molecular correlates of QOL, NCF, seizure control, and PFS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Association between change in cognitive function and symptomatic progression or clinical progression [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01417507"], "EPCD": ["December 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients With Supratentorial Low-Risk Grade II Glioma"], "COOM": ["Not Provided"], "SD": ["October 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00898755"], "CPOM": [], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00898755?rank=49&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Tissue From Young Patients With "], "OOOM": ["Not Provided"], "LUD": ["November 22, 2012"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00898755"], "EPCD": ["Not Provided"], "OT": ["Establishing Continuous Cell Lines and Xenografts From Pediatric ", " for Biological and Pre-Clinical Therapeutic Studies"], "COOM": ["Not Provided"], "SD": ["March 2007"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT00437060"], "CPOM": [], "FRD": ["February 15, 2007"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00437060?rank=51&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Correlation between neuropsychological outcomes and acute neurotoxicity [\u00a0Time\u00a0Frame:\u00a0Up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</td>"], "BT": ["Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia"], "OOOM": ["Not Provided"], "LUD": ["February 21, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00437060"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Study of Neurocognitive Function in Children Treated for ALL"], "COOM": ["Not Provided"], "SD": ["January 2007"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02012699"], "CPOM": ["Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC) [\u00a0Time\u00a0Frame:\u00a025 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 2, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02012699?rank=46&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Procurement and banking of excess biological material for future analysis [\u00a0Time\u00a0Frame:\u00a025 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">This is a registry and biobank and will continue to accrue indefinitely</div></td>"], "BT": [" Research Repository for Individuals With ", " Diagnosis and High Risk Individuals."], "OOOM": [], "LUD": ["December 10, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02012699"], "EPCD": ["December 2099 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Integrated ", " Repository for ", " Research"], "COOM": ["Collection and banking of blood, DNA, and urine samples for future analysis that will be proposed in future IRB submissions [\u00a0Time\u00a0Frame:\u00a025 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "SD": ["November 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02115282"], "CPOM": [], "FRD": ["April 14, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02115282?rank=50&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response, defined as the proportion of patients with complete response (CR) or partial response (PR) among all patients assessed per RESIST v1.1 [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Objective response in the two arms will be evaluated by comparing objective response rate (ORR, PR+CR) using a Fisher's exact test on the intention-to-treat patients with one-sided type I error of 2.5%. ORR will be summarized along with the exact binomial 95% confidence interval. In all analyses, P-values will be two-sided.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of toxicity graded according to National Cancer Institute CTCAE version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">All treatment-emergent and baseline adverse events and hematological/biochemical toxicities based on laboratory measurements, as well as drug related AEs, will be summarized by treatment group and worst grade. The incidence of deaths and treatment-emergent serious AEs (defined as number of patients experiencing the AE divided by all treated patients) will be summarized and compared between treatment arms using Fisher's exact test. Also, the incidence of adverse events leading to discontinuation of investigational product and/or withdrawal from the study will be summarized and listed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to treatment deterioration (TTD) assessed per RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0Time from randomization to disease progression or death or worsening of symptoms, whichever occurs first, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The distribution of TTD will be estimated using Kaplan-Meier method, and TTD comparisons between treatment arms will be tested primarily using log-rank test. Cox proportional-hazards models will be conducted to estimate the HR for treatment effect for TTD as a supportive analysis.</div></li>\n</ul></td>"], "BT": ["Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast ", " That Is Locally Advanced or Metastatic"], "OOOM": [], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02115282"], "EPCD": ["February 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients With Hormone Receptor-Positive Advanced Breast "], "COOM": [], "SD": ["March 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01242800"], "CPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 16, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01242800?rank=52&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Uncontrolled chest wall disease [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Health-related quality of life [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast "], "OOOM": ["Not Provided"], "LUD": ["February 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Uncontrolled chest wall disease [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Health-related quality of life [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01242800"], "EPCD": ["June 2025 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary ", " in Patients With Metastatic Breast "], "COOM": ["Not Provided"], "SD": ["February 2011"]},
{"OPOM": ["Disease-free survival"], "CH": ["/ct2/archive/NCT00499330"], "CPOM": ["Disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 10, 2007"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00499330?rank=54&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of loco-regional and systemic recurrence [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pulmonary function as measured by expiratory flow rate 6 months postoperatively [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["February 15, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival</li>\n<li style=\"margin:1ex 0.5ex\">Rate of loco-regional and systemic recurrence</li>\n<li style=\"margin:1ex 0.5ex\">Pulmonary function as measured by expiratory flow rate 6 months postoperatively</li>\n</ul></td>"], "record_id": ["NCT00499330"], "EPCD": ["March 2021 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (\u2264 2 CM) Peripheral Non-Small Cell Lung "], "COOM": ["Not Provided"], "SD": ["June 2007"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00939770"], "CPOM": [], "FRD": ["July 14, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00939770?rank=53&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Antitumor activity of crizotinib in children with relapsed or refractory solid tumors or ALCL [\u00a0Time\u00a0Frame:\u00a0Up to 30 days post treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Antitumor activity of crizotinib in children with relapsed or refractory neuroblastoma or ALCL [\u00a0Time\u00a0Frame:\u00a0Up to 30 days post treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relationship between response to treatment and anaplastic lymphoma kinase gene status in children with relapsed or refractory neuroblastoma or ALCL [\u00a0Time\u00a0Frame:\u00a0Up to 30 days post treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relationship between minimal residual disease status and clinical response to treatment in children with ALCL [\u00a0Time\u00a0Frame:\u00a0Up to 30 days post treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Crizotinib in Treating Young Patients With Relapsed or Refractory Solid ", " or Anaplastic Large Cell Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["June 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Antitumor activity of MET tyrosine kinase inhibitor PF-02341066 in children with relapsed or refractory solid tumors or ALCL [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Antitumor activity of MET tyrosine kinase inhibitor PF-02341066 in children with relapsed or refractory neuroblastoma or ALCL [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relationship between response to treatment and anaplastic lymphoma kinase gene status in children with relapsed or refractory neuroblastoma or ALCL [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relationship between minimal residual disease status and clinical response to treatment in children with ALCL [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00939770"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid ", ", Primary CNS ", ", and Anaplastic Large Cell Lymphoma"], "COOM": ["Not Provided"], "SD": ["September 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01652196"], "CPOM": ["Proportion of patients alive and progression-free [\u00a0Time\u00a0Frame:\u00a0At 15 months from initiation of therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 25, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01652196?rank=47&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) defined as the proportion of patients who achieve a PR or CR based on RECIST 1.1 criteria divided by the total number of evaluable patients [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summarized as a proportion with corresponding 95% confidence interval.</div></li>\n<li style=\"margin:1ex 0.5ex\">Percentage of patients able to undergo surgery [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summarized as a proportion with corresponding 95% confidence interval.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0From study entry to the time of progressive disease and/or death, assessed up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be evaluated using the methods of Kaplan and Meier.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0From study entry to time of death due to any cause, assessed up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be evaluated using the methods of Kaplan and Meier.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of severe (grade 3+) adverse events or toxicities, assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Tolerability in terms of number of patients who require dose modifications and/or dose delays [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal "], "OOOM": ["Not Provided"], "LUD": ["March 18, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) defined as the proportion of patients who achieve a PR or CR based on RECIST 1.1 criteria divided by the total number of evaluable patients [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summarized as a proportion with corresponding 95% confidence interval.</div></li>\n<li style=\"margin:1ex 0.5ex\">Percentage of patients able to undergo surgery [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summarized as a proportion with corresponding 95% confidence interval.</div></li>\n<li style=\"margin:1ex 0.5ex\">PFS [\u00a0Time\u00a0Frame:\u00a0From study entry to the time of progressive disease and/or death, assessed up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be evaluated using the methods of Kaplan and Meier.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0From study entry to time of death due to any cause, assessed up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be evaluated using the methods of Kaplan and Meier.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of severe (grade 3+) adverse events or toxicities, assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Tolerability in terms of number of patients who require dose modifications and/or dose delays [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients who go off treatment due to adverse reactions or even those who refuse further treatment for lesser toxicities that inhibit their willingness to continue participation on the trial [\u00a0Time\u00a0Frame:\u00a0Up to 4 weeks post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01652196"], "EPCD": ["September 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal "], "COOM": ["Not Provided"], "SD": ["November 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00919750"], "CPOM": [], "FRD": ["June 11, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00919750?rank=55&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Blood and Brain ", " Tissue Samples From Children With Brain "], "OOOM": ["Not Provided"], "LUD": ["November 9, 2012"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00919750"], "EPCD": ["Not Provided"], "OT": ["A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain ", " Research Specimens"], "COOM": ["Not Provided"], "SD": ["March 2005"]},
{"OPOM": ["to determine the feasibility of using a resistance training and nutritional counseling intervention in head and neck cancer patients, including study acceptance, recruitment rates, intervention process evaluation, and adherence [\u00a0Time\u00a0Frame:\u00a0March 2009 - January 2011\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00827164"], "CPOM": ["Number of head and neck cancer patients recruited to participate [\u00a0Time\u00a0Frame:\u00a0up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 21, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00827164?rank=59&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">change in muscle strength [\u00a0Time\u00a0Frame:\u00a0baseline, week 6, and week 12\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">dynamometer measurement</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of patients who adhere to cohort activity schedule [\u00a0Time\u00a0Frame:\u00a0baseline, week 6, and week 12\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">completion of exercise or diet recommendations</div></li>\n<li style=\"margin:1ex 0.5ex\">change in lean body mass [\u00a0Time\u00a0Frame:\u00a0baseline, week 6, week 12\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">bioelectrical impedence</div></li>\n<li style=\"margin:1ex 0.5ex\">change in physical functioning [\u00a0Time\u00a0Frame:\u00a0baseline, week 6, week 12\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">physical performance by doing a semi-tandem, tandem, or side by side stance with the feet, an 8 foot walk time, and 5 chair rise and sits</div></li>\n<li style=\"margin:1ex 0.5ex\">change in fatigue level [\u00a0Time\u00a0Frame:\u00a0baseline, week 6, week 12\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">13-item Functional Assessment of Cancer Therapy-Fatigue scale</div></li>\n<li style=\"margin:1ex 0.5ex\">change in quality of life [\u00a0Time\u00a0Frame:\u00a0baseline, week 6, week 12\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">37-item Functional Assessment of Cancer Therapy-Head and Neck scale</div></li>\n</ul></td>"], "BT": ["Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal "], "OOOM": ["Not Provided"], "LUD": ["January 3, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">to compare the effect of resistance training plus nutritional counseling versus nutritional counseling alone on muscle strength, lean body mass, physical functioning, fatigue, and quality of life in head and neck patients [\u00a0Time\u00a0Frame:\u00a0March 2009 - January 2011\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "record_id": ["NCT00827164"], "EPCD": ["May 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal "], "COOM": ["Not Provided"], "SD": ["January 2011"]},
{"OPOM": ["physical activity assessment [\u00a0Time\u00a0Frame:\u00a014 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT00929617"], "CPOM": [], "FRD": ["June 26, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00929617?rank=57&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">change in treadmill fitness [\u00a0Time\u00a0Frame:\u00a0baseline, 3 months, 6 months,  12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Treadmill fitness will be measured by sub-maximal fitness test. Change will be calculated as difference between baseline and 3 endpoints (3, 6 and 12 months).</div></li>\n<li style=\"margin:1ex 0.5ex\">change in muscle strength test [\u00a0Time\u00a0Frame:\u00a0baseline, 3 months, 6 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Muscle strength will be measured with a back and leg dynamometer. Change will be calculated as difference between baseline and 3 endpoints (3, 6 and 12 months).</div></li>\n<li style=\"margin:1ex 0.5ex\">change in waist-to-hip ratio [\u00a0Time\u00a0Frame:\u00a0baseline, 3 months, 6 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Waist-to-hip ratio will be measured with a tape measure. Change will be calculated as difference between baseline and 3 endpoints (3, 6 and 12 months).</div></li>\n<li style=\"margin:1ex 0.5ex\">change in 3-day dietary intake [\u00a0Time\u00a0Frame:\u00a0baseline, 3 months, 6 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">3-day dietary intake will be measured by questionnaire. Change will be calculated as difference between baseline and 3 endpoints (3, 6 and 12 months).</div></li>\n</ul></td>"], "BT": ["Enhancing Physical Activity Adherence After Breast ", " Diagnosis (BEAT ", " II)"], "OOOM": ["Not Provided"], "LUD": ["March 24, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">treadmill [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">muscle strength test [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">waist-to-hip ratio [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">3-day dietary intake [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00929617"], "EPCD": ["August 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Enhancing Physical Activity Adherence After Breast ", " Diagnosis (BEAT ", " Study II)"], "COOM": ["Not Provided"], "SD": ["June 2010"]},
{"OPOM": ["Overall survival (OS) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00936390"], "CPOM": ["Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death due to any cause.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 8, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00936390?rank=56&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Biochemical failure according to  the Phoenix (nadir + 2) definition [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented rise in PSA of 2 ng/ml above the post treatment nadir value.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local recurrence [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first palpable progression or pathologic confirmation of local progression or to the date of first biochemical failure (nadir +2ng/ml) once the possibility of distant metastasis is ruled out.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Regional recurrence [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented progression in pelvic lymph nodes or the date of first documented biochemical failure (BCF) if the CT of the pelvis was prompted by a BCF.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Distant metastasis [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented metastatic disease by any measure or to the date of first documented biochemical failure if diagnostic imaging is prompted by BCF.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prostate cancer-specific mortality [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death due to prostate cancer/complication of treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Non-prostate cancer-specific mortality [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death without the evidence of prostate cancer/complication of treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of salvage androgen-deprivation therapy [\u00a0Time\u00a0Frame:\u00a0From the end of treatment to the date of first administration of ADT.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates of OS for patients treated with the 3 different radiotherapy modalities in each arm [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death due to any cause.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of \"acute\" adverse events as assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE)  v. 4.0 [\u00a0Time\u00a0Frame:\u00a0From the start of radiation therapy (RT) to first occurrence of worse severity of adverse event within 30 days after the completion of RT.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to \"late\" grade 3+ adverse events as assessed by NCI CTCAE v. 4.0 [\u00a0Time\u00a0Frame:\u00a0From the date of completion of RT to the date of first grade 3 or above adverse event occurring 30 days after the completion of RT.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Freedom from Failure [\u00a0Time\u00a0Frame:\u00a0From date of randomization to the date of first event of biochemical failure or local recurrence or regional reccurrence or distant metastasis.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Comparison of prostate cancer-specific health related quality of life (HRQOL) change as measured by EPIC [\u00a0Time\u00a0Frame:\u00a0From date of randomization to the following times: last week of RT, 6 months, 1 year and 5 years post RT.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Comparison of fatigue status as measured by the Patient Reported Outcome Measurement Information System (PROMIS) fatigue domain [\u00a0Time\u00a0Frame:\u00a0From date of randomization to the following times: last week of RT, 6 months, 1 year and 5 years post RT.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Assessment and comparison of Quality Adjusted Life Years (QALYs) [\u00a0Time\u00a0Frame:\u00a0From date of randomization to the following times: last week of RT, 6 months, 1 year and 5 years post RT.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation between the fatigue PROMIS score change and plasma cytokine change [\u00a0Time\u00a0Frame:\u00a0From date of randomization to 3 weeks from start of RT.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate "], "OOOM": ["Not Provided"], "LUD": ["July 21, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Biochemical failure according to  the Phoenix (nadir + 2) definition [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local recurrence [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Regional recurrence [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Distant metastasis [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prostate cancer-specific mortality [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Non-prostate cancer-specific mortality [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of salvage ADT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates of OS for patients treated with the 3 different RT modalities in each arm [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of \"acute\" adverse events as assessed by NCI CTCAE  v. 3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to \"late\" grade 3+ adverse events as assessed by NCI CTCAE v. 3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00936390"], "EPCD": ["December 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate "], "COOM": ["Not Provided"], "SD": ["September 2009"]},
{"OPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00956007"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0From randomization to date of death or last follow-up.  Analysis occurs after 372 events have been reported.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 8, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00956007?rank=58&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Adverse events (dysphagia, xerostomia, and skin toxicity) according to CTCAE, v. 4 and their relationships with patient-reported outcomes at  3, 12, and 24 months [\u00a0Time\u00a0Frame:\u00a0From start of treatment to 2 years after end of treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Other acute adverse events (\u2264 90 days from start of radiotherapy [RT]) according to CTCAE, v. 4 [\u00a0Time\u00a0Frame:\u00a0From start of treatment to 90 days.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Other late  adverse events (&gt; 90 days from start of RT) according to CTCAE, v. 4 [\u00a0Time\u00a0Frame:\u00a0From 90 days after start of treatment to last follow-up.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease-free survival [\u00a0Time\u00a0Frame:\u00a0From randomization to date of failure (local, regional or distant progression or death) or last follow-up.  Analysis occurs at the same time as the primary outcome.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Loco-regional control [\u00a0Time\u00a0Frame:\u00a0From randomization to date of failure (local or regional progression or distant progression or death) or last follow-up. Analysis occurs at the same time as the primary outcome.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life as measured by Functional Assessment of Cancer Therapy-Head &amp; Neck (FACT-HN) and EuroQol (EQ-5D) at baseline and at 3, 12, and 24 months [\u00a0Time\u00a0Frame:\u00a0From randomization to 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Xerostomia as measured by University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS) at baseline and at 3, 12, and 24 months [\u00a0Time\u00a0Frame:\u00a0From randomization to 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Swallowing as measured by the normalcy of diet subscale of the Performance Status Scale for Head and Neck Cancer (PSS-HN) at baseline and at  3, 12, and 24 months [\u00a0Time\u00a0Frame:\u00a0From randomization to 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Skin toxicity as measured by the Dermatology Life Quality Index (DLQI) at baseline and at 3, 12, and 24 months [\u00a0Time\u00a0Frame:\u00a0From randomization to 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck "], "OOOM": ["Not Provided"], "LUD": ["May 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Adverse events (dysphagia, xerostomia, and skin toxicity) according to CTCAE v3.0 and their relationships with patient-reported outcomes at  3, 12, and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Other acute adverse events (\u2264 90 days from start of radiotherapy [RT]) according to CTCAE v3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Other late  adverse events (&gt; 90 days from start of RT) according to CTCAE v3.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Loco-regional control [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life as measured by Functional Assessment of Cancer Therapy-Head &amp; Neck (FACT-HN) and EuroQol (EQ-5D) at baseline and at 3, 12, and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Xerostomia as measured by University of Michigan Xerostomia-Related Quality of Life Scale (XeQOLS) at baseline and at 3, 12, and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Swallowing as measured by the normalcy of diet subscale of the Performance Status Scale for Head and Neck Cancer (PSS-HN) at baseline and at  3, 12, and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Skin toxicity as measured by the Dermatology Life Quality Index (DLQI) at baseline and at 3, 12, and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00956007"], "EPCD": ["August 2021 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck "], "COOM": ["Not Provided"], "SD": ["November 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01498289"], "CPOM": [], "FRD": ["December 22, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01498289?rank=60&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response rate [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction "], "OOOM": ["Not Provided"], "LUD": ["July 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response rate [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01498289"], "EPCD": ["March 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) "], "COOM": ["Not Provided"], "SD": ["February 2012"]},
{"OPOM": ["Change in age-adjusted scores at week six from baseline in any of the 5 questionnaires [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01381718"], "CPOM": ["Change in age-adjusted scores at week six from baseline in any of the 5 questionnaires [\u00a0Time\u00a0Frame:\u00a06 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 23, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01381718?rank=61&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and toxicity of modafinil [\u00a0Time\u00a0Frame:\u00a030 days post intervention\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Improved executive function (apart from working memory) as assessed by BRIEF and CogState [\u00a0Time\u00a0Frame:\u00a06 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Reduced fatigue as assessed by PedsQL [\u00a0Time\u00a0Frame:\u00a06 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Modafinil in Treating Children With Memory and Attention Problems Caused by ", " Treatment for a Brain "], "OOOM": ["Not Provided"], "LUD": ["May 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and toxicity of modafinil [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Improved executive function (apart from working memory) as assessed by BRIEF and CogState [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Reduced fatigue as assessed by PedsQL [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01381718"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain "], "COOM": ["Not Provided"], "SD": ["August 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01564368"], "CPOM": [], "FRD": ["March 24, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01564368?rank=63&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Changes in ADC value, DCE-MRI tumor volume, and SER [\u00a0Time\u00a0Frame:\u00a0Until surgery\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Effectiveness of the individual measurement's changes in ADC value, DCE-MRI tumor volume, and SER [\u00a0Time\u00a0Frame:\u00a0Until surgery\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Test-retest reproducibility of DW-MRI ADC metric [\u00a0Time\u00a0Frame:\u00a0Pre-treatment MRI\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["DWI in Assessing Treatment Response in Patients With Breast ", " Receiving Neoadjuvant Chemotherapy"], "OOOM": ["Not Provided"], "LUD": ["May 1, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Changes in ADC value, DCE-MRI tumor volume, and SER [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Effectiveness of the individual measurement's changes in ADC value, DCE-MRI tumor volume, and SER [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Test-retest reproducibility of DW-MRI ADC metric [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01564368"], "EPCD": ["February 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast ", " Response to Neoadjuvant Treatment: A Sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And MoLecular Analysis)"], "COOM": ["Not Provided"], "SD": ["August 2012"]},
{"OPOM": ["Tolerance to study treatment, defined as completing four cycles of study treatment, without dose reductions or treatment delays of over seven days [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT01366183"], "CPOM": [], "FRD": ["June 2, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01366183?rank=62&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Changes in quality-of-life measured by FACT-O, FACT/GOG-Ntx-4 subscale, IADL, and ADL [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 6 weeks after completion of course 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The changes in FACT-O, FACT/GOG-Ntx-4 subscale, IADL, and ADL will be summarized descriptively as the differences of scores between pre and post chemotherapy. Assuming 80% of patients complete the assessment at the completion of chemotherapy, then a sample of 148 patients will provide 90% power to detect 5 unit changes in FACT-O, 0.5 unit change in FACT/GOG-Ntx subscale score, 1 unit change in IADL or ADL score using paired t-test at significant level of 0.05.</div></li>\n<li style=\"margin:1ex 0.5ex\">Changes in comorbidity index measured by the Charlson scale [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 6 weeks after completion of course 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in nutritional status measured by weight [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 6 weeks after completion of course 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The changes in weight will be summarized descriptively as the differences of scores between pre and post chemotherapy. The change of nutritional status after completing chemotherapy will be examined using McNemar's test.</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical response of elderly patients with ovarian, primary peritoneal cavity, or fallopian tube cancer [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Percent of patients reporting adverse events as assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events [\u00a0Time\u00a0Frame:\u00a0Up to 6 weeks after course 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The probability of an adverse event will be estimated as the percent of patients reporting an adverse event out of all patients beginning treatment.</div></li>\n</ul></td>"], "BT": ["Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube "], "OOOM": ["Not Provided"], "LUD": ["March 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Quality-of-life, comorbidity index, and nutritional status  at baseline, prior to course 3, and  at 3-6 weeks after completion of course 4 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical response of elderly patients with ovarian, primary peritoneal cavity, or fallopian tube cancer [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Adverse events as assessed by NCI CTCAE [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01366183"], "EPCD": ["December 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube "], "COOM": ["Pharmacokinetic parameters including paclitaxel AUC, carboplatin AUC, paclitaxel total body clearance, and time that plasma paclitaxel concentration remains above threshold 0.05 uM/L [\u00a0Time\u00a0Frame:\u00a0Pre-dose, 1, 6, and 24 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "SD": ["August 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01266460"], "CPOM": [], "FRD": ["December 23, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01266460?rank=68&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Distribution of overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Characterized with Kaplan-Meier plots and estimates of the median time until death.</div></li>\n<li style=\"margin:1ex 0.5ex\">Distribution of progression-free survival [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Characterized with Kaplan-Meier plots and estimates of the median time until progression.</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients who have objective tumor response (complete or partial) [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical "], "OOOM": ["Not Provided"], "LUD": ["March 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Distribution of overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Distribution of progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients who have objective tumor response (complete or partial) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01266460"], "EPCD": ["October 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Evaluation of ADXS11-001 (NSC 752718, BB-IND#13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix"], "COOM": ["Changes in clinical immunology based upon serum [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 24 hours after dose 3\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "SD": ["May 2011"]},
{"OPOM": ["Freedom from progression (FFP)"], "CH": ["/ct2/archive/NCT00567580"], "CPOM": ["Freedom from progression (FFP) [\u00a0Time\u00a0Frame:\u00a0From date of randomization to the first occurrence of biochemical failure by the Phoenix definition (PSA >= 2 ng/ml over the nadir PSA), clinical failure (local, regional or distant) or death from any cause.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 4, 2007"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00567580?rank=66&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Secondary biochemical failure [\u00a0Time\u00a0Frame:\u00a0From date of randomization to a detectable PSA rising for at least two values with the second value at 0.4 ng/mL or greater.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Hormone-refractory disease [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the third of three rises of PSA after the institution of salvage hormone therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local failure [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the development of a new palpable abnormality in the prostate bed after enrollment in the protocol.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Distant metastasis [\u00a0Time\u00a0Frame:\u00a0From randomization to documented (by imaging) distant disease.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cause-specific mortality [\u00a0Time\u00a0Frame:\u00a0From date of randomization to the date of death due to prostate cancer.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall mortality [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death due to any cause.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of acute adverse events \u2264 90 days of the completion of radiotherapy (RT) [\u00a0Time\u00a0Frame:\u00a0From the date radiation treatment completion to the first occurrence of worst severity of an adverse event within 90 days.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to late grade 2+ and 3+ adverse events assessed &gt; 90 days from the completion of RT [\u00a0Time\u00a0Frame:\u00a0From date of randomization to the first occurrence of grade 2+ or 3+ adverse event &gt; 90 days after the radiation therapy completion date.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Comparison of disease-specific health related quality of life (HRQOL) change by EPIC, Hopkins Verbal Learning Test Revised (HVLT-R), Trail Making Test, parts A &amp; B, and Controlled Oral Word Association Test (COWAT) [\u00a0Time\u00a0Frame:\u00a0From the 6th week of radiation therapy to 5 years post radiation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Assessment of mood and depression change using QOL measured by the Hopkins Symptom Checklist (HSCL-25) [\u00a0Time\u00a0Frame:\u00a0From the 6th week of radiation therapy to 5 years post radiation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Assessment and comparison of Quality Adjusted Life Year (QALY) and Quality Adjusted FFP Year (QAFFPY) [\u00a0Time\u00a0Frame:\u00a0From the 6th week of radiation therapy to 5 years post radiation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Evaluation and comparison of the cost-utility using EuroQoL - 5 Dimensions (EQ-5D) [\u00a0Time\u00a0Frame:\u00a0From the 6th week of radiation therapy to 5 years post radiation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Association between serum levels of beta-amyloid (Abeta) and measures of HSCL-25, the HVLT-R, Trail Making Test, parts A &amp; B, or the COWAT [\u00a0Time\u00a0Frame:\u00a0From the 6th week of radiation therapy to 5 years post radiation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prognostic value of genomic and proteomic markers for the primary and secondary clinical endpoints [\u00a0Time\u00a0Frame:\u00a0Date of randomization to timepoint of the respective primary or secondary endpoint.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Assessment of  the relationship(s) between the American Urological Association Symptom Index (AUA SI) and urinary morbidity (Adverse Event terms: Urinary frequency/urgency) using the CTCAE v. 3.0 grading system [\u00a0Time\u00a0Frame:\u00a0From the 6th week of radiation therapy to 5 years post radiation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate "], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Secondary biochemical failure</li>\n<li style=\"margin:1ex 0.5ex\">Hormone-refractory disease</li>\n<li style=\"margin:1ex 0.5ex\">Local failure</li>\n<li style=\"margin:1ex 0.5ex\">Distant metastasis</li>\n<li style=\"margin:1ex 0.5ex\">Cause-specific mortality</li>\n<li style=\"margin:1ex 0.5ex\">Overall mortality</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of acute adverse events \u2264 90 days of the completion of radiotherapy (RT)</li>\n<li style=\"margin:1ex 0.5ex\">Time to late grade 2+ and 3+ adverse events assessed &gt; 90 days from the completion of RT</li>\n<li style=\"margin:1ex 0.5ex\">Comparison of disease-specific health related quality of life (HRQOL) change by EPIC, HVLT-R, Trail Making Test, parts A &amp; B, and COWAT</li>\n<li style=\"margin:1ex 0.5ex\">Assessment of mood and depression change using QOL measured by the HSCL-25</li>\n<li style=\"margin:1ex 0.5ex\">Assessment and comparison of Quality Adjusted Life Year (QALY) and Quality Adjusted FFP Year (QAFFPY)</li>\n<li style=\"margin:1ex 0.5ex\">Evaluation and comparison of the cost-utility using EQ-5D</li>\n<li style=\"margin:1ex 0.5ex\">Association between serum levels of beta-amyloid (Abeta) and measures of HSCL-25, the HVLT-R, Trail Making Test, parts A &amp; B, or the COWAT</li>\n<li style=\"margin:1ex 0.5ex\">Prognostic value of genomic and proteomic markers for the primary and secondary clinical endpoints</li>\n<li style=\"margin:1ex 0.5ex\">Collection of  paraffin-embedded tissue blocks, serum, plasma, urine, and buffy coat cells for future translational research analyses</li>\n<li style=\"margin:1ex 0.5ex\">Assessment of  the relationship(s) between the American Urological Association Symptom Index (AUA SI) and urinary morbidity (Adverse Event terms: Urinary frequency/urgency) using the CTCAE v. 3.0 grading system</li>\n</ul></td>"], "record_id": ["NCT00567580"], "EPCD": ["December 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate ", " Patients With a Rising PSA After Radical Prostatectomy"], "COOM": ["Not Provided"], "SD": ["February 2008"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01150045"], "CPOM": ["Disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 23, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01150045?rank=64&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Recurrence-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival at 3 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity of celecoxib [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cardiovascular-specific events [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Differences in toxicity, particularly cumulative peripheral neuropathy, of 6 vs 12 courses of FOLFOX [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon ", " Previously Treated With Surgery"], "OOOM": ["Not Provided"], "LUD": ["February 17, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01150045"], "EPCD": ["December 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon "], "COOM": ["Not Provided"], "SD": ["June 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01625260"], "CPOM": [], "FRD": ["June 19, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01625260?rank=71&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of response [\u00a0Time\u00a0Frame:\u00a0up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">All responding patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their duration of response</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Time\u00a0Frame:\u00a0up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">All enrolled patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their progression-free survival</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Event free survival [\u00a0Time\u00a0Frame:\u00a0up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">All enrolled patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their event-free survival</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">All enrolled patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their overall survival</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Immunogenicity of ALT-801 [\u00a0Time\u00a0Frame:\u00a08 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">Measures the anti-ALT-801 and IL-2 neutralizing effects</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Tumor Typing [\u00a0Time\u00a0Frame:\u00a01 month\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">Assess the relationship between the tumor presentation of HLA-A*0201/p53 aa 264-272 complexes and the safety, immune response and clinical benefit of study treatment</p></div></li>\n</ul></td>"], "BT": ["A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder "], "OOOM": ["Not Provided"], "LUD": ["January 27, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of response [\u00a0Time\u00a0Frame:\u00a0up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">All responding patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their duration of response</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Time\u00a0Frame:\u00a0up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">All enrolled patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their progression-free survival</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Event free survival [\u00a0Time\u00a0Frame:\u00a0up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">All enrolled patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their event-free survival</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">All enrolled patients will be followed every 3 months during years 1 and 2 and every 6 month during year 3 to determine their overall survival</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Immunogenicity and pharmacokinetics profile of ALT-801 [\u00a0Time\u00a0Frame:\u00a08 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">Measures the anti-ALT-801 and IL-2 neutralizing effects</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-801</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Tumor Typing [\u00a0Time\u00a0Frame:\u00a01 month\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">For Phase Ib &amp; II</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">Assess the relationship between the tumor presentation of HLA-A*0201/p53 aa 264-272 complexes and the safety, immune response and clinical benefit of study treatment</p></div></li>\n</ul></td>"], "record_id": ["NCT01625260"], "EPCD": ["April 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder "], "COOM": ["Not Provided"], "SD": ["April 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01305941"], "CPOM": ["intracranial response rate- modified RECIST Criteria [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["February 25, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01305941?rank=72&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Intracranial Response Rate- MacDonald Criteria [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">intracranial response rate will be evaluated via gadolinium-enhanced MRI using MacDonald criteria</div></li>\n<li style=\"margin:1ex 0.5ex\">Extracranial response [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Extracranial response will be measured using RECIST 1.1 criteria.</div></li>\n<li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Toxicity will be assessed according to the NCI CTCAE v4.</div></li>\n</ul></td>"], "BT": ["A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast ", " Brain Metastases"], "OOOM": ["Not Provided"], "LUD": ["April 14, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01305941"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast ", " Brain Metastases"], "COOM": ["Not Provided"], "SD": ["September 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01874353"], "CPOM": ["Progression Free Survival (PFS) by central review of RECIST data. [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 7, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01874353?rank=73&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Efficacy in patients following platinum based chemotherapy by assessment of overall survival [\u00a0Time\u00a0Frame:\u00a0Survival assessed every 4 weeks until treatment discontinues, then assessed every 12 weeks. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of overall survival (OS).</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients following platinum based chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen (CA-125) or death [\u00a0Time\u00a0Frame:\u00a0CA-125 performed at baseline then every 4 weeks. Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks until objective radiological disease progression. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of time to earliest progression by RECIST or CA-125 or death.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients following platinum based chemotherapy by assessment of time from randomisation to second progression [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every 12 weeks for 72 weeks, then every 24 weeks thereafter until first progression. Disease then assessed per local practice until second progression. Study data collection expected to last until 2018\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation up to second progression</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to deterioration of Health-Related Quality of Life (HRQoL) as assessed by TOI and FACT-O [\u00a0Time\u00a0Frame:\u00a0Paper questionnaires completed by patient at baseline, at Day 29 and then in line with RECIST assessments, until disease progression. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the effects of olaparib maintenance monotherapy compared to placebo on the rate of deterioration of Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients with a deleterious or suspected deleterious variant in either of the BRCA genes by assessment of PFS. [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every ~12 weeks for the first 72 weeks, then every ~24 weeks thereafter, assessed until disease progression. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).</div></li>\n<li style=\"margin:1ex 0.5ex\">To determine the exposure to olaparib by Pharmacokinetic analysis [\u00a0Time\u00a0Frame:\u00a0Pharmacokinetics sampling to be performed in a subset of patients. Sampling times: Day 1 pre-dose &amp; 1 hour; Day 15 pre-dose &amp; 1 hour; Day 29 pre-dose, 0.5-1 hour, 1-3 hours 3-6 hours and 6-12 hours.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the exposure to olaparib in patients receiving olaparib maintenance monotherapy</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of olaparib by assessment of the number of AEs. [\u00a0Time\u00a0Frame:\u00a0AEs collected from informed consent until post treatment 30-day follow-up period. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of olaparib maintenance monotherapy in BRCA mutated relapsed ovarian cancer patients.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of olaparib by review of laboratory parameters, ECG and vital signs [\u00a0Time\u00a0Frame:\u00a0ssessments until study treatment discontinuation. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of olaparib maintenance monotherapy in BRCA mutated relapsed ovarian cancer patients.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy of olaparib by time to first subsequent therapy or death (TFST). [\u00a0Time\u00a0Frame:\u00a0Time elapsed from randomisation to first subsequent therapy or death. Assessed at time of primary PFS analysis and at final OS analysis. Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to first subsequent therapy or death (TFST).</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy of olaparib by time to second subsequent therapy or death (TSST). [\u00a0Time\u00a0Frame:\u00a0Time elapsed from randomisation to second subsequent therapy or death. Assessed at time of primary PFS analysis and at final OS analysis. Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second subsequent therapy or death (TSST).</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy of olaparib by time from randomisation to study treatment discontinuation or death (TDT). [\u00a0Time\u00a0Frame:\u00a0Time elapsed from randomisation to study treatment discontinuation or death. Assessed at time of primary PFS analysis and at final OS analysis. Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to study treatment discontinuation or death (TDT).</div></li>\n</ul></td>"], "BT": ["Olaparib Treatment in BRCA Mutated Ovarian ", " Patients After Complete or Partial Response to Platinum Chemotherapy"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Efficacy in patients following platinum based chemotherapy by assessment of overall survival [\u00a0Time\u00a0Frame:\u00a0Survival assessed every 4 weeks until treatment discontinues, then assessed every 12 weeks. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of overall survival (OS).</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in relapsed patients following platinum based chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen (CA-125) or death [\u00a0Time\u00a0Frame:\u00a0CA-125 performed at baseline then every 4 weeks. Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks until objective radiological disease progression. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy by assessment of time to earliest progression by RECIST or CA-125 or death.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients following platinum based chemotherapy by assessment of time from randomisation to second progression [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every 12 weeks for 72 weeks, then every 24 weeks thereafter until first progression. Disease then assessed per local practice until second progression. Study data collection expected to last until 2018\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated relapsed ovarian cancer patients who are in complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation up to second progression</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to deterioration of Health-Related Quality of Life (HRQoL) as assessed by TOI and FACT-O [\u00a0Time\u00a0Frame:\u00a0Paper questionnaires completed by patient at baseline, at Day 29 and then in line with RECIST assessments, until disease progression. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the effects of olaparib maintenance monotherapy compared to placebo on the rate of deterioration of Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated relapsed ovarian cancer patients who are in complete or partial response following platinum based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients with a deleterious or suspected deleterious variant in either of the BRCA genes by assessment of PFS. [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every ~12 weeks for the first 72 weeks, then every ~24 weeks thereafter, assessed until disease progression. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and future BRCA mutation assays (gene sequencing and large rearrangement analysis).</div></li>\n<li style=\"margin:1ex 0.5ex\">To determine the exposure to olaparib by Pharmacokinetic analysis [\u00a0Time\u00a0Frame:\u00a0Pharmacokinetics sampling to be performed in a subset of patients. Sampling times: Day 1 pre-dose &amp; 1 hour; Day 15 pre-dose &amp; 1 hour; Day 29 pre-dose, 0.5-1 hour, 1-3 hours 3-6 hours and 6-12 hours.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the exposure to olaparib in patients receiving olaparib maintenance monotherapy</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of olaparib by assessment of the number of AEs. [\u00a0Time\u00a0Frame:\u00a0AEs collected from informed consent until post treatment 30-day follow-up period. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of olaparib maintenance monotherapy in BRCA mutated relapsed ovarian cancer patients.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of olaparib by review of laboratory parameters, ECG and vital signs [\u00a0Time\u00a0Frame:\u00a0Assessments until study treatment discontinuation. Study data collection expected to last until 2018.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of olaparib maintenance monotherapy in BRCA mutated relapsed ovarian cancer patients.</div></li>\n</ul></td>"], "record_id": ["NCT01874353"], "EPCD": ["July 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian ", " Patients With a Complete or Partial Response Following Platinum Based Chemotherapy"], "COOM": ["Not Provided"], "SD": ["September 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02047253"], "CPOM": ["Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["January 20, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02047253?rank=74&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Prostate-Specific Antigen (PSA) changes [\u00a0Time\u00a0Frame:\u00a0Day 1 of every cycle (4 weeks) for the duration of treatment and then 30 days following the last treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Linear regression with PSA as the dependent variable and time as the dependent variable will be performed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Circulating Tumor Cell (CTC) enumeration [\u00a0Time\u00a0Frame:\u00a0Three collections: before study initiation, Day 1 of Cycles 2 and 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The CTC marker will be used to evaluate efficacy of response to treatment. CTC changes will include changes from unfavorable (less than or equal to 5/7.5 ml) to favorable and declines by &gt;30%.</div></li>\n<li style=\"margin:1ex 0.5ex\">Baseline whole blood 20S proteasome level [\u00a0Time\u00a0Frame:\u00a0One time blood collection prior to therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">This marker will be used to evaluate the efficacy of response to the treatment. The association of baseline whole blood 20S proteasome level with progression free survival will be examined using Cox regression.</div></li>\n<li style=\"margin:1ex 0.5ex\">Measurable disease response rate [\u00a0Time\u00a0Frame:\u00a0Every 3 cycles (12 weeks) until treatment discontinuation and then 30 days after the last treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Response and progression will be evaluated using conventional techniques (CT, MRI, x-ray).</div></li>\n<li style=\"margin:1ex 0.5ex\">Pain response [\u00a0Time\u00a0Frame:\u00a0On Day 1 of each cycle (4 weeks) for the duration of treatment and then 30 days following the last treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Pain response is defined as a two-point reduction in the present pain index (PPI) score from baseline without an increase in the analgesic use or as a reduction in analgesic use without an increase in the PPI score. Pain progression is defined as an increase in the PPI score of at least one point from the nadir, an increase in analgesic use, or a requirement of palliative radiotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Participants will be followed through survival, an expected average of 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kaplan-Meier method will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Assessment of toxicities [\u00a0Time\u00a0Frame:\u00a0On Day 1 of each cycle (4 weeks) for the duration of treatment and then 30 days following the last treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Hematologic and non-hematologic toxicities will be graded. The new international criteria proposed by the Response Evaluation Criteria In Solid Tumors (RECIST) will serve as the guideline.</div></li>\n</ul></td>"], "BT": ["Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate ", " Following Treatment"], "OOOM": ["Not Provided"], "LUD": ["June 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02047253"], "EPCD": ["April 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate ", " Following Chemotherapy and Androgen Pathway Inhibitors"], "COOM": ["Not Provided"], "SD": ["April 2014"]},
{"OPOM": ["Recurrence-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01120249"], "CPOM": ["Compare Recurrence-free survival in those patients randomized to everolimus versus those randomized to placebo. [\u00a0Time\u00a0Frame:\u00a0up to 10 years after registration\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 7, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01120249?rank=67&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Compare Overall survival in those patients randomized to everolimus versus those randomized to placebo. [\u00a0Time\u00a0Frame:\u00a0up to 10 years after registration\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Measured from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.</div></li>\n<li style=\"margin:1ex 0.5ex\">Compare Toxicity between the two study arms [\u00a0Time\u00a0Frame:\u00a0up to 54 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.</div></li>\n</ul></td>"], "BT": ["S0931, Everolimus in Treating Patients With Kidney ", " Who Have Undergone Surgery"], "OOOM": ["Not Provided"], "LUD": ["February 21, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01120249"], "EPCD": ["October 2021 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["EVEREST: EVErolimus for Renal ", " Ensuing Surgical Therapy, A Phase III Study"], "COOM": ["Not Provided"], "SD": ["April 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02095145"], "CPOM": ["Change in plasma IGF-1 [\u00a0Time\u00a0Frame:\u00a0Baseline to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 20, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02095145?rank=65&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Compliance, in terms of the number of pills missed [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summarized by treatment arm with descriptive statistics, and tested for imbalance using Wilcoxon rank-sum test.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events graded per Common Terminology Criteria for Adverse Events (CTCAE) [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Patient toxicity throughout the study will be summarized in several ways; the presence or absence of any toxicity, worst CTCAE grade, and strongest investigator-defined relationship will all be examined and characterized by treatment arm, and analyzed appropriately (Wilcoxon rank-sum for ordinal data, Fisher's exact test for dichotomous data, and log rank test for time to event data).</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in plasma biomarker levels [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Total serum PSA [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in tissue biomarker levels [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in levels of PFD constituents/metabolites [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in Gleason grade [\u00a0Time\u00a0Frame:\u00a0Baseline to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in tumor volume on prostate biopsy [\u00a0Time\u00a0Frame:\u00a0Baseline to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Pomegranate-Extract Pill in Preventing ", " Growth in Patients With Localized Prostate ", " Undergoing Active Surveillance"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Compliance, in terms of the number of pills missed [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summarized by treatment arm with descriptive statistics, and tested for imbalance using Wilcoxon rank-sum test.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events graded per Common Terminology Criteria for Adverse Events (CTCAE) [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Patient toxicity throughout the study will be summarized in several ways; the presence or absence of any toxicities, worst CTCAE grade, and strongest investigator-defined relationship will all be examined and characterized by treatment arm, and analyzed appropriately (Wilcoxon rank-sum for ordinal data, Fisher's exact test for dichotomous data, and log rank test for time to event data).</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in plasma biomarker levels [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Total serum PSA [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in tissue biomarker levels [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in levels of PFD constituents/metabolites [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Differences between the groups will be examined for the change from baseline with the appropriate tests; for dichotomous data Fisher's exact test will be used, for ordinal data Wilcoxon rank-sum test will be used, and for continuous data, and a two-sample t-test with normalizing transformation if necessary or Wilcoxon rank-sum test will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in Gleason grade [\u00a0Time\u00a0Frame:\u00a0Baseline to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in tumor volume on prostate biopsy [\u00a0Time\u00a0Frame:\u00a0Baseline to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT02095145"], "EPCD": ["May 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomx in Subjects With Clinically Localized Prostate ", " Undergoing Active Surveillance"], "COOM": ["Not Provided"], "SD": ["May 2014"]},
{"OPOM": ["MTD and/or recommended phase 2 dose of cabozantinib [\u00a0Time\u00a0Frame:\u00a028 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT01709435"], "CPOM": ["MTD and/or recommended phase 2 dose of cabozantinib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [\u00a0Time\u00a0Frame:\u00a028 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["October 16, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01709435?rank=70&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Pharmacokinetic (PK) parameters of cabozantinib including systemic exposure and drug clearance [\u00a0Time\u00a0Frame:\u00a0Course 1, day 1 (pre-dose and 4 hours post dose), course 1 day 21 (+/- 2 days) (pre-dose, 2, 4, 8 and 24 hours post dose), course 3 day 1 (pre-dose)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit). PK parameters will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease response assessed according to Response Evaluation Criteria in Solid Tumors [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be reported descriptively.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS will also be assessed and summarized using the Kaplan-Meier method.</div></li>\n</ul></td>"], "BT": ["Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid "], "OOOM": ["Not Provided"], "LUD": ["July 22, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Pharmacokinetic (PK) parameters of cabozantinib including systemic exposure and drug clearance [\u00a0Time\u00a0Frame:\u00a0Course 1, day 1 (pre-dose and 4 hours post dose), course 1 day 21 (+/- 2 days) (pre-dose, 2, 4, 8 and 24 hours post dose), course 3 day 1 (pre-dose)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease response assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be reported descriptively.</div></li>\n</ul></td>"], "record_id": ["NCT01709435"], "EPCD": ["October 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid ", ", Including CNS "], "COOM": ["Not Provided"], "SD": ["November 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01877811"], "CPOM": ["Objective Response Rate [\u00a0Time\u00a0Frame:\u00a0Approximately 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 6, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01877811?rank=69&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of Objective Response [\u00a0Time\u00a0Frame:\u00a0Approximately 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The duration of objective response is defined as the time interval from the date of first documented response (CR or PR) to disease progression or death, whichever occurs first</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease Control Rate [\u00a0Time\u00a0Frame:\u00a0Approximately 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The disease control rate is defined as the proportion of patients achieving best overall response of CR, PR, or stable disease (SD), as assessed using RECIST v1.1</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression-free Survival [\u00a0Time\u00a0Frame:\u00a0Approximately 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Progression-free survival is defined as the time interval from date of first dose of study drug to first documented disease progression or death from any cause, whichever occurs first</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a0Approximately 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Overall survival is defined as the time interval from date of first dose of study drug to date of death from any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Maximum observed plasma drug concentration (Cmax) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time of maximum observed plasma drug concentration (tmax) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the plasma drug concentration versus time curve from time 0 to infinity (AUC0-\u221e) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the plasma drug concentration versus time curve from time 0 to the last measureable drug concentration (AUC0-t) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the plasma drug concentration versus time curve from time 0 to 24 hours [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Terminal elimination rate constant (\u03bbz) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Terminal elimination half-life (t1/2) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Apparent clearance of study drug from plasma (CL/F) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Apparent volume of distribution (V/F) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Percentage extrapolation [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Predicted accumulation ratio [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 16\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">AUC for 1 dosing interval following multiple doses only (AUC\u03c4) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">AUC0-t [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cmax [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Tmax [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Observed accumulation ratio (Robs) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Steady-state accumulation ratio (Rss) [\u00a0Time\u00a0Frame:\u00a0Day 1 to Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Dose Limiting Toxicities [\u00a0Time\u00a0Frame:\u00a0From signing of the informed consent up to approximately 12 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Occurrence of Adverse Events [\u00a0Time\u00a0Frame:\u00a0From signing of the informed consent up to approximately 12 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["CEP-32496 in Patients With Advanced Solid ", " in Phase 1 and Advanced Melanoma and Metastatic Colorectal ", " in Phase 2"], "OOOM": ["Not Provided"], "LUD": ["July 29, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01877811"], "EPCD": ["March 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients With Advanced Solid ", " in Phase 1 and in Patients With Advanced Melanoma and Metastatic Colorectal ", " With BRAF Mutation in Phase 2"], "COOM": ["Not Provided"], "SD": ["June 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01120353"], "CPOM": ["To characterize survivors' health outcomes with respect to disease-, treatment, and genetic-related factors. [\u00a0Time\u00a0Frame:\u00a025 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 6, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01120353?rank=75&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Childhood ", " Survivor Study"], "OOOM": ["Not Provided"], "LUD": ["April 17, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01120353"], "EPCD": ["March 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Childhood ", " Survivor Study"], "COOM": ["Not Provided"], "SD": ["March 1994"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02116777"], "CPOM": [], "FRD": ["April 15, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02116777?rank=76&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent "], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT02116777"], "EPCD": ["January 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent "], "COOM": ["Not Provided"], "SD": ["May 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00715832"], "CPOM": ["toxicity [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["July 10, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00715832?rank=77&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Response, Survival, Immunological Monitoring, Time to Disease Progression [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["A Phase I ", " Vaccine Study for Patients With Metastatic Breast "], "OOOM": ["Not Provided"], "LUD": ["August 25, 2009"], "OSOM": ["<td class=\"body3\" valign=\"top\">Response, Survival, Immunolgical Monitoring, Time to Disease Progression [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "record_id": ["NCT00715832"], "EPCD": ["February 2010 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase I Vaccine Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast "], "COOM": ["Not Provided"], "SD": ["May 2008"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01886677"], "CPOM": ["Tumor Proliferation Rate (Ki-67) [\u00a0Time\u00a0Frame:\u00a0Participants will be followed until their prostatectomy (minimum of 3.5 weeks, up to 24 weeks)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 19, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01886677?rank=78&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Changes in  body weight and composition, energy intake and physical activity [\u00a0Time\u00a0Frame:\u00a0Participants will be followed until their prostatectomy (minimum of 3.5 weeks, up to 24 weeks)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Changes in body composition, energy intake and physical activity over the presurgical study period (minimum of 3.5 weeks, up to 24 weeks) will be explored and compared between the intervention and wait-list control arms.</div></td>"], "BT": ["Improving Energy Balance in Men With Prostate "], "OOOM": ["Not Provided"], "LUD": ["July 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Changes in  body composition, energy intake and physical activity [\u00a0Time\u00a0Frame:\u00a0Participants will be followed until their prostatectomy (minimum of 3.5 weeks, up to 24 weeks)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Changes in body composition, energy intake and physical activity over the presurgical study period (minimum of 3.5 weeks, up to 24 weeks) will be explored and compared between the intervention and wait-list control arms.</div></td>"], "record_id": ["NCT01886677"], "EPCD": ["September 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Exploring the Impact of Negative Energy Balance in Men With Prostate "], "COOM": ["Not Provided"], "SD": ["September 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01843062"], "CPOM": ["Complete remission rate in overall study population [\u00a0Time\u00a0Frame:\u00a0Measured at 18 months post radioactive iodine treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 14, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01843062?rank=79&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Clinical remission rate in overall study population [\u00a0Time\u00a0Frame:\u00a0Measured at 18 months post radioactive iodine treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical remission rate in sub-group of patients with tumours known to be mutation positive for v-raf murine sarcoma viral oncogene homolog B1 or NRAS [\u00a0Time\u00a0Frame:\u00a0Measured at 18 months post radioactive iodine treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequency of adverse events graded according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE)\" [\u00a0Time\u00a0Frame:\u00a0Measured throughout the study until 3 years post radioactive iodine treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Selumetinib concentration profile over time [\u00a0Time\u00a0Frame:\u00a0In total 8 blood samples will be collected: 4 samples on pre defined time windows on Day1, and 4 samples on Day 29 or Day 30\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">N-desmethyl selumetinib concentration profile over time [\u00a0Time\u00a0Frame:\u00a0in total 8 blood samples will be collected: 4 samples on pre defined time windows on Day1, and 4 samples on Day 29 or Day 30\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Selumetinib amide concentration profile over time [\u00a0Time\u00a0Frame:\u00a0in total 8  blood samples will be collected: 4 samples on pre defined time windows on  Day1, and 4 samples on Day 29 or Day 30\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Complete remission rate in sub-group of patients with tumours known to be mutation positive for v-raf murine sarcoma viral oncogene homolog B1 or NRAS [\u00a0Time\u00a0Frame:\u00a0Measured at 18 months post radioactive iodine treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid "], "OOOM": ["Not Provided"], "LUD": ["April 2, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Clinical remission rate in overall study population [\u00a0Time\u00a0Frame:\u00a0Measured at 18 months post radioactive iodine treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical remission rate in sub-group of patients with tumours known to be mutation positive for v-raf murine sarcoma viral oncogene homolog B1 or NRAS [\u00a0Time\u00a0Frame:\u00a0Measured at 18 months post radioactive iodine treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequency of adverse events graded according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE)\" [\u00a0Time\u00a0Frame:\u00a0Measured throughout the study until 3 years post radioactive iodine treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Selumetinib concentration profile over time [\u00a0Time\u00a0Frame:\u00a0In total 8 blood samples will be collected: 4 samples on pre defined time windows on Day1, and 4 samples on Day 29 or Day 30\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">N-desmethyl selumetinib concentration profile over time [\u00a0Time\u00a0Frame:\u00a0in total 8 blood samples will be collected: 4 samples on pre defined time windows on Day1, and 4 samples on Day 29 or Day 30\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Selumetinib amide concentration profile over time [\u00a0Time\u00a0Frame:\u00a0in total 8  blood samples will be collected: 4 samples on pre defined time windows on  Day1, and 4 samples on Day 29 or Day 30\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01843062"], "EPCD": ["June 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid "], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": ["Overall clinical benefit (CR+PR+SD\u22656months) of neratinib in patients with metastatic HER2 breast cancer that carry HER2 mutation [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01670877"], "CPOM": ["Overall clinical activity (CR+PR+SD\u22656months) of neratinib in patients with metastatic HER2 breast cancer that carry HER2 mutation [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 17, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01670877?rank=80&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">PFS of patients treated with neratinib [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time to progression or death will be listed, and the progression-free survival (PFS) will be estimated using Kaplan-Meier product limit method.  For all the enrolled patients, the number and percentage of patients with HER2 mutation will be presented, and its 95% CI will also be calculated. The agreement for the occurrence of HER2 mutation in paired primary and metastatic sites will be described using contingency tables and assess by McNemar test. The association of the presence of HER2 mutation with histology subtype (invasive lobular vs invasive ductal cancer), tumor grade, tumor staging at initial diagnosis (I vs II or III vs IV), and progression-free survival (PFS) will be assessed using Fisher's exact test, Mann-Whitney rank sum test, or log-rank test as appropriate.</div></li>\n<li style=\"margin:1ex 0.5ex\">Correlate the presence of HER2 mutation with histology subtype (invasive lobular vs. invasive ductal cancer), tumor grade (grade 1-2 vs 3), tumor staging at initial diagnosis (I vs. II or III vs. IV), disease free survival in HER2- breast cancer. [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast "], "OOOM": ["Not Provided"], "LUD": ["June 2, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">PFS of patients treated with neratinib [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time to progression or death will be listed, and the progression-free survival (PFS) will be estimated using Kaplan-Meier product limit method.  For all the enrolled patients, the number and percentage of patients with HER2 mutation will be presented, and its 95% CI will also be calculated. The agreement for the occurrence of HER2 mutation in paired primary and metastatic sites will be described using contingency tables and assess by McNemar test. The association of the presence of HER2 mutation with histology subtype (invasive lobular vs invasive ductal cancer), tumor grade, tumor staging at initial diagnosis (I vs II or III vs IV), and progression-free survival (PFS) will be assessed using Fisher's exact test, Mann-Whitney rank sum test, or log-rank test as appropriate.</div></li>\n<li style=\"margin:1ex 0.5ex\">Correlate the presence of HER2 mutation with histology subtype (invasive lobular vs. invasive ductal cancer), tumor grade (grade 1-2 vs 3), tumor staging at initial diagnosis (I vs. II or III vs. IV), disease free survival in HER2- breast cancer. [\u00a0Time\u00a0Frame:\u00a0Baseline\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed using RECIST guidelines version 1.1</div></li>\n<li style=\"margin:1ex 0.5ex\">Compare the occurrence of HER2 mutation in paired primary and metastatic sites. [\u00a0Time\u00a0Frame:\u00a0Baseline\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01670877"], "EPCD": ["December 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Study of Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast "], "COOM": ["Not Provided"], "SD": ["December 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01844986"], "CPOM": ["Progression Free Survival (PFS) by central review of RECIST data [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every ~12 weeks for ~2 years, then every ~24 weeks thereafter until objective radiological disease progression.  Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 30, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01844986?rank=81&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Efficacy in patients following First Line Platinum Based Chemotherapy by assessment of overall survival. [\u00a0Time\u00a0Frame:\u00a0Survival assessed every 4 weeks until treatment discontinues or for 2 years (whichever is earlier), then assessed every 12 weeks. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of overall survival (OS).</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to deterioration of Health-Related Quality of Life (HRQoL) as assessed by TOI and FACT-O. [\u00a0Time\u00a0Frame:\u00a0Paper questionnaires completed by patient at baseline, Day 29 and then in line with RECIST assessments, until disease progression. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the effects of olaparib maintenance monotherapy compared to placebo on the rate of deterioration of Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients with a deleterious or suspected deleterious variant in either of the BRCA genes by assessment of progression free survival. [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every ~12 weeks for ~2 years, then every ~24 weeks thereafter, until disease progression. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and potential future BRCA mutation assays (gene sequencing and large rearrangement analysis).</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of olaparib by assessment of the number of AEs [\u00a0Time\u00a0Frame:\u00a0AEs collected from informed consent until post treatment 30-day follow-up period. Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of olaparib maintenance monotherapy in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients following First Line Platinum Based Chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen-125 (CA-125). [\u00a0Time\u00a0Frame:\u00a0CA125 assessed every 4 weeks for ~2 years, then every 12 weeks. Radiologic scans performed every ~12 weeks for ~2 years, then every ~24 weeks until disease progression. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen-125 (CA-125) or death.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients following First Line Platinum Based Chemotherapy by assessment of time from randomisation to second progression. [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every ~12 weeks for ~2 years, then every ~24 weeks until first progression. Then disease is assessed as per local clinical practice until 2nd progression. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation up to study completion at the latest.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of olaparib by assessment and review of laboratory parameters. [\u00a0Time\u00a0Frame:\u00a0Laboratory parameter assessments collected until study treatment discontinued. Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of olaparib maintenance monotherapy in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy of olaparib by time to first subsequent therapy or death (TFST). [\u00a0Time\u00a0Frame:\u00a0Time elapsed from randomisation to first subsequent therapy or death. Assessed at time of primary PFS analysis and at final OS analysis.  Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to first subsequent therapy or death (TFST).</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy of olaparib by time to second subsequent therapy or death (TSST). [\u00a0Time\u00a0Frame:\u00a0Time elapsed from randomisation to second subsequent therapy or death. Assessed at time of primary PFS analysis and at final OS analysis.  Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to second subsequent therapy or death (TSST).</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy of olaparib by time from randomisation to study treatment discontinuation or death (TDT). [\u00a0Time\u00a0Frame:\u00a0Time elapsed from randomisation to study treatment discontinuation or death. Assessed at time of primary PFS analysis and at final OS analysis.  Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation to study treatment discontinuation or death (TDT).</div></li>\n</ul></td>"], "BT": ["Olaparib Monotherapy in Patients With BRCA Mutated Ovarian ", " Following First Line Platinum Based Chemotherapy."], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Efficacy in patients following First Line Platinum Based Chemotherapy by assessment of overall survival. [\u00a0Time\u00a0Frame:\u00a0Survival assessed every 4 weeks until treatment discontinues or for 2 years (whichever is earlier), then assessed every 12 weeks. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of overall survival (OS).</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to deterioration of Health-Related Quality of Life (HRQoL) as assessed by TOI and FACT-O. [\u00a0Time\u00a0Frame:\u00a0Paper questionnaires completed by patient at baseline, Day 29 and then in line with RECIST assessments, until disease progression. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the effects of olaparib maintenance monotherapy compared to placebo on the rate of deterioration of Health-related Quality of Life (HRQoL) as assessed by the trial outcome index (TOI) of the Functional Assessment of Cancer Therapy - Ovarian (FACT-O) in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients with a deleterious or suspected deleterious variant in either of the BRCA genes by assessment of progression free survival. [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every ~12 weeks for ~2 years, then every ~24 weeks thereafter, until disease progression. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess efficacy of olaparib in patients identified as having a deleterious or suspected deleterious variant in either of the BRCA genes using variants identified with current and potential future BRCA mutation assays (gene sequencing and large rearrangement analysis).</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of olaparib. [\u00a0Time\u00a0Frame:\u00a0AEs collected from informed consent until post treatment 30-day follow-up period. Laboratory parameter assessments collected until study treatment discontinued. Study data collection expected to last ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of olaparib maintenance monotherapy in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients following First Line Platinum Based Chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen-125 (CA-125). [\u00a0Time\u00a0Frame:\u00a0CA125 assessed every 4 weeks for ~2 years, then every 12 weeks. Radiologic scans performed every ~12 weeks for ~2 years, then every ~24 weeks until disease progression. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time to earliest progression by RECIST or Cancer Antigen-125 (CA-125) or death.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy in patients following First Line Platinum Based Chemotherapy by assessment of time from randomisation to second progression. [\u00a0Time\u00a0Frame:\u00a0Radiologic scans performed at baseline then every ~12 weeks for ~2 years, then every ~24 weeks until first progression. Then disease is assessed as per local clinical practice until 2nd progression. Study data collection expected to last for ~7 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the efficacy of olaparib maintenance monotherapy compared to placebo in BRCA mutated high risk advanced ovarian cancer patients who are in clinical complete response or partial response following first line platinum based chemotherapy by assessment of time from randomisation up to study completion at the latest.</div></li>\n</ul></td>"], "record_id": ["NCT01844986"], "EPCD": ["July 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian ", " Following First Line Platinum Based Chemotherapy."], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01438307"], "CPOM": ["Second line treatment objective response rate [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["September 15, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01438307?rank=84&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to progression [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessment will be made on subjects with Stage IV NSCLC who receive Cabazitaxel-XRP6258 after progressing with first line platinum-based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety in subjects with Stage IV NSCLC who received Cabazitaxel-XRP6258 [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessment will be made in subjects after progressing with first line platinum-based chemotherapy. Safety will be assessed using the NCI common toxicity criteria (Version 4.0).</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessment will be made in subjects with Stage IV NSCLC who receive Cabazitaxel-SRP6258 after progressing with first line platinum-based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessment will be made in subjects with Stage IV NSCLC who receive Cabazitaxel-SRP6258 after progressing with first line platinum-based chemotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to progression in a subset of subjects [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The subset of subjects to be assessed have Stage IV NSCLC and asymptomatic brain metastases.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety in a subset of subjects [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The subset of subjects to be assessed have Stage IV NSCLC and asymptomatic brain metastases. Safety will be assessed using the NCI common toxicity criteria (Version 4.0)in addition to an MRI of the brain after every other chemotherapy cycle or at any time there is new neurological symptoms.</div></li>\n<li style=\"margin:1ex 0.5ex\">Response rate in a subset of subjects [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The subset of subjects to be assessed have Stage IV NSCLC and asymptomatic brain metastases.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival in a subset of patients [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The subset of subjects to be assessed have Stage IV NSCLC and asymptomatic brain metastases.</div></li>\n<li style=\"margin:1ex 0.5ex\">Exploratory laboratory correlation of MDR 1p-glycoprotein as to the response rate [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Demographic and baseline laboratory results will be summarized using descriptive statistics such as mean, median and frequencies. Duration of response, time to progression and overall survival will be calculated using Kaplan Meier, along with two-sided 95% confidence levels.</div></li>\n<li style=\"margin:1ex 0.5ex\">Exploratory laboratory correlation of MDR 1p-glycoprotein as to the time to progression [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Demographic and baseline laboratory results will be summarized using descriptive statistics such as mean, median and frequencies. Duration of response, time to progression and overall survival will be calculated using Kaplan Meier, along with two-sided 95% confidence levels.</div></li>\n<li style=\"margin:1ex 0.5ex\">Exploratory laboratory correlation of MDR 1p-glycoprotein as to the overall survival [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Demographic and baseline laboratory results will be summarized using descriptive statistics such as mean, median and frequencies. Duration of response, time to progression and overall survival will be calculated using Kaplan Meier, along with two-sided 95% confidence levels.</div></li>\n<li style=\"margin:1ex 0.5ex\">Exploratory laboratory correlation of MRP3 as to the response rate [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Demographic and baseline laboratory results will be summarized using descriptive statistics such as mean, median and frequencies. Duration of response, time to progression and overall survival will be calculated using Kaplan Meier, along with two-sided 95% confidence levels.</div></li>\n<li style=\"margin:1ex 0.5ex\">Exploratory laboratory correlation of MRP3 as to the time to progression [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Demographic and baseline laboratory results will be summarized using descriptive statistics such as mean, median and frequencies. Duration of response, time to progression and overall survival will be calculated using Kaplan Meier, along with two-sided 95% confidence levels.</div></li>\n<li style=\"margin:1ex 0.5ex\">Exploratory laboratory correlation of MRP3 as to the overall survival [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Demographic and baseline laboratory results will be summarized using descriptive statistics such as mean, median and frequencies. Duration of response, time to progression and overall survival will be calculated using Kaplan Meier, along with two-sided 95% confidence levels.</div></li>\n</ul></td>"], "BT": ["Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["January 16, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01438307"], "EPCD": ["July 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung ", " (NSCLC) Patients"], "COOM": ["Not Provided"], "SD": ["September 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01042379"], "CPOM": ["Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry. [\u00a0Time\u00a0Frame:\u00a0Post surgery based on upto 24-week treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 31, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01042379?rank=83&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Establishing predictive and prognostic indices based on qualification and exploratory markers to predict pCR and residual cancer burden (RCB). [\u00a0Time\u00a0Frame:\u00a0Blood and Tissue Collection: Baseline, Post-Randomization, Pre-AC, Pre- and Post-Surgery\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To determine three- and five-year relapse-free survival (RFS) and OS among the treatment arms. [\u00a0Time\u00a0Frame:\u00a0Three- and Five-Year Post-surgery Follow-up\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To determine incidence of adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities of each investigational agent tested. [\u00a0Time\u00a0Frame:\u00a0Post-Randomization, Pre-AC, Pre-Surgery, Post-Surgery upto One Year during follow-up\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">MRV [\u00a0Time\u00a0Frame:\u00a0Four time points during the on-study phase: Baseline, Post-randomization, Pre-AC treatment and Pre-Surgery\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast "], "OOOM": ["Not Provided"], "LUD": ["February 20, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01042379"], "EPCD": ["February 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)"], "COOM": ["Not Provided"], "SD": ["March 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01164163"], "CPOM": [], "FRD": ["July 15, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01164163?rank=85&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Antitumor activity [\u00a0Time\u00a0Frame:\u00a0Up to 30 days post treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity and biologic activity [\u00a0Time\u00a0Frame:\u00a0Day 1 and Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["INCB18424 in Treating Young Patients With Relapsed or Refractory Solid ", ", Leukemia, or Myeloproliferative Disease"], "OOOM": ["Not Provided"], "LUD": ["January 29, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Antitumor activity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Biologic activity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01164163"], "EPCD": ["October 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid ", ", Leukemias, and Myeloproliferative "], "COOM": ["Not Provided"], "SD": ["September 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01013649"], "CPOM": [], "FRD": ["November 13, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01013649?rank=87&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Disease-free survival [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Disease-free survival will be estimated by the Kaplan-Meier method.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequency of objective criteria of resectability as measured by preoperative imaging [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in fatigue as measured by the FACIT-F (primary) and the PROMIS derived short form (exploratory) [\u00a0Time\u00a0Frame:\u00a0Baseline up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The primary HRQoL hypothesis will be tested using the log-rank statistic with a significance level of 0.05. Additionally, analyses of fatigue effect will be performed using the Cox proportional hazard model.</div></li>\n</ul></td>"], "BT": ["Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic ", " That Has Been Removed By Surgery"], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Adverse events [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequency of objective criteria of resectability as measured by preoperative imaging [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life as measured by fatigue (FACIT-Fatigue and PROMIS-derived short form) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Laboratory correlative studies related to K-Ras in patients treated with gemcitabine hydrochloride with vs without erlotinib hydrochloride (first randomization) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01013649"], "EPCD": ["August 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II-R and a Phase III Trial Evaluating Both *Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma"], "COOM": ["Not Provided"], "SD": ["November 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01953588"], "CPOM": [], "FRD": ["September 25, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01953588?rank=86&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast ", " Undergoing Surgery"], "OOOM": ["Not Provided"], "LUD": ["March 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Pathologic complete response rate - (pCR rate) [\u00a0Time\u00a0Frame:\u00a07 years from study opening\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "record_id": ["NCT01953588"], "EPCD": ["April 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast ", " Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study"], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01846611"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 2 months after the last participant has received the last dose of study medication or when 514 deaths have been observed, whichever is later\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 1, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01846611?rank=89&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression free survival [\u00a0Time\u00a0Frame:\u00a0Up to the date of disease progression or death measured up to 2 months after the last participant has received the last dose of study medication or when 514 deaths have been\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate [\u00a0Time\u00a0Frame:\u00a0Up to 2 months after the last participant has received the last dose of study medication or when 514 deaths have been observed, whichever is later\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the concentration curve of trabectedin as derived from sparse population pharmacokinetics [\u00a0Time\u00a0Frame:\u00a0Predose Day 1, 1 hour after start of study dose infusion, 10 minutes before the end of study dose infusion, and 0.5, 24, and 168 hours after the end of study dose infusion on Cycle 1 only\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Minimum observed plasma concentration of trabectedin as derived from sparse population pharmacokinetics [\u00a0Time\u00a0Frame:\u00a0Predose Day 1, 1 hour after start of study dose infusion, 10 minutes before the end of study dose infusion, and 0.5, 24, and 168 hours after the end of study dose infusion on Cycle 1 only\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Maximum observed plasma concentration of trabectedin as derived from sparse population pharmacokinetics [\u00a0Time\u00a0Frame:\u00a0Predose Day 1, 1 hour after start of study dose infusion, 10 minutes before the end of study dose infusion, and 0.5, 24, and 168 hours after the end of study dose infusion on Cycle 1 only\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants affected by an adverse event [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after the last participant has received the last dose of study medication\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube "], "OOOM": ["Not Provided"], "LUD": ["July 15, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01846611"], "EPCD": ["October 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube "], "COOM": ["Not Provided"], "SD": ["October 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01107626"], "CPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 20, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01107626?rank=90&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective response  as measured by RECIST [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Association between bevacizumab and pemetrexed disodium population pharmacokinetics [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Association between proteomic profiles and ICAM, VEGF, and FGF-beta with the clinical outcomes  (Closed as of 04/01/2010) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["December 5, 2012"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01107626"], "EPCD": ["April 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC"], "COOM": ["Not Provided"], "SD": ["August 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02158507"], "CPOM": ["Number of subjects experiencing study-related toxicities when taking Veliparib in Combination with Lapatinib [\u00a0Time\u00a0Frame:\u00a0baseline to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["May 29, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02158507?rank=92&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Number of subjects with objective response rate (ORR) at 4 years post baseline (Complete responses [CRs] plus partial responses [PRs] [\u00a0Time\u00a0Frame:\u00a04 years post baseline\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Complete responses plus partial responses will be included as indicators of an objective response rates.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of subjects with progression free survival (PFS) at 4 years after start of study. [\u00a0Time\u00a0Frame:\u00a0Baseline to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Number of subjects who survive to 4 years with no disease progression</div></li>\n<li style=\"margin:1ex 0.5ex\">DNA methylation and RNA transcriptome will be evaluated before and after therapy; baseline pattern will be compared with the post treatment pattern to identify markers of response or resistance. [\u00a0Time\u00a0Frame:\u00a0Within 4 weeks of baseline (treatment initiation)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Analysis of the genomic data from tumors may allow us to identify if there is a gene or groups of genes that will be able to predict response  or resistance to the research combination; in order to conduct the genomic evaluation it is necessary to correlate with clinical response. In addition, we will conduct IHC studies in order to analyze markers that will indicate us if the combination of the research agents inhibit the targets for which they were designed (H2AX, BRCA and EGFR); this data needs to be correlated with clinical data to see if the lab evaluations correlate with the response of the patient. In addition, we will evaluate by IHC markers of apoptosis that will indicate us if the combination of research agents was cytotoxic against the tumor cells ; this data needs to be correlated with clinical data to see if the lab evaluations correlate with the response of the patient.</div></li>\n<li style=\"margin:1ex 0.5ex\">Measure numbers of circulating tumor cells before and after therapy [\u00a0Time\u00a0Frame:\u00a0Before and during Cycle 1 (consisting of 28 days)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Circulating tumor cells will be measured before and after therapy and will indicate if the therapy is active against the tumor; a decrease in the number of the circulating tumor cells will indicate effectiveness of the combination.</div></li>\n<li style=\"margin:1ex 0.5ex\">Peak Plasma concentration of  Veliparib and Palatinib when given in combination. [\u00a0Time\u00a0Frame:\u00a0Throughout Cycle 1 up to day 10\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">Blood samples for the first day will be collected 5 minutes before the start of therapy, 30 and 60 minutes after the first dose of Lapatinib and then 2, 4, 6, 8, and 24 hours after the start of Lapatinib. On day 2, Lapatinib and Veliparib will be given and samples will be taken 30 and 60 minutes after the first dose and then at 2, 4, 6, 8, and 24 hours. Additional blood samples will be taken on day 3, before the third day dose of the combined study drugs. The same schema will be followed on days 8, 9, and 10.</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">Each pharmacokinetic variable will be divided by dose groups for descriptive statistical analyses (mean, standard deviation, coefficient of variation, geometric mean, median, minimum and maximum per dose group).</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Measure level of the M30 before and after therapy [\u00a0Time\u00a0Frame:\u00a0baseline to cycle 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Serum levels of the apoptosis protein M30 will be measured before and after therapy and will indicate if the therapy is active against the tumor;  an increase in the level of M30 will indicate effectiveness of the combination.</div></li>\n</ul></td>"], "BT": ["Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast "], "OOOM": ["Not Provided"], "LUD": ["July 27, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02158507"], "EPCD": ["June 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast "], "COOM": ["Not Provided"], "SD": ["July 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01856855"], "CPOM": ["Early toxicity of SBRT with Integrated Boost for localized prostate cancer [\u00a0Time\u00a0Frame:\u00a0Within 3 months of the completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["April 10, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01856855?rank=88&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Treatment planning feasibility [\u00a0Time\u00a0Frame:\u00a0Within 6 months of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">Feasibility will be defined as the ability of the treatment planner to create a plan that meets the following criteria:</p>\n<ul style=\"margin-top:1ex; margin-bottom:1ex;\"><li style=\"margin-top:0.7ex;\">100% of radiation target prescription (36.25 Gy) covers greater than or equal to 95% of the target (prostate)</li>\n<li style=\"margin-top:0.7ex;\">At least 95% of the boost prostate (area within the prostate most likely harboring cancer) prescription (38.0 Gy) covers 95% of this boost target volume</li>\n<li style=\"margin-top:0.7ex;\">All normal tissue dose constraints are met -i.e., nearby rectum, bladder, and femoral heads do not exceed the recommended radiation dose limits</li>\n</ul><p style=\"margin-top:0ex; margin-bottom:1ex;\">If the physician must utilize a plan that compromises target coverage or normal tissue dose constraints to levels not meeting the criteria above, then the plan will be scored as not meeting technical feasibility requirements.</p></div></li>\n<li style=\"margin:1ex 0.5ex\">Treatment delivery quality assurance [\u00a0Time\u00a0Frame:\u00a0Within 2 years of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">All radiation plans will be validated with physicists measuring linear accelerator dose output utilizing a combination of a solid water phantom or a dose calibrated diode array. The phantom will be irradiated with the same plan as the patient including all couch angles and beam projections and will be assessed as to whether the plan meets a pre-specified validation value</div></li>\n<li style=\"margin:1ex 0.5ex\">Early Efficacy [\u00a0Time\u00a0Frame:\u00a0Within 6 months of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">Efficacy will be defined as the absence of biochemically detected (via PSA lab testing) prostate cancer or clinically detected prostate cancer at each interval follow-up visit (every three months for year one, then every 6 months for year two after treatment). \"Absence of prostate cancer\" is defined as no evidence of tumor recurrence by two methods:</p>\n<ol style=\"margin-top:1ex; margin-bottom:1ex;\"><li style=\"margin-top:0.7ex;\">No prostate cancer recurrence evident on the physical examination performed by the physician.</li>\n<li style=\"margin-top:0.7ex;\">No rise in the PSA more than 2 ng/ml above the lowest PSA value ever obtained pre or post treatment. A rise in the PSA more than 2 ng/ml from a patient's lowest value is the standard definition for post-radiation PSA biochemical prostate cancer failure.</li>\n</ol></div></li>\n<li style=\"margin:1ex 0.5ex\">Late Toxicity [\u00a0Time\u00a0Frame:\u00a0Within 6 months of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Late toxicity (defined as toxicity occuring &gt;90 days after treatment) will be assessed with regular clinical exams and patient toxicity questionnaires.</div></li>\n<li style=\"margin:1ex 0.5ex\">Late Quality of Life [\u00a0Time\u00a0Frame:\u00a0Within 6 months of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Late quality of life will be assessed with regular clinical exams and patient quality of life questionnaires.</div></li>\n</ul></td>"], "BT": ["Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate ", " (RAD 1203)"], "OOOM": ["Not Provided"], "LUD": ["December 31, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Treatment planning dosimetric goals met for target coverage and normal tissue constraints [\u00a0Time\u00a0Frame:\u00a0Within 6 months of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Dosimetric goals will be evaluated via dose volume histogram analysis and scored on ability on meet pre-set radiation dose target coverage (treating all targets with adequate dose) and normal tissue constraints (limiting radiation to normal surrounding structures)</div></li>\n<li style=\"margin:1ex 0.5ex\">Treatment delivery quality assurance [\u00a0Time\u00a0Frame:\u00a0Within 2 years of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">All radiation plans will be validated with physicists measuring linear accellarator dose output utilizing a combination of a solid water phantom or a dose calibrated diode array. The phantom will be irradiated with the same plan as the patient including all couch angles and beam projections and will be assessed as to whether the plan meets a pre-specified validation value</div></li>\n<li style=\"margin:1ex 0.5ex\">Early Efficacy [\u00a0Time\u00a0Frame:\u00a0Within 6 months of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Efficacy will be determined based upon clinical exams and lab values (PSA) done at regular intervals</div></li>\n<li style=\"margin:1ex 0.5ex\">Late Toxicity [\u00a0Time\u00a0Frame:\u00a0Within 6 months of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Late toxicity (defined as toxicity occuring &gt;90 days after treatment) will be assessed with regular clinical exams and patient toxicity questionnaires.</div></li>\n<li style=\"margin:1ex 0.5ex\">Late Quality of Life [\u00a0Time\u00a0Frame:\u00a0Within 6 months of completion of radiation therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Late quality of life will be assessed with regular clinical exams and patient quality of life questionnaires.</div></li>\n</ul></td>"], "record_id": ["NCT01856855"], "EPCD": ["February 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["RAD 1203: Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate "], "COOM": ["Not Provided"], "SD": ["February 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02041533"], "CPOM": ["Progression Free Survival (PFS) as assessed by independent radiology review committee (IRRC) in subjects with strongly Programmed death-ligand 1+ (PD-L1+) tumor expression [\u00a0Time\u00a0Frame:\u00a0Up to approximately 33 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 19, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02041533?rank=91&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) as determined per IRRC in subjects with strongly PD-L1+ tumor expression [\u00a0Time\u00a0Frame:\u00a0Up to approximately 33 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR is defined as the number of subjects whose best confirmed objective response is a complete response (CR) or partial response (PR), divided by the number of randomized subjects among strongly PD-L1+ subjects</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival (OS) in subjects with strongly PD-L1+ tumor expression [\u00a0Time\u00a0Frame:\u00a0At least 33 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS is defined as the time from randomization to the date of death</div></li>\n<li style=\"margin:1ex 0.5ex\">PFS in all subjects with any PD-L1+ tumor expression [\u00a0Time\u00a0Frame:\u00a0Up to approximately 33 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease related symptom improvement in all subjects [\u00a0Time\u00a0Frame:\u00a0Up to approximately 33 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Disease-related symptom improvement rate is defined as the proportion of randomized subjects who had a disease-related symptom improvement as measured by the lung cancer symptom scale (LCSS) among all PD-L1+ subjects</div></li>\n</ul></td>"], "BT": ["An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung ", " (CheckMate 026)"], "OOOM": ["Not Provided"], "LUD": ["July 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02041533"], "EPCD": ["January 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung "], "COOM": ["Not Provided"], "SD": ["July 2013"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT00085735"], "CPOM": ["Time to event-free survival (EFS) [\u00a0Time\u00a0Frame:\u00a0Time from study entry to disease progression, disease recurrence, death from any cause, or occurrence of a second malignant neoplasm, assessed up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 14, 2004"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00085735?rank=82&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to recurrence, progression, or death due to cancer [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Used to compute progression-free survival (PFS) percent. Death from causes that are clearly not associated with tumor recurrence or progression will be censored in this analysis</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to death from any cause [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Used to compute survival (S) percent.</div></li>\n<li style=\"margin:1ex 0.5ex\">Local posterior fossa (LPF) failure [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">LPF failure is defined as tumor recurrence or progression within the tumor bed; i.e., within clinical target volume (CTV)boost for patients randomized to tumor-bed-only (involved field) boost (or within a theoretical CTVboost for patients randomized to standard PF radiation therapy). Recurrent tumors that straddle the boundary of CTVboost will be classified as LPF if more than 50% of the tumor volume is within CTVboost.</div></li>\n<li style=\"margin:1ex 0.5ex\">Non-local posterior fossa (NLPF) failure [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">NLPF failure is defined as tumor outside CTVboost, but within CTVPF. Recurrent tumors that straddle the boundary of CTVboost will be classified as non-local posterior fossa (NLPF) if more than 50% of the tumor volume is outside of CTVboost. Recurrent tumors that straddle the boundary of CTVPF will be classified as LPF if more than 50% of the tumor volume is within CTVPF</div></li>\n<li style=\"margin:1ex 0.5ex\">Non-posterior fossa (NPF) failure [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">NPF is defined as tumor recurrence within the neuroaxis but outside of CTVPF. Recurrent tumors that straddle the boundary of CTVPF will be classified as NPF if more than 50% of the tumor volume is outside of CTVPF.</div></li>\n<li style=\"margin:1ex 0.5ex\">Post-treatment neurocognitive function as measured by neuropsychometric battery [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The analysis of toxicity and morbidity will compare the rates of adverse consequences of radiation therapy between treatment groups. The power of these comparisons can be demonstrated by reference to a two-sample test of means of normal random variables.</div></li>\n<li style=\"margin:1ex 0.5ex\">Post-treatment hearing loss as measure by audiogram or brainstem auditory evoked response (BAER) [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The analysis of toxicity and morbidity will compare the rates of adverse consequences of radiation therapy between treatment groups. The power of these comparisons can be demonstrated by reference to a two-sample test of means of normal random variables.</div></li>\n<li style=\"margin:1ex 0.5ex\">Post-treatment endocrine function (e.g., growth, sexual maturation, and need for hormone replacement) by laboratory assessment, clinical history, and exam [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The analysis of toxicity and morbidity will compare the rates of adverse consequences of radiation therapy between treatment groups. The power of these comparisons can be demonstrated by reference to a two-sample test of means of normal random variables.</div></li>\n<li style=\"margin:1ex 0.5ex\">Quality of Life as measured by Pediatric Quality of Life Inventory (PedsQL),  Behavior Assessment System for Children (BASC), Behavior Rating Inventory of Executive Function (BRIEF),  and Adaptive Behavior Assessment System (ABAS) at  3 years [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of grade 3 and grade 4 toxicities in any body system as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events v 4.0 [\u00a0Time\u00a0Frame:\u00a0At baseline, during and after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma"], "OOOM": ["Not Provided"], "LUD": ["February 11, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00085735"], "EPCD": ["July 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial"], "COOM": ["Not Provided"], "SD": ["April 2004"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01309126"], "CPOM": ["Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["February 8, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01309126?rank=93&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of complete response (CR) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of partial response (PR) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of overall response (CR + PR) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of the dosing regimen as measured by the incidence and severity of adverse events observed in study participants [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Sparse pharmacokinetic profile of Imprime PGG will be determined to expand current Imprime PGG PK data [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Samples for sparse PK will be taken at specified times on Cycle 1/Day 1 in the first 30 available subjects randomized to Arm 1 (Subjects 1-30). Samples will be collected, at multiple times, in the next 60 subjects randomized to Arm 1 who reach Cycle 2/Day 1 of dosing (subjects 31-90). Additionally, any subject after the first 90 subjects (subjects 91-795) who have a screening/baseline calculated creatinine clearance (based on age, weight and serum creatinine) of &lt;60 mL/minute will have sparse PK samples collected.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in Quality of Life [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Study of Imprime PGG\u00ae in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal "], "OOOM": ["Not Provided"], "LUD": ["July 8, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of complete response (CR) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of partial response (PR) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of overall response (CR + PR) [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of the dosing regimen as measured by the incidence and severity of adverse events observed in study participants [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Sparse pharmacokinetic profile of Imprime PGG will be determined to expand current Imprime PGG PK data [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Sparse sampling will be conducted in first 90 enrolled in Arm 1 and any subject in Arm 1 with a creatinine clearance &lt;60mL/min (analyses to include area under the curve, maximum concentration, and half-life determinations).</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in Quality of Life [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01309126"], "EPCD": ["April 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG\u00ae in Combination With Cetuximab (Erbitux\u00ae) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal "], "COOM": ["Not Provided"], "SD": ["April 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01901653"], "CPOM": [], "FRD": ["July 11, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01901653?rank=94&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Pharmacokinetics of SC16LD6.5 [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Standard PK variables, including Cmax, AUC, Vd, CL, and T1/2, will be assessed for SC16LD6.5, SC16, and D6.5</div></li>\n<li style=\"margin:1ex 0.5ex\">RECIST v1.1 Assessed Progression Free Survival [\u00a0Time\u00a0Frame:\u00a018 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a024 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["SC16LD6.5 in Recurrent Small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["May 29, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01901653"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung "], "COOM": ["Not Provided"], "SD": ["July 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01875666"], "CPOM": ["difference in kinome activation pre and post treatment [\u00a0Time\u00a0Frame:\u00a07-10 days prior to surgery and at surgery\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 4, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01875666?rank=95&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">predictability in kinome activation [\u00a0Time\u00a0Frame:\u00a0kinoming analysis of tissue will be done after subject participation, which will last from 7-10 days prior to surgery.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">to see if different kinase activation patterns can predict the optimal HER2 inhibition for treatment.</div></td>"], "BT": ["Defining the HER2 Positive (+) Breast ", " Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib"], "OOOM": [], "LUD": ["July 26, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01875666"], "EPCD": ["May 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Defining the HER2 Positive (+) Breast ", " Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib"], "COOM": [], "SD": ["September 2013"]},
{"OPOM": ["Percentage of patients progression-free after completion of 1st line treatment (everolimus + letrozole) [\u00a0Time\u00a0Frame:\u00a012 months after last patient recruited\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01698918"], "CPOM": ["Percentage of patients progression-free after completion of 1st line treatment (everolimus + letrozole) [\u00a0Time\u00a0Frame:\u00a012 months after last patient recruited\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 1, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01698918?rank=97&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall response rate and clinical benefit rate in patients receiving the first line study treatment (everolimus + letrozole) [\u00a0Time\u00a0Frame:\u00a0Baseline, every 8 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Overall response rate (ORR) is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST. Clinical benefit rate (CBR) is defined as the proportion of patients with best overall response of CR, PR or stable disease with a duration of 24 weeks or longer according to RECIST. ORR and CBR will be calculated based on the full analysis set, using local radiologist's/investigator's tumor assessment. Patients with only non-measurable disease at baseline will be included in the numerator if they achieve a complete response</div></li>\n<li style=\"margin:1ex 0.5ex\">Percentage of patients progression-free after completion of 2nd line treatment (everolimus + exemestane) [\u00a0Time\u00a0Frame:\u00a0Baseline, every 8 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">In this study progression free survival in the second line is defined as the time interval between the start of the second line treatment and documented disease progression or death due to any cause reported during or after second line treatment</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival of patients receiving first line study treatment (everolimus + letrozole) [\u00a0Time\u00a0Frame:\u00a0Continuous during the study and every 12 weeks after last treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The overall survival (OS) following first line treatment with Everolimus + Letrozole is defined as the time from the date of receiving first line study treatment to date of death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Reduction in severity and duration of oral stomatitis [\u00a0Time\u00a0Frame:\u00a0Upon onset of 1st stomatitis, patient will complete diary daily until resolution of stomatitis\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Analysis for this objective will be based on Patient reported outcomes data for the first incidence of stomatitis AE. The mean, standard deviation and 95% confidence interval of each severity item in the questionnaire will be calculated at each day for the two therapeutic interventions for stomatitis groups and presented graphically. The duration of the first stomatitis incidence will be calculated using the dates reported in the PRO.</div></li>\n<li style=\"margin:1ex 0.5ex\">Assessment of safety based on the frequency of adverse events that fall outside normal pre-specified ranges [\u00a0Time\u00a0Frame:\u00a0Continuous during the study, up to 28 days after last treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g., electrocardiogram, vital signs) will be considered as appropriate. All safety data will be listed. For all safety analyses, the safety population will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall response rate and clinical benefit rate in patients receiving the second line study treatment (everolimus + exemestane) [\u00a0Time\u00a0Frame:\u00a0Baseline, every 8 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Overall response rate (ORR) is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST. Clinical benefit rate (CBR) is defined as the proportion of patients with best overall response of CR, PR or stable disease with a duration of 24 weeks or longer according to RECIST. ORR and CBR will be calculated based on the full analysis set, using local radiologist's/investigator's tumor assessment. Patients with only non-measurable disease at baseline will be included in the numerator if they achieve a complete response</div></li>\n<li style=\"margin:1ex 0.5ex\">Reduction in severity and duration of oral stomatitis [\u00a0Time\u00a0Frame:\u00a0Upon onset of 1st stomatitis and in countries where the alcohol-free dexamethasone solution (0.5mg/5ml) is commercially available, patient will be randomised to dexamethasone oral solution rinse or standard of care\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Analysis for this objective will be based on Patient reported outcomes data for the first incidence of stomatitis AE. The mean, standard deviation and 95% confidence interval of each severity item in the questionnaire will be calculated at each day for the two therapeutic interventions for stomatitis groups and presented graphically. The duration of the first stomatitis incidence will be calculated using the dates reported in the PRO.</div></li>\n</ul></td>"], "BT": ["Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast "], "OOOM": ["Not Provided"], "LUD": ["May 15, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall response rate in patients receiving the first line study treatment (everolimus + letrozole) [\u00a0Time\u00a0Frame:\u00a0Baseline, every 8 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Overall response rate (ORR) is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) according to RECIST. ORR will be calculated based on the full analysis set, using local radiologist's/investigator's tumor assessment. Patients with only non-measurable disease at baseline will be included in the numerator if they achieve a complete response</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival in the second line is defined as the time interval between start of 2nd line treatment and documented disease progression or death due to any cause reported during or after second-line treatment [\u00a0Time\u00a0Frame:\u00a0Baseline, every 8 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">In this study progression free survival in the second line is defined as the time interval between the start of the second line treatment and documented disease progression or death due to any cause reported during or after second line treatment</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival of patients receiving first line study treatment (everolimus + letrozole) [\u00a0Time\u00a0Frame:\u00a0Baseline, every 8 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The overall survival (OS) following first line treatment with Everolimus + Letrozole is defined as the time from the date of receiving first line study treatment to date of death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Reduction in severity and duration of oral stomatitis [\u00a0Time\u00a0Frame:\u00a0Upon onset of 1st stomatitis, patient will complete diary daily until resolution of stomatitis\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Analysis for this objective will be based on Patient reported outcomes data for the first incidence of stomatitis AE. The mean, standard deviation and 95% confidence interval of each severity item in the questionnaire will be calculated at each day for the two therapeutic interventions for stomatitis groups and presented graphically. The duration of the first stomatitis incidence will be calculated using the dates reported in the PRO.</div></li>\n<li style=\"margin:1ex 0.5ex\">Assessment of safety based on the frequency of adverse events that fall outside normal pre-specified ranges [\u00a0Time\u00a0Frame:\u00a0Continuous during the study, up to 28 days after last treatmen\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g., electrocardiogram, vital signs) will be considered as appropriate. All safety data will be listed.</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">For all safety analyses, the safety population will be used.</p></div></li>\n</ul></td>"], "record_id": ["NCT01698918"], "EPCD": ["October 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast "], "COOM": ["Not Provided"], "SD": ["March 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01164228"], "CPOM": ["Response rate [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 15, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01164228?rank=100&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney ", " That Cannot Be Removed By Surgery"], "OOOM": ["Not Provided"], "LUD": ["July 24, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01164228"], "EPCD": ["June 2021 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features"], "COOM": ["Not Provided"], "SD": ["June 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01326481"], "CPOM": ["Determine Maximum Tolerated Dose of TRC105 in Combination with Capecitabine [\u00a0Time\u00a0Frame:\u00a01.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["March 25, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01326481?rank=99&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">TRC105 pharmacokinetic concentrations [\u00a0Time\u00a0Frame:\u00a01.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Peak and trough concentrations will be evaluated.</div></li>\n<li style=\"margin:1ex 0.5ex\">Immune response to TRC105 [\u00a0Time\u00a0Frame:\u00a01.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Serial blood samples will be tested for immune response to TRC105.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response according to RECIST 1.1 [\u00a0Time\u00a0Frame:\u00a01.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The best response according to RECIST 1.1 for each patient with measurable disease who received at least one dose of study drug will be listed by cohort and tumor type</div></li>\n<li style=\"margin:1ex 0.5ex\">Angiogenic biomarker sample analysis [\u00a0Time\u00a0Frame:\u00a01.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Serial blood samples will be tested for change in angiogenic biomarkers.</div></li>\n</ul></td>"], "BT": ["Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast "], "OOOM": ["Not Provided"], "LUD": ["May 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01326481"], "EPCD": ["September 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast "], "COOM": ["Not Provided"], "SD": ["June 2011"]},
{"OPOM": ["PFS defined as the interval from randomization to progression or death, whichever occurs first [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01399372"], "CPOM": ["Progression free survival (PFS) defined as the interval from randomization to progression or death, whichever occurs first [\u00a0Time\u00a0Frame:\u00a0From randomization to date of progression, death or last follow-up.  Analysis occurs after 67 events (deaths or progression) have been reported.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 20, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01399372?rank=96&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival (OS) defined as the interval from randomization to death due to any cause [\u00a0Time\u00a0Frame:\u00a0From randomization to date of death or last follow-up.  Analysis occurs at the same time as the primary outcome analysis.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response rate  (partial response or complete response) [\u00a0Time\u00a0Frame:\u00a0Analysis occurs at the same time as the primary outcome analysis.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core/Brain Cancer Module (QLQ-C30/BCM20) [\u00a0Time\u00a0Frame:\u00a0From start of treatment to five years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Neurocognitive function measured by the Hopkins Verbal Learning Test-Revised (HVLT-R), Trail Making Test Part A, Trail Making Test Part B, Controlled Oral Word Association Test (COWAT) [\u00a0Time\u00a0Frame:\u00a0From start of treatment to five years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS defined as the interval from randomization to death due to any cause [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response rate  (partial response or complete response) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Chemotherapy-related toxicity as measured by CTCAE, v 4.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01399372"], "EPCD": ["December 2022 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma"], "COOM": ["Not Provided"], "SD": ["September 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01823978"], "CPOM": ["Number of Participants with adverse events as a measure of safety and tolerability [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["March 21, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01823978?rank=98&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">prostatic specific antigen [\u00a0Time\u00a0Frame:\u00a03 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Measure PSA response and PSA doubling time as measured from PSA nadir through 12 weeks</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Reduction in circulating tumor cells [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Change from baseline in number of circulating tumor cells</div></li>\n<li style=\"margin:1ex 0.5ex\">Response to chemotherapy after vaccine [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Response to chemotherapy upon progression</div></li>\n</ul></td>"], "BT": ["Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate "], "OOOM": ["Not Provided"], "LUD": ["February 13, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01823978"], "EPCD": ["March 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate ", " (mCRPC)"], "COOM": ["Not Provided"], "SD": ["April 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02043678"], "CPOM": ["Symptomatic skeletal event free survival (SSE-FS) [\u00a0Time\u00a0Frame:\u00a0At 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 21, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02043678?rank=101&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a0At 3 years for interim and at 6 years for final\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to opiate use for cancer pain [\u00a0Time\u00a0Frame:\u00a0At 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to pain progression [\u00a0Time\u00a0Frame:\u00a0At 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to cytotoxic chemotherapy [\u00a0Time\u00a0Frame:\u00a0At 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Radiological progression free survival (rPFS) [\u00a0Time\u00a0Frame:\u00a0At 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with adverse events as a measure of safety and tolerability [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With ", " of the Prostate When Medical or Surgical Castration Does Not Work and When the ", " Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms"], "OOOM": ["Not Provided"], "LUD": ["July 10, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02043678"], "EPCD": ["July 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-na\u00efve Subjects With Bone Predominant Metastatic Castration-resistant Prostate ", "(CRPC)"], "COOM": ["Not Provided"], "SD": ["March 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02014545"], "CPOM": ["Determine the efficacy of lucanthone when given during WBRT [\u00a0Time\u00a0Frame:\u00a02 weeks to 13 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 12, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02014545?rank=103&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Evaluate the safety and toxicity of lucanthone when used in combination with standard doses of WBRT in the primary treatment of brain metastases secondary to non-small cell lung cancer [\u00a0Time\u00a0Frame:\u00a02 weeks to 13 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety will be monitored throughout the study by physical exams, review of adverse events, and laboratory studies.</div></td>"], "BT": ["Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["March 26, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02014545"], "EPCD": ["December 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung "], "COOM": ["Not Provided"], "SD": ["November 2013"]},
{"OPOM": [], "CH": [], "CPOM": ["Discovery of biomarkers that allow for the early detection of ovarian cancer [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["February 6, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01787656?rank=102&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["A Novel Method of Screening for Ovarian ", " Using Gynecologic Fluids and Mucus"], "OOOM": ["Not Provided"], "LUD": ["February 6, 2013"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01787656"], "EPCD": ["August 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Novel Method of Screening for Ovarian ", " Using Gynecologic Fluids and Mucus"], "COOM": ["Not Provided"], "SD": ["January 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02108652"], "CPOM": ["Objective response rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 7, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02108652?rank=104&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of response (DOR) [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of anti-therapeutic antibodies to MPDL3280A [\u00a0Time\u00a0Frame:\u00a0Up to 14 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Maximum serum concentration (Cmax) of MPDL3280A [\u00a0Time\u00a0Frame:\u00a0Up to 14 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder "], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02108652"], "EPCD": ["November 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder "], "COOM": ["Not Provided"], "SD": ["May 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01748721"], "CPOM": [], "FRD": ["December 11, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01748721?rank=106&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid ", " or Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["July 15, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01748721"], "EPCD": ["May 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid "], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": ["Time to Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0From date of randomization to disease progression or death (up to 24 months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01528345"], "CPOM": ["Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Every 8 weeks assessed up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 31, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01528345?rank=107&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Every 8 weeks assessed up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR is defined as the percentage of patients with a best overall response of Complete Response (CR) or Partial Response (PR) as per RECIST</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (DOR) [\u00a0Time\u00a0Frame:\u00a0From date of first documented efficacy response (CR or PR) to time of documented progression (PD) whichever comes first, assessed up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DOR is defined as time from the date of the first documented response (CR or PR) to the date of the first documented or death due to disease. If a patient does not have a progression event, DOR will be censored on the date of the last adequate tumor assessment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0From date of randomization to date of death from any cause whichever comes first, assessed up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS is defined as the time from the date of randomization to the date of death from any cause. If a patient is not known to have died at the date of analysis cut-off, the OS will be censored at the last date of contact.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety (type, frequency and severity of adverse events, and laboratory values) [\u00a0Time\u00a0Frame:\u00a0Screening, Week 2, Week 4 and approximately every 4 weeks during treatment period (approximately 6-9 months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The type, frequency and severity of adverse events, laboratory values, and Electrocardiograms (ECGs) experienced by patients will be assessed according to Common Terminology Criteria for Adverse Events</div></li>\n<li style=\"margin:1ex 0.5ex\">Eastern Cooperative Oncology Group (ECOG) Performance Status (scales and criteria used by doctors and researchers to assess how a patient's disease is progressing and assess how the disease affects the daily living abilities of the patient.) [\u00a0Time\u00a0Frame:\u00a0Screening, Every 4 weeks during treatment period, and every 8 weeks during follow-up (approximately 9-12 months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time to worsening of ECOG performance status will be measured.</div></li>\n</ul></td>"], "BT": ["Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast "], "OOOM": ["Not Provided"], "LUD": ["March 20, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01528345"], "EPCD": ["October 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast ", " That Have Evidence of Disease Progression on or After Prior Endocrine Therapy"], "COOM": ["Not Provided"], "SD": ["April 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01817374"], "CPOM": ["VCEUS Quantitative Response vs grayscale US [\u00a0Time\u00a0Frame:\u00a0Post neoadjuvant therapy (aproximately 2-3 months after start of treatment)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 7, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01817374?rank=109&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Predicting tumor response [\u00a0Time\u00a0Frame:\u00a0Post Neoadjuvant Chemotherapy (aproximately 2-3 months after start of treatment)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compare quantitative VCEUS to planar CEUS tumor perfusion measurements and enhancement patterns in predicting tumor response to neoadjuvant treatment utilizing final surgical pathology and clinical outcome as reference standards. Specifically, co-temporal early peak signal intensity and area under the curve will be compared to determine whether increased VCEUS has increased efficacy to determine response to neoadjuvant therapy in breast cancer.  Additionally, pre-surgical imaging will be compared to final surgical pathology,</div></td>"], "BT": ["Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy"], "OOOM": ["Not Provided"], "LUD": ["June 12, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01817374"], "EPCD": ["June 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Pilot Study Evaluating Quantitative Volume Contrast Enhanced Ultrasound (VCEUS) Imaging for Determining Early Breast ", " Response to Neoadjuvant Chemotherapy"], "COOM": ["Not Provided"], "SD": ["June 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01963052"], "CPOM": [], "FRD": ["October 7, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01963052?rank=108&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of Anti-Drug Antibody (ADA) [\u00a0Time\u00a0Frame:\u00a0Up to 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Tumor response [\u00a0Time\u00a0Frame:\u00a0Up to 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Incidence of tumor response defined as either a complete response (CR) or partial response (PR) per RECIST criteria (version 1.1) that should be confirmed \u2265 28 days later</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate [\u00a0Time\u00a0Frame:\u00a0Up to 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the percentage of subjects who experience a best response of either CR or PR in that cohort.  CR and PR should be confirmed \u2265 28 days later.</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease control rate [\u00a0Time\u00a0Frame:\u00a0Up to 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the percentage of subjects who experience a best response of CR, PR or stable disease (SD)</div></li>\n</ul></td>"], "BT": ["ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial "], "OOOM": ["Not Provided"], "LUD": ["June 19, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of Anti-Drug Antibody (ADA) [\u00a0Time\u00a0Frame:\u00a0Up to 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Tumor response [\u00a0Time\u00a0Frame:\u00a0Up to 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Incidence of tumor response defined as either a complete response (CR) or partial response (PR) per RECIST criteria (version 1.1) that is confirmed \u2265 28 days later</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate [\u00a0Time\u00a0Frame:\u00a0Up to 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the percentage of subjects who experience a best response of either CR or PR in that cohort.  CR and PR must be confirmed \u2265 28 days later.</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease control rate [\u00a0Time\u00a0Frame:\u00a0Up to 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the percentage of subjects who experience a best response of CR, PR or stable disease (SD)</div></li>\n</ul></td>"], "record_id": ["NCT01963052"], "EPCD": ["October 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial "], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01506609"], "CPOM": ["Progression -Free Survival [\u00a0Time\u00a0Frame:\u00a0Radiographic evaluation every 9 weeks, clinical evaluation every cycle\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 6, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01506609?rank=110&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a0From Cycle 1 Day 1 until patient's death or 3 years post discontinuation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical Benefit Rate (CBR) [\u00a0Time\u00a0Frame:\u00a0From Cycle 1 Day1 until patient's death or 3 years post discontinuation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective Response Rate [\u00a0Time\u00a0Frame:\u00a0From Cycle 1 Day 1 until patient's death or 3 years post discontinuation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast "], "OOOM": ["Not Provided"], "LUD": ["July 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a0From Randomization until patient's death or 3 years post discontinuation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical Benefit Rate (CBR) [\u00a0Time\u00a0Frame:\u00a0From Randomization until patient's death or 3 years post discontinuation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective Response Rate [\u00a0Time\u00a0Frame:\u00a0From Randomization until patient's death or 3 years post discontinuation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01506609"], "EPCD": ["October 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast "], "COOM": ["Chemotherapy-Induced Peripheral Neuropathy (CIPN) [\u00a0Time\u00a0Frame:\u00a0From Cycle 1 Day 1 for subjects on the carboplatin and paclitaxel treatment arm, through 30 Day Follow-up Visit.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "SD": ["January 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01711658"], "CPOM": ["Progression-Free survival [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 16, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01711658?rank=112&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Distant metastasis [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time from randomization until development of distant metastasis.</div></li>\n<li style=\"margin:1ex 0.5ex\">Adverse Events [\u00a0Time\u00a0Frame:\u00a0Participants are followed for up to 17 months from the start of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Data is collected during protocol treatment and 30 days after whether or not related to the study drug.</div></li>\n<li style=\"margin:1ex 0.5ex\">Compliance with planned treatment [\u00a0Time\u00a0Frame:\u00a0maintenance therapy is 12 months and could be different for each patient.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local-regional failure [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time from randomization until local-regional recurrence or progression.</div></li>\n<li style=\"margin:1ex 0.5ex\">Performance Status Scale for Head &amp; Neck Cancer. [\u00a0Time\u00a0Frame:\u00a03 months, 1 year, and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Functional Assessment of Cancer Therapy - Head &amp; Neck. [\u00a0Time\u00a0Frame:\u00a03 months, 1 year, and 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">University of Michigan Xerostomia-Related Quality of Life Scale. [\u00a0Time\u00a0Frame:\u00a03 months, 1 year, and 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">HER2, EGFR, EMT as biomarkers of response. [\u00a0Time\u00a0Frame:\u00a0End of Study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time from randomization until death</div></li>\n</ul></td>"], "BT": ["TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck ", "."], "OOOM": ["Not Provided"], "LUD": ["July 14, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Distant metastasis [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time from randomization until development of distant metastasis.</div></li>\n<li style=\"margin:1ex 0.5ex\">Adverse Events [\u00a0Time\u00a0Frame:\u00a0Participants are followed for up to 17 months for start of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Data is collected during protocol treatment and 30 days after whether or not related to the study drug.</div></li>\n<li style=\"margin:1ex 0.5ex\">Compliance with planned treatment [\u00a0Time\u00a0Frame:\u00a0maintenance therapy is 12 months and could be different for each patient.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local-regional failure [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time from randomization until local-regional recurrence or progression.</div></li>\n<li style=\"margin:1ex 0.5ex\">Performance Status Scale for Head &amp; Neck Cancer. [\u00a0Time\u00a0Frame:\u00a03 months, 1 year, and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Functional Assessment of Cancer Therapy - Head &amp; Neck. [\u00a0Time\u00a0Frame:\u00a03 months, 1 year, and 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">University of Michigan Xerostomia-Related Quality of Life Scale. [\u00a0Time\u00a0Frame:\u00a03 months, 1 year, and 2 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">HER2, EGFR, EMT as biomarkers of response. [\u00a0Time\u00a0Frame:\u00a0No specified time frame for this outcome\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The time from randomization until death</div></li>\n</ul></td>"], "record_id": ["NCT01711658"], "EPCD": ["September 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb\u00ae) for Non-HPV Locally Advanced Head and Neck ", " With Concurrent Chemoradiation"], "COOM": ["Not Provided"], "SD": ["November 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01803282"], "CPOM": ["Safety as evaluated by incidence of AEs, assessment of clinical laboratory test findings, physical examination, 12-lead ECG, and vital signs measurements [\u00a0Time\u00a0Frame:\u00a0Baseline to completion of follow up evaluation. If follow up evaluation is not completed, baseline to date of first documented progression or date of death from any cause, whichever came first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["February 27, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01803282?rank=113&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Safety and Tolerability Study in Solid "], "OOOM": ["Not Provided"], "LUD": ["July 11, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">To characterize the pharmacokinetics of GS-5745 [\u00a0Time\u00a0Frame:\u00a0From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">This outcome will be measured by: serum concentrations of the study drug over time.</div></li>\n<li style=\"margin:1ex 0.5ex\">To evaluate the formation of anti-GS-5745 antibodies [\u00a0Time\u00a0Frame:\u00a0From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">This outcome will be measured by: the formation of anti-GS-5745 antibodies in serum and/or plasma samples.</div></li>\n<li style=\"margin:1ex 0.5ex\">To evaluate exploratory pharmacodynamic biomarkers related to GS-5745 mechanism of action and biologic target coverage [\u00a0Time\u00a0Frame:\u00a0From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">This outcome will be measured by: serum, plasma, urine, and tumor tissue biomarkers at baseline and over time.</div></li>\n<li style=\"margin:1ex 0.5ex\">To evaluate exploratory predictive and prognostic biomarkers associated with disease prognosis and/or benefit from drug [\u00a0Time\u00a0Frame:\u00a0From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">This outcome will be measured by: serum, plasma, urine, and tumor tissue biomarkers at baseline and over time.</div></li>\n</ul></td>"], "record_id": ["NCT01803282"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid "], "COOM": ["Not Provided"], "SD": ["March 2013"]},
{"OPOM": ["Clearance of HPV 16 and other coexisting HR-HPV and incidence of CIN \u2265 2 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00703196"], "CPOM": ["Clearance of HPV 16 and other coexisting HR-HPV and incidence of CIN \u2265 2 [\u00a0Time\u00a0Frame:\u00a0One Year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 20, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00703196?rank=111&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Folic Acid Clinical Trial for the Prevention of Cervical "], "OOOM": ["Not Provided"], "LUD": ["January 21, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00703196"], "EPCD": ["May 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["HPV Clearance by Folic Acid Supplementation (FACT for HPV)"], "COOM": ["Not Provided"], "SD": ["March 2007"]},
{"OPOM": ["Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01082224"], "CPOM": ["Sensitivity of contrast-enhanced CT scan vs contrast-enhanced MRI for diagnosing hepatocellular carcinoma (HCC) [\u00a0Time\u00a0Frame:\u00a0Within 90 Days Before Transplantation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 5, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01082224?rank=114&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Positive predictive value (PPV) of CT scan vs MRI for diagnosing HCC [\u00a0Time\u00a0Frame:\u00a0Within 90 Days Before Transplantation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-level sensitivity and PPV of contrast CT scan vs contrast MRI [\u00a0Time\u00a0Frame:\u00a0Within 90 Days Before Transplantation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Sensitivity and specificity of multiphase contrast-enhanced CT scan vs MRI for diagnosing residual or recurrent HCC [\u00a0Time\u00a0Frame:\u00a0Within 90 Days Before Transplantation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Accuracy of imaging-based diagnosis and staging of HCC in clinical practice using the new OPTN liver-imaging criteria compared with the reference standard of pathologic diagnosis and staging at the time of explantation [\u00a0Time\u00a0Frame:\u00a0Within 90 Days Before Transplantation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Diagnostic value of sensitivity and PPV when patients are stratified by AFP level (elevated vs normal) [\u00a0Time\u00a0Frame:\u00a0Within 90 Days Before Transplantation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver ", " Using UNOS Policy"], "OOOM": ["Not Provided"], "LUD": ["August 19, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Positive predictive value of CT scan vs MRI for diagnosing HCC [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-level sensitivity and positive predictive value of contrast CT scan vs contrast MRI [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Sensitivity and specificity of multiphase contrast-enhanced CT scan vs MRI for diagnosing residual or recurrent HCC [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Accuracy of imaging-based diagnosis and staging of HCC in clinical practice using the new OPTN liver-imaging criteria compared with the reference standard of pathologic diagnosis and staging at the time of explantation [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Diagnostic value of sensitivity and positive predictive value patients are stratified by AFP level (elevated vs normal) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01082224"], "EPCD": ["July 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation"], "COOM": ["Not Provided"], "SD": ["December 2010"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT00020566"], "CPOM": [], "FRD": ["July 11, 2001"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00020566?rank=117&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Feasibility, toxicity, and response at 1 month following  induction therapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Feasibility and  toxicity of consolidation regimens at 1 month following consolidation therapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma"], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00020566"], "EPCD": ["December 2011 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["European Ewing ", " Working Initiative of National Groups Ewing ", " Studies 1999 (EURO-E.W.I.N.G.99)"], "COOM": ["Not Provided"], "SD": ["February 2001"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02095132"], "CPOM": [], "FRD": ["March 13, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02095132?rank=119&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Response rate according to Response Evaluation Criteria in Solid Tumors [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Response rates will be calculated as the percent of patients whose best response is a complete response (CR) or partial response (PR) and confidence intervals will be constructed according to the method of Chang. A responder is defined as a patient who achieves a best confirmed response of PR or CR on the study.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in phosphorylated-cyclin-dependent kinase 1 (p-CDK1) levels [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Decreased p-CDK1 indicating Wee1 inhibition by WEE1 inhibitor MK-1775 will be investigated. These analyses will be descriptive and exploratory and hypotheses generating in nature.</div></li>\n<li style=\"margin:1ex 0.5ex\">Predictive biomarkers of WEE1 inhibitor MK-1775 sensitivity [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">These analyses will be descriptive and exploratory and hypotheses generating in nature.</div></li>\n</ul></td>"], "BT": ["WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid "], "OOOM": ["Not Provided"], "LUD": ["July 18, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02095132"], "EPCD": ["April 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1/2 Study of MK-1775 in Combination With Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid "], "COOM": ["Not Provided"], "SD": ["March 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01822756"], "CPOM": ["Adverse events that are defined as dose limiting toxicities occurring in the first 28 days of treatment. [\u00a0Time\u00a0Frame:\u00a0Approximately 28 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["March 28, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01822756?rank=116&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Plasma concentrations will be used to estimate peak plasma concentration (cmax) and area under the plasma concentration curve (AUC). [\u00a0Time\u00a0Frame:\u00a0Day 1 and Day 8\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration of tumor specific biomarkers and cytokines before and during treatment. [\u00a0Time\u00a0Frame:\u00a0Up to 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical activity as measured by the greatest decrease in tumor burden compared to baseline. [\u00a0Time\u00a0Frame:\u00a0Approximately 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid "], "OOOM": ["Not Provided"], "LUD": ["August 12, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01822756"], "EPCD": ["June 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid "], "COOM": ["Not Provided"], "SD": ["April 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01969643"], "CPOM": [], "FRD": ["October 21, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01969643?rank=115&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Blood concentrations of SGN-LIV1A and metabolites [\u00a0Time\u00a0Frame:\u00a0Through 3 weeks after dosing\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of antitherapeutic antibodies [\u00a0Time\u00a0Frame:\u00a0Through 1 month following last dose\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate [\u00a0Time\u00a0Frame:\u00a0Through 1 month following last dose\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of response [\u00a0Time\u00a0Frame:\u00a0Up to approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Time\u00a0Frame:\u00a0Up to approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival relative to prior therapy [\u00a0Time\u00a0Frame:\u00a0Up to approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Safety Study of SGN-LIV1A in Breast ", " Patients"], "OOOM": ["Not Provided"], "LUD": ["July 29, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01969643"], "EPCD": ["October 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast "], "COOM": ["Not Provided"], "SD": ["September 2013"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT00969579"], "CPOM": ["Not Provided"], "FRD": ["August 29, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00969579?rank=118&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Characterizing Lone Parenting: A Multi-institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With "], "OOOM": ["Not Provided"], "LUD": ["May 20, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00969579"], "EPCD": ["Not Provided"], "OT": ["Characterizing Lone Parenting: A Multi-Institutional Pilot Study of the Perceptions of Support and Perceived Stress of Lone Parents of Children With "], "COOM": ["Not Provided"], "SD": ["August 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01937117"], "CPOM": ["Change in SUV on FDG PET [\u00a0Time\u00a0Frame:\u00a03 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["September 3, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01937117?rank=105&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Change in ptDNA with response [\u00a0Time\u00a0Frame:\u00a03 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To correlate PIK3CA mutation status and other genomic alterations (mutations/somatic rearrangements) qualitatively and quantitatively in plasma tumor DNA (ptDNA) with pCR</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in PI3K pathway activation with response [\u00a0Time\u00a0Frame:\u00a03 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To correlate PI3K pathway activation (e.g. PTEN low and/or PIK3CA mutation, HER 1-4 expression and/or phosphorylation) in tumor samples and pCR</div></li>\n<li style=\"margin:1ex 0.5ex\">Changes in Ki67 with response [\u00a0Time\u00a0Frame:\u00a03 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To correlate baseline and change (day 15) in Ki67 with pCR</div></li>\n</ul></td>"], "BT": ["Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast "], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01937117"], "EPCD": ["January 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast "], "COOM": ["Not Provided"], "SD": ["January 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01384253"], "CPOM": ["Safety and tolerability: To measure the number of participants who experience adverse events after intraperitoneal (IP) administration of \u00b2\u00b9\u00b2Pb-TCMC-Trastuzumab. [\u00a0Time\u00a0Frame:\u00a0Assessed periodically during study treatment follow-up, up to five years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["June 27, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01384253?rank=120&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Immunogenicity: To characterize the human immune response against \u00b2\u00b9\u00b2Pb-TCMC-Trastuzumab given via IP infusion. [\u00a0Time\u00a0Frame:\u00a0Assessed at six weeks visit\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Anti-tumor effects: To monitor for anti-tumor effects as assessed by physical examination, radiographic imaging, and tumor marker studies. [\u00a0Time\u00a0Frame:\u00a0Assessed after six and twelve weeks, and then at twelve-week intervals until progression.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics: To determine the plasma pharmacokinetics and assess the extent of exit of radioactivity from the peritoneal cavity by \u03b3-camera imaging. [\u00a0Time\u00a0Frame:\u00a0Up to 3 days post-injection\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Safety Study of \u00b2\u00b9\u00b2Pb-TCMC-Trastuzumab Radio Immunotherapy"], "OOOM": ["Not Provided"], "LUD": ["March 11, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01384253"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase I Trial of Intraperitoneal \u00b2\u00b9\u00b2Pb-TCMC-Trastuzumab for HER-2 Expressing "], "COOM": ["Not Provided"], "SD": ["July 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01403415"], "CPOM": [], "FRD": ["July 21, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01403415?rank=123&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">MRD levels present at the end of induction [\u00a0Time\u00a0Frame:\u00a0Up to 30 days post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared to a historical control in patients with bone marrow involvement of disease using a t-test or nonparametric analog.</div></li>\n<li style=\"margin:1ex 0.5ex\">CR rate according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria [\u00a0Time\u00a0Frame:\u00a0Up to 30 days post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">mTOR inhibitor effects on downstream signaling in patient lymphoblasts In vitro and in vivo [\u00a0Time\u00a0Frame:\u00a0Up to 30 days post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The pharmacodynamic data will be summarized with simple summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).</div></li>\n</ul></td>"], "BT": ["Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Comparison between MRD levels present at the end of induction with  historical control in patients with bone marrow involvement of disease [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">CR rate [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">In vitro and in vivo pharmacodynamics of temsirolimus [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01403415"], "EPCD": ["January 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1 Study of Temsirolimus in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma"], "COOM": ["Not Provided"], "SD": ["September 2011"]},
{"OPOM": ["Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Up to approx. 5.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01633060"], "CPOM": ["Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Up to approx. 5.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 29, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01633060?rank=126&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0Up to approx. 21 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from date of randomization to the date of death from any cause. Patients will be followed up for the duration of the study and for an expected average of every 3 months after end of treatment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall response rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Up to approx. 5.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with best overall response of complete response (CR) or partial response (PR). ORR will be assessed according to RECIST 1.1 criteria. Patients will be followed up for the duration of the study and for an expected average of every 6 weeks after randomization.</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical benefit rate (CBR) [\u00a0Time\u00a0Frame:\u00a0Up to approx. 5.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with best overall response of complete response (CR) or partial response (PR). ORR will be assessed according to RECIST 1.1 criteria. Patients will be followed up for the duration of the study and for an expected average of every 6 weeks after randomization.</div></li>\n<li style=\"margin:1ex 0.5ex\">Type, frequency and severity of adverse events [\u00a0Time\u00a0Frame:\u00a0at minimum at each study visit and up to approx. 8 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety will be determined by type, frequency and severity of adverse events per CTCAEv4.03 and Type, frequency and severity of laboratory toxicities per CTCAEv4.03. Patients will be followed up for the duration of the study.</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration-time profiles of BKM120 - pharmacokinetics (PK) [\u00a0Time\u00a0Frame:\u00a0C1D1, C1D15, C2D1,C3D1 and C4D1 (a cycle [C] = 4 weeks), D = Day\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Plasma concentration-time profiles of BKM120 and appropriate individual PK parameters.</div></li>\n<li style=\"margin:1ex 0.5ex\">Patient reported outcome for global health status/QoL [\u00a0Time\u00a0Frame:\u00a0C1D1, C2D15, C4D1, then every 8 weeks until discontinuation (a cycle [C] = 4 weeks).\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive deterioration in the global health status/QoL scale score. Change from baseline in the global health status/QOL scale score. Patients will be assessed up to approx. 5.5 months.</div></li>\n</ul></td>"], "BT": ["A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast ", " Who Progressed on or After mTORi"], "OOOM": ["Not Provided"], "LUD": ["March 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0Up to approx. 21 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from date of randomization to the date of death from any cause. Patients will be followed up for the duration of the study and for an expected average of every 3 months after end of treatment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall response rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Up to approx. 5.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with best overall response of complete response (CR) or partial response (PR). ORR will be assessed according to RECIST 1.1 criteria. Patients will be followed up for the duration of the study and for an expected average of every 8 weeks after randomization.</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical benefit rate (CBR) [\u00a0Time\u00a0Frame:\u00a0Up to approx. 5.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with best overall response of complete response (CR) or partial response (PR). ORR will be assessed according to RECIST 1.1 criteria. Patients will be followed up for the duration of the study and for an expected average of every 8 weeks after randomization.</div></li>\n<li style=\"margin:1ex 0.5ex\">Type, frequency and severity of adverse events [\u00a0Time\u00a0Frame:\u00a0at minimum at each study visit and up to approx. 8 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety will be determine by type, frequency and severity of adverse events per CTCAEv4.03 and Type, frequency and severity of laboratory toxicities per CTCAEv4.03. Patients will be followed up for the duration of the study.</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration-time profiles of BKM120 - pharmacokinetics (PK) [\u00a0Time\u00a0Frame:\u00a0C1D1, C1D15, C2D1,C3D1 and C4D1 (a cycle [C] = 4 weeks), D = Day\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Plasma concentration-time profiles of BKM120 and appropriate individual PK parameters.</div></li>\n<li style=\"margin:1ex 0.5ex\">Patient reported outcome for global health status/QoL [\u00a0Time\u00a0Frame:\u00a0C1D1, C2D15, C4D1, then every 8 weeks until discontinuation (a cycle [C] = 4 weeks).\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive deterioration in the global health status/QoL scale score. Change from baseline in the global health status/QOL scale score. Patients will be assessed up to approx. 5.5 months.</div></li>\n</ul></td>"], "record_id": ["NCT01633060"], "EPCD": ["October 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast ", " Who Progressed on or After mTOR Inhibitor Based Treatment"], "COOM": ["Not Provided"], "SD": ["October 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01987375"], "CPOM": ["Number of subjects in a cohort experiencing a DLT (gr 2 or greater AE considered at least possibly related to study drug & clinically significant by the PI) after receiving cetuximab conjugated to the optical dye IRDye800CW(cetuximab-IRDye800) [\u00a0Time\u00a0Frame:\u00a030 days post intervention\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["October 8, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01987375?rank=124&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Number of subjects with identifiable cancer as compared to surrounding normal tissue by correlating fluorescence with histological evidence of tumor post receipt of cetuximab conjugated to the optical dye, IRDye800CW (cetuximab-IRDye800) [\u00a0Time\u00a0Frame:\u00a0One year post intervention\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect ", " During Surgical Procedures"], "OOOM": ["Not Provided"], "LUD": ["May 12, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01987375"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect ", " During Surgical Procedures"], "COOM": ["Not Provided"], "SD": ["October 2013"]},
{"OPOM": ["Progression free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0up to approx. 8.3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01610284"], "CPOM": ["Progression free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0up to approx. 8.3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 11, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01610284?rank=122&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0up to approx. 32 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from date of randomization to the date of death from any cause. Patients will be followed up for the duration of the study and for an expected average of every 3 months after end of treatment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall response rate (ORR) [\u00a0Time\u00a0Frame:\u00a0up to approx. 8.3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with best overall response of complete response (CR) or partial response (PR) based according to RECIST 1.1.Patients will be followed up for the duration of the study and for an expected average of every 8 weeks after randomisation.</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical benefit rate (CBR) [\u00a0Time\u00a0Frame:\u00a0up to approx. 8.3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) lasting more than 24 weeks as defined in RECIST 1.1. Patients will be followed up for the duration of the study and for an expected average of every 8 weeks after randomisation.</div></li>\n<li style=\"margin:1ex 0.5ex\">Type, frequency and severity of adverse events [\u00a0Time\u00a0Frame:\u00a0at minimum at each study visit and up to approx. 10 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety will be determined by type, frequency and severity of adverse events per CTCAEv4.03 and type, frequency and severity of laboratory toxicities per CTCAEv4.03. Patients will be followed up for the duration of the study.</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration of BKM120 and Fulvestrant (Pharmacokinetics) [\u00a0Time\u00a0Frame:\u00a0Cycle 1 day 1, Cycle 1 day 15, cycle 2 day 1, cycle 2 day 2, cycle 2 day 15, cycle 3 day 1, cycle 4 day 1, cycle 5 day 1 and cycle 6 day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PK parameters; Patients will be assessed up to approx. 6 months after randomisation date.      cycle = 28 days</div></li>\n<li style=\"margin:1ex 0.5ex\">Time profile of BKM120 and Fulvestrant (Pharmacokinetics) [\u00a0Time\u00a0Frame:\u00a0Cycle 1 day 1, Cycle 1 day 15, cycle 2 day 1, cycle 2 day 2, cycle 2 day 15, cycle 3 day 1, cycle 4 day 1, cycle 5 day 1 and cycle 6 day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PK parameters; Patients will be assessed up to approx. 6 months after randomisation date. cycle = 28 days</div></li>\n<li style=\"margin:1ex 0.5ex\">Patient reported outcomes for global health status/QOL [\u00a0Time\u00a0Frame:\u00a0Cycle 1 day 1, cycle 1 day 15, 6 weeks after randomisation and then every 8 weeks until  end of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive deterioration in global health status/QOL; Change from baseline in global health status/Quality of Life (QOL). Patients will be assessed up to approx. 8.3 months</div></li>\n</ul></td>"], "BT": ["Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast ", " Refractory to Aromatase Inhibitor"], "OOOM": ["Not Provided"], "LUD": ["June 26, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a0up to approx. 32 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from date of randomization to the date of death from any causPatients will be followed up for the duration of the study and for an expected average of every 3 months after end of treatment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall response rate (ORR) [\u00a0Time\u00a0Frame:\u00a0up to approx. 8.3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with best overall response of complete response (CR) or partial response (PR) based according to RECIST 1.1.Patients will be followed up for the duration of the study and for an expected average of every 8 weeks after randomisation.</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical benefit rate (CBR) [\u00a0Time\u00a0Frame:\u00a0up to approx. 8.3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) lasting more than 24 weeks as defined in RECIST 1.1. Patients will be followed up for the duration of the study and for an expected average of every 8 weeks after randomisation.</div></li>\n<li style=\"margin:1ex 0.5ex\">Type, frequency and severity of adverse events [\u00a0Time\u00a0Frame:\u00a0at minimum at each study visit and up to approx. 10 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety will be determined by type, frequency and severity of adverse events per CTCAEv4.03 and type, frequency and severity of laboratory toxicities per CTCAEv4.03. Patients will be followed up for the duration of the study.</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration of BKM120 and Fulvestrant (Pharmacokinetics) [\u00a0Time\u00a0Frame:\u00a0Cycle 1 day 1, Cycle 1 day 15, cycle 2 day 1, cycle 2 day 2, cycle 2 day 15, cycle 3 day 1, cycle 4 day 1, cycle 5 day 1 and cycle 6 day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PK parameters; Patients will be assessed up to approx. 6 months after randomisation date.      cycle = 28 days</div></li>\n<li style=\"margin:1ex 0.5ex\">Time profile of BKM120 and Fulvestrant (Pharmacokinetics) [\u00a0Time\u00a0Frame:\u00a0Cycle 1 day 1, Cycle 1 day 15, cycle 2 day 1, cycle 2 day 2, cycle 2 day 15, cycle 3 day 1, cycle 4 day 1, cycle 5 day 1 and cycle 6 day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PK parameters; Patients will be assessed up to approx. 6 months after randomisation date. cycle = 28 days</div></li>\n<li style=\"margin:1ex 0.5ex\">Patient reported outcomes for global health status/QOL [\u00a0Time\u00a0Frame:\u00a0Cycle 1 day 1, cycle 1 day 15, 6 weeks after randomisation and then every 8 weeks until  end of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive deterioration in global health status/QOL; Change from baseline in global health status/Quality of Life (QOL). Patients will be assessed up to approx. 8.3 months</div></li>\n</ul></td>"], "record_id": ["NCT01610284"], "EPCD": ["March 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast ", " Which Progressed on or After Aromatase Inhibitor Treatment"], "COOM": ["Not Provided"], "SD": ["August 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01999673"], "CPOM": ["Overall Survival [\u00a0Time\u00a0Frame:\u00a0Approximately up to 36 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 25, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01999673?rank=128&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Time\u00a0Frame:\u00a0Approximately up to 36 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate [\u00a0Time\u00a0Frame:\u00a0Approximately up to 36 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety [\u00a0Time\u00a0Frame:\u00a0Approximately up to 36 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">As measured by adverse event rates and laboratory evaluations</div></li>\n</ul></td>"], "BT": ["Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung "], "OOOM": ["Not Provided"], "LUD": ["July 31, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01999673"], "EPCD": ["December 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non Small-Cell Lung "], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": ["Progression Free Survival [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT01839487"], "CPOM": [], "FRD": ["April 22, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01839487?rank=129&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Estimate relative benefit of PAG treatment vs. AG treatment, as assessed by the PFS ratio [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Estimate relative benefit of PAG vs AG treatment as assessed by the PFS hazard ratio based on subject tumor-associated HA levels [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Estimate ORR as defined by RECIST 1.1 of PAG treatment and the relative benefit of PAG treatment vs AG treatment [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To estimate the OS duration of PAG treatment and the relative benefit of PAG treatment vs AG treatment, as assessed by the OS hazard ratio. [\u00a0Time\u00a0Frame:\u00a016 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To evaluate the safety and tolerability profile of PAG and AG treatment groups [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To characterize the plasma PK of PEGPH20 when given in combination with NAB + GEM [\u00a0Time\u00a0Frame:\u00a0Various visits and timepoints\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic "], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01839487"], "EPCD": ["April 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic "], "COOM": ["Not Provided"], "SD": ["April 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01946204"], "CPOM": ["Metastasis-free survival [\u00a0Time\u00a0Frame:\u00a0Up to death, loss to follow-up, or withdrawal of consent, whichever comes first (up to Month 59)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["September 17, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01946204?rank=130&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to death, loss to follow-up, or withdrawal of consent, whichever comes first (up to Month 59)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to symptomatic progression [\u00a0Time\u00a0Frame:\u00a0Up to documented radiographic progression or the development of unacceptable toxicity (up to Month 59)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to initiation of cytotoxic chemotherapy [\u00a0Time\u00a0Frame:\u00a0Up to documented radiographic progression or the development of unacceptable toxicity (up to Month 59)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Radiographic progression-free survival [\u00a0Time\u00a0Frame:\u00a0Up to Month 59\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to metastasis [\u00a0Time\u00a0Frame:\u00a0Up to documented radiographic progression or the development of unacceptable toxicity (up to Month 59)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Participants with change in FACT-P and EQ-5D questionnaire scores [\u00a0Time\u00a0Frame:\u00a0Up to documented radiographic progression or the development of unacceptable toxicity (up to Month 59)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT) [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after the last dose of study medication\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentrations of ARN-509 and metabolites ARN000308 and ARN000066 [\u00a0Time\u00a0Frame:\u00a0Day 1 of Cycles 1, 2, 3, 6, 12, 18, 24, 36, yearly thereafter, and at the end-of-treatment visit (up to Month 59)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate "], "OOOM": ["Not Provided"], "LUD": ["July 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01946204"], "EPCD": ["December 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate "], "COOM": ["Not Provided"], "SD": ["September 2013"]},
{"OPOM": ["Comparison of disease-free survival in vaccine treated patients and control patients [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01479244"], "CPOM": ["Comparison of DFS in vaccine treated patients and control patients [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 20, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01479244?rank=125&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Assessment of DFS and OS at 3, 5 and 10 years  in vaccine and control groups, respectively; assessment of safety [\u00a0Time\u00a0Frame:\u00a03 through 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">The secondary objectives are to evaluate the 2 groups of subjects for:</p>\n<ul style=\"margin-top:1ex; margin-bottom:1ex;\"><li style=\"margin-top:0.7ex;\">5- and 10-year DFS</li>\n<li style=\"margin-top:0.7ex;\">3-year OS</li>\n<li style=\"margin-top:0.7ex;\">5- and 10-year OS</li>\n<li style=\"margin-top:0.7ex;\">Time to recurrence (TTR), time to local recurrence (TTLR), time to distant recurrence (TTDR), time to bone metastases (TTBM)</li>\n<li style=\"margin-top:0.7ex;\">Overall safety profile and adverse events (AEs)</li>\n</ul></div></td>"], "BT": ["Efficacy and Safety Study of NeuVax\u2122 (Nelipepimut-S or E75) Vaccine to Prevent Breast ", " Recurrence"], "OOOM": ["Not Provided"], "LUD": ["May 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Assessment of Disease-Free Survival and Overall Survival at 3, 5 and 10 years  in vaccine and control groups, respectively; assessment of safety [\u00a0Time\u00a0Frame:\u00a03 through 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">The secondary objectives are to evaluate the 2 groups of subjects for:</p>\n<ul style=\"margin-top:1ex; margin-bottom:1ex;\"><li style=\"margin-top:0.7ex;\">5- and 10-year DFS</li>\n<li style=\"margin-top:0.7ex;\">3-year Overall survival (OS)</li>\n<li style=\"margin-top:0.7ex;\">5- and 10-year OS</li>\n<li style=\"margin-top:0.7ex;\">Time to recurrence (TTR), time to local recurrence (TTLR), time to distant recurrence (TTDR), time to bone metastases (TTBM)</li>\n<li style=\"margin-top:0.7ex;\">Overall safety profile and adverse events (AEs)</li>\n</ul></div></td>"], "record_id": ["NCT01479244"], "EPCD": ["June 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast ", " With Low to Intermediate HER2 Expressions With NeuVax\u2122Treatment"], "COOM": ["Not Provided"], "SD": ["November 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01351415"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0Approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 9, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01351415?rank=133&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) [\u00a0Time\u00a0Frame:\u00a0Approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) [\u00a0Time\u00a0Frame:\u00a0Approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease control rate according to Response Evaluation Criteria in Solid Tumors (RECIST) [\u00a0Time\u00a0Frame:\u00a0Approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of response according to Response Evaluation Criteria in Solid Tumors (RECIST) [\u00a0Time\u00a0Frame:\u00a0Approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety (incidence of adverse events) [\u00a0Time\u00a0Frame:\u00a0Approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung "], "OOOM": ["Not Provided"], "LUD": ["August 13, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01351415"], "EPCD": ["January 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung ", " (NSCLC) After First (1st)-Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy"], "COOM": ["Not Provided"], "SD": ["June 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02069093"], "CPOM": ["Incidence of Grade \u2265 2 stomatitis at 2 months [\u00a0Time\u00a0Frame:\u00a056 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["February 20, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02069093?rank=131&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Average time to resolution [\u00a0Time\u00a0Frame:\u00a056 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Average number of times per day mouthwash regimen performed at 2-months (56 days). Dose intensity of everolimus and exemestane at 2-months (56 days). Incidence of all grades stomatitis at 2-months (56 days). Time to resolution (total # days) from diagnosis of stomatitis (Gr&gt;2) to resolution (Gr\u2264 1).</div></td>"], "BT": ["Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast "], "OOOM": ["Not Provided"], "LUD": ["May 15, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02069093"], "EPCD": ["January 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast ", " Being Treated With Everolimus Plus Exemestane"], "COOM": ["Not Provided"], "SD": ["May 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02149173"], "CPOM": [], "FRD": ["May 1, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02149173?rank=132&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to disease progression [\u00a0Time\u00a0Frame:\u00a0From the start of endocrine therapy to the time the patient is first recorded as having disease progression, assessed up to 20 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Expression of biologic correlates [\u00a0Time\u00a0Frame:\u00a0Up to 20 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estrogen receptor is examined in descriptive analyses.</div></li>\n<li style=\"margin:1ex 0.5ex\">Expression of biologic correlates [\u00a0Time\u00a0Frame:\u00a0Up to 20 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Progesterone receptor is examined in descriptive analyses.</div></li>\n<li style=\"margin:1ex 0.5ex\">Expression of biologic correlates [\u00a0Time\u00a0Frame:\u00a0Up to 20 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Human epidermal growth factor receptor is examined in descriptive analyses.</div></li>\n</ul></td>"], "BT": ["F-18 FES PET in Measuring Hormone Expression in Patients With Recurrent or Metastatic Breast ", " Undergoing Endocrine-Targeted Therapy"], "OOOM": ["Not Provided"], "LUD": ["May 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02149173"], "EPCD": ["September 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy"], "COOM": ["Not Provided"], "SD": ["September 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02132949"], "CPOM": [], "FRD": ["May 6, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02132949?rank=127&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of adverse events [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of anti-therapeutic antibodies to Perjeta [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Total pathological complete response defined as the eradication of invasive disease according to pathologist assessment [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical response as assessed by the investigator according to response evaluation criteria in solid tumors (RECIST) v. 1.1 [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Event-free survival defined as time from enrollment to first occurrence of progressive disease, relapse, or death from any cause. [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Invasive disease-free survival defined as the time from the first date of no disease to the first documentation of progressive invasive disease, relapse, or death from any cause. [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival, defined as the time from enrollment to death from any cause. [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast ", "."], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02132949"], "EPCD": ["February 2021 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Multicenter, Multinational, Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast "], "COOM": ["Not Provided"], "SD": ["June 2014"]},
{"OPOM": [], "CH": [], "CPOM": ["Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0Randomization until death due to any cause. Approximately 29 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 18, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02120417?rank=138&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Randomization to disease progression, or death due to any cause if sooner. Approximately 29 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PFS is defined as the time from randomization through until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) (v1.1)., or death due to any cause if sooner.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective Response Rate [\u00a0Time\u00a0Frame:\u00a0Baseline through end of study. Approximately 29 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Objective Response Rate determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical Benefit Rate [\u00a0Time\u00a0Frame:\u00a0Baseline through end of study. Approximately 29 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Clinical benefit rate defined as a complete response, partial response, or stable disease, determined by investigator assessment of objective radiographic disease assessments per RECIST (v1.1) that lasts for \u2265 6 months.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments. [\u00a0Time\u00a0Frame:\u00a0Baseline through approximately 30 days post treatment discontinuation. Approximately 29 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response [\u00a0Time\u00a0Frame:\u00a0Baseline through end of study. Approximately 29 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Duration of response determined by radiographic disease assessments per RECIST (v1.1), by investigator assessment</div></li>\n</ul></td>"], "BT": ["A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast "], "OOOM": ["Not Provided"], "LUD": ["April 18, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02120417"], "EPCD": ["August 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast "], "COOM": ["Not Provided"], "SD": ["March 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00584363"], "CPOM": ["To diagnose Pancreatic Cancer [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 24, 2007"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00584363?rank=137&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Preventing patient form being misdiagnosed [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["Pancreatic and Gastrointestinal ", " Registry and Tissue Collection"], "OOOM": ["Not Provided"], "LUD": ["June 1, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT00584363"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Pancreatic and Gastrointestinal ", " Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic ", ")"], "COOM": ["Not Provided"], "SD": ["June 2004"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01983501"], "CPOM": [], "FRD": ["October 28, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01983501?rank=139&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">anti-tumor activity of ONT-380 given at the MTD/RD in combination with T-DM1 [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</td>"], "BT": ["A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast "], "OOOM": ["Not Provided"], "LUD": ["July 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01983501"], "EPCD": ["July 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1b, Open-label Study to Assess the Safety and Tolerability of ONT-380 Combined With T-DM1"], "COOM": ["Not Provided"], "SD": ["February 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02088684"], "CPOM": [], "FRD": ["March 12, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02088684?rank=135&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and Tolerability of the combinations of LEE011 with fulvestrant, LEE011 + BKM120 with fulvestrant and LEE011 + BYL719 with fulvestrant [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adverse Events (AEs), serious AEs (SAEs), changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration-time profiles of LEE011, BKM120, BYL719 and fulvestrant. [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To characterize the PK profiles of LEE011, BKM120, BYL719, and fulvestrant when used in combination as well as to evaluate any other clinically significant metabolites that may be identified. PK parameters for LEE011, BKM120 and BYL719, including but not limited to Cmax, Cmin, Tmax, AUCtau, accumulation ratio (Racc),and Ctrough values for fulvestrant.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR is defined as the proportion of patients with a best overall response of complete response or partial response.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (DOR) [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Duration of Response is calculated as the time from the date of first documented response (complete response (CR) or partial response (PR)) to the first documented date of progression or death due to underlying cancer.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) (phase l only) [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) - Phase II only [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.</div></li>\n</ul></td>"], "BT": ["Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast "], "OOOM": ["Not Provided"], "LUD": ["July 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and Tolerability of the combinations of LEE011 with fulvestrant, LEE011 + BKM120 with fulvestrant and LEE011 + BYL719 with fulvestrant [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adverse Events (AEs), serious AEs (SAEs), changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration-time profiles of LEE011, BKM120, BYL719 and fulvestrant. [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To characterize the PK profiles of LEE011, BKM120, BYL719, and fulvestrant when used in combination as well as to evaluate any other clinically significant metabolites that may be identified. PK parameters for LEE011, BKM120 and BYL719, including but not limited to Cmax, Cmin, Tmax, AUCtau, accumulation ratio (Racc),and Ctrough values for fulvestrant.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR is defined as the proportion of patients with a best overall response of complete response or partial response.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (DOR) [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Duration of Response is calculated as the time from the date of first documented response (complete response (CR) or partial response (PR)) to the first documented date of progression or death due to underlying cancer.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) (pahse l only) [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) - Phase II only [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS is defined as the time from date of randomization/start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last known date patient alive.</div></li>\n</ul></td>"], "record_id": ["NCT02088684"], "EPCD": ["February 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast "], "COOM": ["Not Provided"], "SD": ["May 2014"]},
{"OPOM": ["progression free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0When a total of 125 PFS events have occurred (about 18-22 months); Estimated average 6-9 months for each patient.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01572727"], "CPOM": ["progression free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Every 8 weeks after randomization\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 4, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01572727?rank=121&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">overall survival [\u00a0Time\u00a0Frame:\u00a0Every 3 months after end of Treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time from date of randomization to the date of death from any cause</div></li>\n<li style=\"margin:1ex 0.5ex\">overall response rate [\u00a0Time\u00a0Frame:\u00a0Every 8 weeks after randomization\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with best overall response of complete response (CR) or partial response (PR) based according to RECIST 1.1</div></li>\n<li style=\"margin:1ex 0.5ex\">duration of response [\u00a0Time\u00a0Frame:\u00a0Every 8 weeks after randomization\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">time from the date of the first documented response (CR or PR, which has to be confirmed subsequently) to the date of the first radiologically documented disease progression or death due to disease</div></li>\n<li style=\"margin:1ex 0.5ex\">time to response [\u00a0Time\u00a0Frame:\u00a0Every 8 weeks after randomization\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">time from date of randomization until first documented response (CR or PR, which has to be confirmed subsequently).</div></li>\n<li style=\"margin:1ex 0.5ex\">clinical benefit rate [\u00a0Time\u00a0Frame:\u00a0Every 8 weeks after randomization\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Proportion of patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) lasting more than 24 weeks as defined in RECIST 1.1.</div></li>\n<li style=\"margin:1ex 0.5ex\">Type, frequency and severity of adverse events [\u00a0Time\u00a0Frame:\u00a0Continuous, until 30 days after treatment stops\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety will be determine by type, frequency and severity of adverse events per CTCAEv4.03 Type, frequency and severity of laboratory toxicities per CTCAEv4.03</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration-time profiles of BKM120 - pharmacokinetics (PK) [\u00a0Time\u00a0Frame:\u00a0Cycle 1 day 1, 15, 16, 22 and Cycle 2 day 1.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summary statistics for PK: plasma concentration-time profiles of BKM120 and appropriate individual PK parameters based on population PK model , if deemed appropriate; each cycle = 28 days</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive deterioration of ECOG performance status [\u00a0Time\u00a0Frame:\u00a0every 4 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive deterioration of the ECOG performance status from baseline</div></li>\n</ul></td>"], "BT": ["A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast ", ", With or Without PI3K Activation"], "OOOM": ["Not Provided"], "LUD": ["March 4, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">overall survival [\u00a0Time\u00a0Frame:\u00a0until 1 year after the progression free survival analysis or 30 days after all patients stop treatment (about 3 years); approximately 1-3 years for each patient\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">time from date of randomization to the date of death from any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">overall response rate [\u00a0Time\u00a0Frame:\u00a0Estimated 4-8 months for each patient\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">proportion of patients with best overall response of complete response (CR) or partial response (PR)</div></li>\n<li style=\"margin:1ex 0.5ex\">duration of response [\u00a0Time\u00a0Frame:\u00a0estimated average 6-9 months for each patient\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">time from the date of the first documented response (CR or PR, which has to be confirmed subsequently) to the date of the first radiologically documented disease progression or death due to disease</div></li>\n<li style=\"margin:1ex 0.5ex\">time to response [\u00a0Time\u00a0Frame:\u00a0estimated 4-8 months for each patient\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">time from date of randomization until first documented response (CR or PR, which has to be confirmed subsequently).</div></li>\n<li style=\"margin:1ex 0.5ex\">clinical benefit rate [\u00a0Time\u00a0Frame:\u00a024 weeks for each patient\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">proportion of patients with best overall response of complete response (CR) or partial response (PR) or stable disease (SD) lasting more than 24 weeks</div></li>\n<li style=\"margin:1ex 0.5ex\">Type, frequency and severity of adverse events [\u00a0Time\u00a0Frame:\u00a030 days after treatment stops. Estimated 6-9 months for each patient.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety will be determine by yype, frequency and severity of adverse events per CTCAEv4.03 Type, frequency and severity of laboratory toxicities per CTCAEv4.03</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration-time profiles of BKM120 - pharmacokinetics (PK) [\u00a0Time\u00a0Frame:\u00a0Cycle 1 day 1, 15, 16, 22 and Cycle 2 day 1.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summary statistics for PK: plasma concentration-time profiles of BKM120 and appropriate individual PK parameters based on population PK model , if deemed appropriate; each cycle = 28 days</div></li>\n</ul></td>"], "record_id": ["NCT01572727"], "EPCD": ["December 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Double-blind, Placebo Controlled, Phase II/III Study of BKM120 Plus Paclitaxel in Patients With HER2 Negative Inoperable Locally Advanced or Metastatic Breast ", ", With or Without PI3K Pathway Activation."], "COOM": ["Not Provided"], "SD": ["August 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02150148"], "CPOM": ["feasibility [\u00a0Time\u00a0Frame:\u00a0baseline to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["May 24, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02150148?rank=134&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">physical function [\u00a0Time\u00a0Frame:\u00a0baseline to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">assessed via the SF 36 physical function subscale and the senior fitness battery</div></li>\n<li style=\"margin:1ex 0.5ex\">diet quality [\u00a0Time\u00a0Frame:\u00a0baseline to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">assessed via the Diet History Questionnaire</div></li>\n<li style=\"margin:1ex 0.5ex\">physical activity [\u00a0Time\u00a0Frame:\u00a0baseline to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">assessed via the CHAMPS questionnaire with accelerometry confirmation</div></li>\n<li style=\"margin:1ex 0.5ex\">quality of life [\u00a0Time\u00a0Frame:\u00a0baseline to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">assessed via the SF-36</div></li>\n<li style=\"margin:1ex 0.5ex\">biomarkers of successful aging [\u00a0Time\u00a0Frame:\u00a0baseline to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">assessed via blood (serum) levels of IL-6, VCAM, d-dimer and telomerase and finger/toenail and saliva measures of cortisol</div></li>\n</ul></td>"], "BT": ["Vegetable Garden Feasibility Trial to Promote Function in Older ", " Survivors"], "OOOM": ["Not Provided"], "LUD": ["July 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02150148"], "EPCD": ["October 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Vegetable Garden Feasibility Trial to Promote Function in Older ", " Survivors"], "COOM": ["Not Provided"], "SD": ["April 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01115790"], "CPOM": [], "FRD": ["April 28, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01115790?rank=136&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Percentage of Participants with Complete Response, Partial Response, or Stable Disease (Disease Control Rate) (Parts A, B, and C) [\u00a0Time\u00a0Frame:\u00a0Baseline until disease progression or death from any cause (estimated as up to 24 weeks)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival (Parts B and C) [\u00a0Time\u00a0Frame:\u00a0Baseline to measured progressive disease (estimated up to 24 weeks)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (Parts B and C) [\u00a0Time\u00a0Frame:\u00a0First observation of complete response (CR), partial response (PR), or stable disease (SD)  to first observation of progressive disease or death (estimated up to 24 weeks)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Preliminary Pharmacokinetics of LY2606368 (Cmax) (Parts A, B, and C) [\u00a0Time\u00a0Frame:\u00a0During Cycles 1 and 2\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Preliminary Pharmacokinetics of LY2606368 (AUC) (Parts A, B, and C) [\u00a0Time\u00a0Frame:\u00a0During Cycles 1 and 2\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Phase 1 Study in Participants With Advanced "], "OOOM": ["Not Provided"], "LUD": ["June 6, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Part A:  document any antitumor activity [\u00a0Time\u00a0Frame:\u00a0During every cycle and initial follow-up visit\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Part B:  Clinical benefit rate by number of complete response (CR), partial response (PR) and stable disease (SD) [\u00a0Time\u00a0Frame:\u00a06 weeks after initiation of treatment and every 6 weeks following until patient discontinues\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Part B:  Progression Free Survival [\u00a0Time\u00a0Frame:\u00a0baseline to measured progressive disease\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Part B:  Duration of response [\u00a0Time\u00a0Frame:\u00a0First observation of complete response (CR) or partial response (PR) to first observation of progressive disease or death\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Part A and B: Preliminary pharmacokinetics of LY2606368 (Cmax) [\u00a0Time\u00a0Frame:\u00a0During Cycles 1 and 2\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Part A and B: Preliminary pharmacokinetics of LY2606368 (AUC) [\u00a0Time\u00a0Frame:\u00a0During cycles 1 and 2\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01115790"], "EPCD": ["May 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1 Study of LY2606368 in Patients With Advanced "], "COOM": ["Not Provided"], "SD": ["February 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01872975"], "CPOM": ["IBC-RFI [\u00a0Time\u00a0Frame:\u00a0Time from randomization until invasive local, regional, or distant recurrence, or death from breast cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 3, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01872975?rank=140&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0Time from randomization to death from any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">LRRFI [\u00a0Time\u00a0Frame:\u00a0Time from randomization to recurrence of primary cancer w/in breast or lymph nodes in ipsilateral axilla, infraclavicular fossa, or ipsilateral internal mammary chain w/out evidence distant disease, or death due to breast cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">DRFI [\u00a0Time\u00a0Frame:\u00a0Time from randomization to the development of tumor in all areas beyond local or regional limits, or death due to breast cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">.</div></li>\n<li style=\"margin:1ex 0.5ex\">DFS-DCIS [\u00a0Time\u00a0Frame:\u00a0Time from randomization to local recurrence post-mastectomy/in ipsilateral breast post-lumpectomy, regional/distant recurrence, contralateral disease, second primary cancer, or death from any cause prior to recurrence or SPC, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to SPC [\u00a0Time\u00a0Frame:\u00a0Time from randomization to the development of a second primary invasive cancer of any site excluding squamous and basal cell carcinoma of the skin, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Effect of radiation therapy on cosmetic outcome in mastectomy and lumpectomy patients as assessed by quality of life questionnaire [\u00a0Time\u00a0Frame:\u00a0Assessed prior to randomization, 3 months or at end of RT, and 6, 12, and 24 months from randomization\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequencies of adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Molecular predictors of recurrence [\u00a0Time\u00a0Frame:\u00a0Tissue samples collected after randomizaiton; the gene expression profiles are measured at the end of study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To test the prognostic role of gene expression profiles in residual tumor tissue and to develop predictors of the degree of reduction of loco-regional recurrence.</div></li>\n</ul></td>"], "BT": ["Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast ", " Previously Treated With Chemotherapy and Surgery"], "OOOM": ["Not Provided"], "LUD": ["July 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01872975"], "EPCD": ["August 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy"], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01871805"], "CPOM": [], "FRD": ["May 28, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01871805?rank=148&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Quality of life: EORTC QLQ-C30/QLQ-LC13 questionnaires [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: CNS progression rate (CPR) evaluated by IRC according to RECIST v. 1.1 and RANO criteria [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics (Phase I): Area under the concentration-time curve (AUC) [\u00a0Time\u00a0Frame:\u00a0Pre-dose and post-dose up to Day 15 Cycle 1, pre- and post-dose Cycles 2 and 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics (Phase II): Trough concentrations (Ctrough) [\u00a0Time\u00a0Frame:\u00a0Pre- and post-dose Day 1 of Cycles 1, 2 and 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety: Incidence of adverse events [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase I: Tumor response [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: ORR evaluated by investigator assessment using RECIST v. 1.1 criteria [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Disease control rate evaluated by IRC and investigator assessment [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Progression-free survival evaluated by IRC and investigator assessment [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Overall survival [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Duration of response evaluated by IRC and investigator assessment [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: CNS objective response rate (CORR) evaluated by IRC according to RECIST v. 1.1 and RANO criteria [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: CNS duration of response (CDOR) evaluated by IRC according to RECIST v. 1.1 and RANO criteria [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["July 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Quality of life: EORTC QLQ-C30/QLQ-LC13 questionnaires [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics (Phase I): Area under the concentration-time curve (AUC) [\u00a0Time\u00a0Frame:\u00a0Pre-dose and post-dose up to Day 15 Cycle 1, pre- and post-dose Cycles 2 and 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics (Phase II): Trough concentrations (Ctrough) [\u00a0Time\u00a0Frame:\u00a0Pre- and post-dose Day 1 of Cycles 1, 2 and 4\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety: Incidence of adverse events [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase I: Tumor response [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Complete response rate [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Disease control rate [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Progression-free survival [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Overall survival [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Duration of response [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: CNS response rate in patients with brain lesions that were not irradiated [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: CNS relapse rate (CNS PFS) [\u00a0Time\u00a0Frame:\u00a0approximately 2.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01871805"], "EPCD": ["August 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung ", " Previously Treated With Chemotherapy and Crizotinib"], "COOM": ["Not Provided"], "SD": ["April 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00555152"], "CPOM": [], "FRD": ["November 6, 2007"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00555152?rank=142&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of ductal carcinoma in situ remaining at resection [\u00a0Time\u00a0Frame:\u00a0Up to 6 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Differences in histologic response (disappearance of DCIS) will be evaluated using Fisher's exact test. Correlation analysis and linear models will be used to evaluate associations among marker values at baseline and among changes in marker values and treatment. All statistical tests will be two-sided.</div></li>\n<li style=\"margin:1ex 0.5ex\">Biomarker analysis of proliferation markers [\u00a0Time\u00a0Frame:\u00a0Up to 6 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Correlation analysis and linear models will be used to evaluate associations among marker values at baseline and among changes in marker values and treatment. All statistical tests will be two-sided.</div></li>\n</ul></td>"], "BT": ["Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ"], "OOOM": ["Not Provided"], "LUD": ["June 27, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of ductal carcinoma in situ seen at resection</li>\n<li style=\"margin:1ex 0.5ex\">Biomarker analysis of proliferation markers in normal breast cells and cancerous breast cells</li>\n</ul></td>"], "record_id": ["NCT00555152"], "EPCD": ["September 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast "], "COOM": ["Not Provided"], "SD": ["January 2008"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01437566"], "CPOM": [], "FRD": ["September 8, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01437566?rank=143&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective tumor response as assessed by the investigator per modified RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0until disease progression, up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical benefit defined as partial response (PR), complete response (CR), or stable disease (SD) per modified RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0until disease progression, up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of confirmed objective response as assessed by the investigator per modified RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0until disease progression, up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients with PIK3CA mutant tumors [\u00a0Time\u00a0Frame:\u00a0until disease progression, up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetic parameters of GDC-0941 and GDC-0980: time to maximum concentration [\u00a0Time\u00a0Frame:\u00a0Cycle 1, Day 15/16; Cycle 2, Day 15; Cycle, 6 Day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetic parameters of GDC-0941 and GDC-0980: maximum concentration [\u00a0Time\u00a0Frame:\u00a0Cycle 1, Day 15/16; Cycle 2, Day 15; Cycle, 6 Day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetic parameters of GDC-0941 and GDC-0980: Area under the concentration time curve [\u00a0Time\u00a0Frame:\u00a0Cycle 1, Day 15/16; Cycle 2, Day 15; Cycle, 6 Day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast ", " in Patients Resistant to Aromatase Inhibitor Therapy"], "OOOM": ["Not Provided"], "LUD": ["July 15, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective tumor response as assessed by the investigator per modified RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0until disease progression, up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical benefit defined as partial response (PR), complete response (CR), or stable disease (SD) per modified RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0until disease progression, up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of confirmed objective response as assessed by the investigator per modified RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0until disease progression, up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01437566"], "EPCD": ["November 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast ", " in Patients Resistant to Aromatase Inhibitor Therapy"], "COOM": ["Not Provided"], "SD": ["October 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01100463"], "CPOM": [], "FRD": ["April 6, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01100463?rank=147&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Anti-Tumor efficacy of Capecitabine [\u00a0Time\u00a0Frame:\u00a0Maximum of 6 months of therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">RECIST - Radiologic Criteria for subjects with measurable disease</div></td>"], "BT": ["Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome"], "OOOM": ["Not Provided"], "LUD": ["April 8, 2010"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01100463"], "EPCD": ["September 2011 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Ointment (1UO)in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast ", " Treated With Capecitabine"], "COOM": ["Not Provided"], "SD": ["December 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01361607"], "CPOM": ["The primary endpoint is the percent improvement from baseline to the end of treatment in NRS average pain score. [\u00a0Time\u00a0Frame:\u00a05 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 25, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01361607?rank=150&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Change from baseline in mean NRS average pain [\u00a0Time\u00a0Frame:\u00a05 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in mean NRS worst pain [\u00a0Time\u00a0Frame:\u00a05 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in mean Sleep Disruption NRS [\u00a0Time\u00a0Frame:\u00a05 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Sativex\u00ae for Relieving Persistent Pain in Patients With Advanced "], "OOOM": ["Not Provided"], "LUD": ["January 14, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01361607"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex\u00ae Oromucosal Spray (Sativex\u00ae; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced ", ", Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy"], "COOM": ["Not Provided"], "SD": ["May 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01016899"], "CPOM": ["Local recurrence of NMSC [\u00a0Time\u00a0Frame:\u00a0at six (6) months, one (1) year, two (2) years, three (3) years, four (4) years, and five (5) years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 13, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01016899?rank=146&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Cosmetic outcomes for patients treated for NMSC [\u00a0Time\u00a0Frame:\u00a0(1) month, three (3) months, six (6) months, one (1) year, two (2) years, three (3) years, four (4) years, and five (5) years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Occurrence of radiation therapy related skin toxicities [\u00a0Time\u00a0Frame:\u00a01, 3, 6 months, and 1, 2, 3, 4, and 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Electronic Brachytherapy for the Treatment of NMSC"], "OOOM": ["Not Provided"], "LUD": ["January 16, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01016899"], "EPCD": ["December 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Xoft Electronic Brachytherapy Clinical Protocol For The Primary Treatment Of Non-Melanoma Skin "], "COOM": ["Not Provided"], "SD": ["July 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01516307"], "CPOM": ["Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Progression or up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 19, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01516307?rank=145&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast ", " Subjects"], "OOOM": ["Not Provided"], "LUD": ["October 24, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01516307"], "EPCD": ["December 2013 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Double-blind, Randomized Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic Breast "], "COOM": ["Not Provided"], "SD": ["December 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01919229"], "CPOM": ["Cell cycle response rate [\u00a0Time\u00a0Frame:\u00a0Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 2, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01919229?rank=144&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and tolerability of the combination [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after the last dose\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Occurrence, frequency and severity of adverse events (AEs), laboratory abnormalities</div></li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in electrocardiogram (ECG) parameters [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 14\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in expression of Retinoblastoma Protein (pRB) [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">PK (pharmacokinetics) parameters, including but not limited to, Cmax, Tmax, AUClast for LEE011 (and any relevant metabolites) and letrozole. [\u00a0Time\u00a0Frame:\u00a0Days 1, 8, 14 and 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in ECG morphology [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 14\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation between PK concentrations and ECG changes [\u00a0Time\u00a0Frame:\u00a0Day 14\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Correlation between the QTc interval change from baseline and plasma concentrations of LEE011 and/or any relevant metabolites</div></li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in expression of Cyclin-Dependent Kinase 1 (CDK1) [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast ", " Patients (MONALEESA-1)"], "OOOM": ["Not Provided"], "LUD": ["June 12, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and tolerability of the combination [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after the last dose\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Occurrence, frequency and severity of adverse events (AEs), laboratory abnormalities</div></li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in electrocariogram (ECG) parameters [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 14\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in expression of Retinoblastoma Protein (pRB) [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">PK (pharmacokinetics) parameters, including but not limited to, Cmax, Tmax, AUClast for LEE011 (and any relevant metabolites) and letrozole. [\u00a0Time\u00a0Frame:\u00a0Days 1, 8, 14 and 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in ECG morphology [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 14\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation between PK concentrations and ECG changes [\u00a0Time\u00a0Frame:\u00a0Day 14\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Correlation between the QTc interval change from baseline and plasma concentrations of LEE011 and/or any relevant metabolites</div></li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in expression of Cyclin-Dependent Kinase 1 (CDK1) [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01919229"], "EPCD": ["February 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast "], "COOM": ["Not Provided"], "SD": ["October 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02087176"], "CPOM": [], "FRD": ["March 7, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02087176?rank=149&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and Tolerability of AZD1775 and an antimiotic in previsously treated NSCLC patiients [\u00a0Time\u00a0Frame:\u00a0Up to projected 20 months, subjects will be restaged after every 2 cycles (every 6 weeks.) continue until disease progression or unacceptable toxicity\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed in terms of adverse events and laboratory data that is collected on all patients</div></li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetic profile of AZD 1775 in combination with an antimitotic [\u00a0Time\u00a0Frame:\u00a0Up to projected 20 months, subjects will be restaged after every 2 cycles (every 6 weeks.) continue until disease progression or unacceptable toxicity\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Venous blood samples taken for determination of AZD1775, metabolites of 1775 Cycle 1, Day 1 pre-dose and 2 hours post dose, Cycle 2 Day 1 pre-dose and 2 hours post dose, and Cycle 4 pre-dose and 2 hours post dose</div></li>\n<li style=\"margin:1ex 0.5ex\">Compare Objective Response Rate and Disease Control Rate between arms [\u00a0Time\u00a0Frame:\u00a0Up to projected 20 months, Subjects will be restaged after every 2 cycles in Part B (every 6 weeks) continue until disease progression or unacceptable toxicity\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The objective response rate is defined as the number of the subjects with a confirmed best overall response of CR or PR divided by the number of subjects in the Full Analysis Set (FAS) for whom measureable disease is present at baseline. The disease control rate is defined as the percentage of FAS subjects with a best overall response of CR, PR or SD.</div></li>\n<li style=\"margin:1ex 0.5ex\">Assess the duration of response (DoR) and overall survival in each treatment arm [\u00a0Time\u00a0Frame:\u00a0Up to projected 20 months, assessed every 6 weeks continue until disease progression or any cause death\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Duration of response is defined as the time from the date of first documented response until the date of documented progression or any cause death. Overall survival is defined as the time from the date of randomization until death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety of AZD 1775 in combination with an antimiototic [\u00a0Time\u00a0Frame:\u00a0Up to projected 20 months , at every Visit\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed in terms of adverse events and laboratory data that is collected on all patients</div></li>\n</ul></td>"], "BT": ["A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung "], "OOOM": ["Not Provided"], "LUD": ["July 10, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02087176"], "EPCD": ["December 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung ", " Patients"], "COOM": ["Not Provided"], "SD": ["March 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01905657"], "CPOM": [], "FRD": ["July 18, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01905657?rank=151&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall response rate (ORR) by RECIST 1.1 [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Response duration by RECIST 1.1 [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung ", " (MK-3475-010/KEYNOTE-010)"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01905657"], "EPCD": ["September 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung "], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01480050"], "CPOM": [], "FRD": ["November 23, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01480050?rank=152&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity and adverse events according to CTCAE v. 4.0 [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Biological activity of treatment determined by radiographic response [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics of mibefradil dihydrochloride [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Potential effect of mibefradil dihydrochloride on tumor metabolism as determined by [F-18]FLT PET scans in the dose-expansion cohort [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma"], "OOOM": ["Not Provided"], "LUD": ["January 17, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity and adverse events according to CTCAE v. 4.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Biological activity of treatment determined by radiographic response [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics of mibefradil dihydrochloride [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Potential effect of mibefradil dihydrochloride on tumor metabolism as determined by [F-18]FLT PET scans in the dose-expansion cohort [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01480050"], "EPCD": ["January 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment"], "COOM": ["Not Provided"], "SD": ["April 2012"]},
{"OPOM": ["Progression-free survival (PFS), defined as the time from randomization to disease progression as assessed by the\\investigator per RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01493843"], "CPOM": ["Progression-free survival (PFS), defined as the time from randomization to disease progression as assessed by the investigator per RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 14, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01493843?rank=141&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective tumor response as assessed by the investigator using RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of objective response, defined as the time from first observation of an objective tumor response until first observation of disease progression as assessed by the investigator using RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival (OS), defined as the time from randomization until death from any cause [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety: Incidence of adverse events [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["July 15, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective tumor response as assessed by the investigator using RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of objective response, defined as the time from first observation of an objective tumor response until first observation of disease progression as assessed by the\\investigator using RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival (OS), defined as the time from randomization until death from any cause [\u00a0Time\u00a0Frame:\u00a0up to approximately 26 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01493843"], "EPCD": ["November 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung "], "COOM": ["Not Provided"], "SD": ["January 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01936636"], "CPOM": ["Quality of Life [\u00a0Time\u00a0Frame:\u00a0One month\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["September 2, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01936636?rank=155&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Rapidity of BTcP [\u00a0Time\u00a0Frame:\u00a0one month\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Trends in improvement or deterioration in these values during treatment and across the dosage groups will be described.</div></td>"], "BT": ["Observational Registry Study of Quality of Life When Treating BTcP With Abstral"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01936636"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Rapid Evaluation of Lifestyle, Independence, and Elimination of Breakthrough ", " Pain With Freedom From Oral Discomfort Through the Use of Abstral\u00ae (Fentanyl) Sublingual Tablets"], "COOM": ["Not Provided"], "SD": ["October 2013"]},
{"OPOM": ["Progression-Free Survival [\u00a0Time\u00a0Frame:\u00a08 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01780545"], "CPOM": ["Overall Survival [\u00a0Time\u00a0Frame:\u00a0Every 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 25, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01780545?rank=158&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and Toxicity of Regimen [\u00a0Time\u00a0Frame:\u00a0Every week\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the safety and toxicity of OGX-427 in combination with docetaxel to that of docetaxel alone.  Treatment-related toxicity rates will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate [\u00a0Time\u00a0Frame:\u00a0Every 6 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare overall response rate (ORR) between the treatment arms.</div></li>\n<li style=\"margin:1ex 0.5ex\">Serum Levels of Hsp27 and Other Proteins [\u00a0Time\u00a0Frame:\u00a0Each cycle\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To evaluate the effect of therapy with docetaxel and OGX-427 on serum Hsp27 levels and other serum proteins and explore their relation with clinical outcomes.</div></li>\n<li style=\"margin:1ex 0.5ex\">Hsp27 Expression in Archival Tissue [\u00a0Time\u00a0Frame:\u00a0Cycle 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To evaluate the association of urothelial carcinoma expression of Hsp27 measured by immunohistochemistry (IHC) in archival tissue with clinical outcomes.</div></li>\n<li style=\"margin:1ex 0.5ex\">Effect of Therapy Regimen on Circulating Tumor Cells (CTCs)and Correlative Analysis of Telomerase Activity [\u00a0Time\u00a0Frame:\u00a0Prior to screening, prior to first loading dose, and prior to cycles 1, 2, 3 and 5\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To evaluate the effect of therapy with docetaxel and OGX-427 on peripheral blood circulating tumor cells (CTCs) enumeration and expression of Hsp27 and other relevant proteins via immunoflourescence, and levels of telomerase by quantitative polymerase chain reaction (PCR), and explore their relation with clinical outcomes.</div></li>\n</ul></td>"], "BT": ["Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder "], "OOOM": ["Not Provided"], "LUD": ["June 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and Toxicity of Regimen [\u00a0Time\u00a0Frame:\u00a08 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the safety and toxicity of OGX-427 in combination with docetaxel to that of docetaxel alone.  Treatment-related toxicity rates will be assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare overall response rate (ORR) between the treatment arms.</div></li>\n<li style=\"margin:1ex 0.5ex\">Serum Levels of Hsp27 and Other Proteins [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To evaluate the effect of therapy with docetaxel and OGX-427 on serum Hsp27 levels and other serum proteins and explore their relation with clinical outcomes.</div></li>\n<li style=\"margin:1ex 0.5ex\">Hsp27 Expression in Archival Tissue [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To evaluate the association of urothelial carcinoma expression of Hsp27 measured by immunohistochemistry (IHC) in archival tissue with clinical outcomes.</div></li>\n</ul></td>"], "record_id": ["NCT01780545"], "EPCD": ["July 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Oncology Group GU12-160"], "COOM": ["Not Provided"], "SD": ["April 2013"]},
{"OPOM": ["To evaluate the MTD or OBD of MEDI-551 in subjects with relapsed or refractory advanced B-cell malignancies and to determine the preliminary safety profile in these populations. [\u00a0Time\u00a0Frame:\u00a0Study Day 28\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT00983619"], "CPOM": ["To evaluate the MTD or highest protocol defined dose of MEDI-551 in subjects with relapsed or refractory advanced B-cell malignancies and to determine the preliminary safety profile in these populations. [\u00a0Time\u00a0Frame:\u00a0Study Day 28\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["September 22, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00983619?rank=156&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">To evaluate the efficacy of MEDI-551 in subjects with advanced B-cell malignancies, and to characterize the PK and effect on circulating lymphocyte populations and Ig levels, and the immunogenicity of MEDI-551. [\u00a0Time\u00a0Frame:\u00a030 days after last dose of study drug\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell "], "OOOM": ["Not Provided"], "LUD": ["May 14, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT00983619"], "EPCD": ["January 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell "], "COOM": ["Not Provided"], "SD": ["April 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01801111"], "CPOM": [], "FRD": ["February 20, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01801111?rank=153&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) per investigator review of radiographs using RECIST v1.1 [\u00a0Time\u00a0Frame:\u00a0approximately 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease control rate, defined as percentage of patients with partial or complete response or stable disease for at least 16 weeks [\u00a0Time\u00a0Frame:\u00a0approximately 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of objective response, defined as time from first observation of an objective tumor response to disease progression or death of any cause [\u00a0Time\u00a0Frame:\u00a0approximately 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival, defined as time from first RO5424802 treatment to disease progression or death from any cause [\u00a0Time\u00a0Frame:\u00a0approximately 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Central nervous System (CNS) response rate in patients with known CNS lesions who did not receive prior CNS radiation therapy [\u00a0Time\u00a0Frame:\u00a0approximately 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">CNS progressive disease rate [\u00a0Time\u00a0Frame:\u00a0approximately 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival, defined as time from treatment initiation to death of any cause [\u00a0Time\u00a0Frame:\u00a0approximately 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of RO5424802 in Patients With Non-Small Cell Lung ", " Who Have ALK Mutation and Failed Crizotinib Treatment"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01801111"], "EPCD": ["January 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG ", " PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT"], "COOM": ["Not Provided"], "SD": ["June 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01337089"], "CPOM": ["Incidence of adverse events (AEs) [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["April 12, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01337089?rank=154&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Columbia Suicide Severity Rating Scale (C-SSRS) [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Columbia Suicide Severity Rating Scale (C-SSRS) summarized by prior treatment and visit. Changes from baseline will be summarized similarly.</div></li>\n<li style=\"margin:1ex 0.5ex\">Vital Signs [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Vital Signs summarized descriptively by visit and prior treatment. Changes from baseline will be summarized similarly.</div></li>\n<li style=\"margin:1ex 0.5ex\">Hematology and Biochemistry Assessments [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Hematology and Biochemistry assessments will be summarized descriptively for baseline and end of treatment, by prior treatment and overall. Summaries of the changes from baseline and categorical shift tables will also be provided.</div></li>\n<li style=\"margin:1ex 0.5ex\">Weekly average NRS Pain [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Weekly average NRS Pain scores will be summarized across time. Descriptive summaries by time (and prior treatment) of changes from baseline will also be provided. The individual patient scores will be averaged within the periods over days E8-E15, E16-E43, \u2026E156-E183 and then summarized by period; the scores from day E1 are the baseline values.</div></li>\n<li style=\"margin:1ex 0.5ex\">Weekly average Sleep Disruption NRS [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Weekly average Sleep Disruption NRS review scores will be analyzed analogously to the weekly average pain scores.</div></li>\n<li style=\"margin:1ex 0.5ex\">Constipation NRS [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Constipation NRS will be summarized by measurement time point and also as changes from baseline.</div></li>\n<li style=\"margin:1ex 0.5ex\">Patient Satisfaction Questionnaire (PSQ) [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Patient Satisfaction Questionnaire (PSQ) scores will be summarized as counts (%) by measurement time-point.</div></li>\n</ul></td>"], "BT": ["Long Term Safety of Sativex\u00ae Oromucosal Spray (Sativex\u00ae; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic ", " Related Pain"], "OOOM": ["Not Provided"], "LUD": ["April 10, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01337089"], "EPCD": ["June 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex\u00ae Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic ", "-related Pain"], "COOM": ["Not Provided"], "SD": ["January 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01923168"], "CPOM": ["Pathological Complete Response [\u00a0Time\u00a0Frame:\u00a0After 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 13, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01923168?rank=159&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response rate according to  RECIST 1.1 criteria [\u00a0Time\u00a0Frame:\u00a0After 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Objective response rate according to  RECIST 1.1 criteria after 24 weeks of treatment</div></li>\n<li style=\"margin:1ex 0.5ex\">Frequency and severity, of AEs and lab abnormalities [\u00a0Time\u00a0Frame:\u00a0During 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To evaluate the safety and tolerability of study treatment based on the frequency, severity AEs, lab abnormalities</div></li>\n<li style=\"margin:1ex 0.5ex\">Rate breast conserving surgery [\u00a0Time\u00a0Frame:\u00a0After 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Rate of breast conserving surgery, following completion of 24 weeks of treatment</div></li>\n<li style=\"margin:1ex 0.5ex\">Molecular markers and correlation with response [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 15 and 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Correlation between pCR and change in Ki67 from baseline to day 15 and baseline to surgery</div></li>\n<li style=\"margin:1ex 0.5ex\">PEPI (preoperative endocrine prognostic index) score [\u00a0Time\u00a0Frame:\u00a0After 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the Preoperative endocrine prognostic index (PEPI) score after 24 weeks of treatment</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration of BYL719/buparlisib and letrozole when given in combination [\u00a0Time\u00a0Frame:\u00a0Cycle 1 (Day 1, 2, 8, 15, 22), Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4(Day 1 and Day 2), Cycle 5 Day 1 and Cycle 6 Day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Plasma concentration time profiles of BYL719/buparlisib and appropriate individual PK parameters Plasma concentration time profiles of letrozole and appropriate individual PK parameters</div></li>\n</ul></td>"], "BT": ["Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women"], "OOOM": ["Not Provided"], "LUD": ["June 20, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response rate according to  RECIST 1.1 criteria [\u00a0Time\u00a0Frame:\u00a0After 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Objective response rate according to  RECIST 1.1 criteria after 24 weeks of treatment</div></li>\n<li style=\"margin:1ex 0.5ex\">Frequency and severity, of AEs and lab abnormalties [\u00a0Time\u00a0Frame:\u00a0During 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To evaluate the safety and tolerability of study treatment based on the frequency, severity AEs, lab abnormalities</div></li>\n<li style=\"margin:1ex 0.5ex\">Rate breast conserving surgery [\u00a0Time\u00a0Frame:\u00a0After 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Rate of breast conserving surgery, following completion of 24 weeks of treatment</div></li>\n<li style=\"margin:1ex 0.5ex\">Molecular markers and correlation with response [\u00a0Time\u00a0Frame:\u00a0Baseline, Day 15 and 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Correlation between pCR and change in Ki67 from baseline to day 15 and baseline to surgery</div></li>\n<li style=\"margin:1ex 0.5ex\">PEPI (preoperative endocrine prognostic index) score [\u00a0Time\u00a0Frame:\u00a0After 24 weeks of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the Preoperative endocrine prognostic index (PEPI) score after 24 weeks of treatment</div></li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration of BYL719/buparlisib and letrozole when given in combination [\u00a0Time\u00a0Frame:\u00a0Cycle 1 (Day 1, 2, 8, 15, 22), Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4(Day 1 and Day 2), Cycle 5 Day 1 and Cycle 6 Day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Plasma concentration time profiles of BYL719/buparlisib and appropriate individual PK parameters Plasma concentration time profiles of letrozole and appropriate individual PK parameters</div></li>\n</ul></td>"], "record_id": ["NCT01923168"], "EPCD": ["October 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast "], "COOM": ["Not Provided"], "SD": ["March 2014"]},
{"OPOM": ["Event-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01371981"], "CPOM": ["Event-free survival [\u00a0Time\u00a0Frame:\u00a0From the time on study to induction failure, relapse or death, up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 10, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01371981?rank=157&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kaplan-Meier method will be used to estimate OS.</div></li>\n<li style=\"margin:1ex 0.5ex\">Remission rate after 1 course of therapy [\u00a0Time\u00a0Frame:\u00a04 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Remission rate after 2 courses of therapy [\u00a0Time\u00a0Frame:\u00a08 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients dying in each course of therapy [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Course duration [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Length of hospitalization [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive statistics will be used to summarize length of hospitalization time.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to blood count recovery [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cumulative incidence estimates that account for competing events will be used to estimate time to count recovery.</div></li>\n<li style=\"margin:1ex 0.5ex\">Relapse rate assessed by bone marrow analsysis for leukemic blasts [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cumulative incidence estimates that account for competing events will be used to estimate relapse rate.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of treatment-related mortality [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Cumulative incidence estimates that account for competing events will be used to estimate treatment-related mortality.</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients expereincing grade 3 or higher non-hematologic toxicities and infections assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The proportion of patients experiencing grade 3 or higher non-hematologic toxicities and infections will be estimated.</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of high risk children without HR FLT3/ITD+ converting from positive MRD at end of Induction I to negative MRD at the end of Induction II [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The proportion of high risk children without HR FLT3/ITD+ converting from positive MRD at end of Induction I to negative MRD at the end of Induction II will be estimated as well as the corresponding confidence interval. In addition, this proportion will be compared with the proportion for high risk children without HR FLT3/ITD+ treated on AAML03P1 and AAML0531.</div></li>\n<li style=\"margin:1ex 0.5ex\">Parent-reported questionnaire scores [\u00a0Time\u00a0Frame:\u00a0At 4 months following start of SCT or intensification II of chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Questionnaires include the Generic Core Scale, Acute Cancer Module, and Multidimensional Fatigue Module summary and dimension scores of HRQOL and Pediatric Inventory for Parents (PIP). Mean values and their 95% confidence intervals (CI) will be presented.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in parent-reported outcomes over time in recipients of SCT or chemotherapy [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Summary measures at each time point as well as the overall trajectory over time in HRQOL and PIP will be described. A mixed linear regression model with repeated measures incorporating covariates as appropriate will be performed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Bortezomib pharmacokinetic plasma concentration-time profiles [\u00a0Time\u00a0Frame:\u00a0Day 8 of induction I\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Analyzed using descriptive statistics and will be graphically displayed by age group. PK data will be analyzed using methods such as nonlinear mixed effects modeling to estimate bortezomib clearance (Cl) and volume of distribution (Vd) with associated 95% confidence intervals in each age group (2-11 years and 12-16 years of age).</div></li>\n<li style=\"margin:1ex 0.5ex\">Systemic exposure of sorafenib and N-oxide metabolite for each course of induction and intensification (CL, Vd, time to maximum concentration [Tmax]\u00bd, area under curve [AUC]) [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive statistics will be used to summarize the systemic exposure of sorafenib and N-oxide metabolite for each course of induction and intensification (CL, Vd, Tmax\u00bd, AUC). If sufficient data is available, comparison to steady state pharmacokinetic data from ADVL0413 will be performed using Wilcoxon sign rank test. For PIA-PK correlations, a random effects linear regression model will be used to describe the relationship between plasma inhibitory assay and PK levels for each of the trough plasma samples collected for each patient.</div></li>\n<li style=\"margin:1ex 0.5ex\">Shortening fraction/ejection fraction percentages and change over time [\u00a0Time\u00a0Frame:\u00a0Up to 11 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Analyzed by repeated measures analysis of variance accounting for dexrazoxane exposure and other clinically relevant covariates, including age, gender, body mass index, risk group, and treatment arm.</div></li>\n<li style=\"margin:1ex 0.5ex\">Serum concentrations of GVHD biomarkers [\u00a0Time\u00a0Frame:\u00a0Up to day 28 after SCT\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Logistic regression modeling will be used to assign individual weights to each individual biomarker and clinical variable to maximize sensitivity and specificity of a mathematical algorithm for the prediction of grade 2-4 GVHD occurring on or before day 56 post-SCT. It will be tested whether algorithms using the day 7, 14, or 28 biomarker panel, or a combination of the biomarker panels at these different time points are most useful for the prediction of GVHD. The different algorithms will be compared on the basis of maximal specificity and sensitivity using the Akaike information criterion.</div></li>\n</ul></td>"], "BT": ["Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia"], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Remission rate after 1 and 2 courses of therapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients dying in each course of therapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Course duration [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Length of hospitalization [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to blood count recovery [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relapse rate [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Treatment-related mortality [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Frequency of toxicities, including infectious and cardiac complications [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01371981"], "EPCD": ["June 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib and Sorafenib ( NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD"], "COOM": ["Not Provided"], "SD": ["June 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01765582"], "CPOM": [], "FRD": ["January 9, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01765582?rank=160&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall response rate during second-line therapy (ORR2), defined as proportion of patients with complete response or partial response during second-line therapy [\u00a0Time\u00a0Frame:\u00a0approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival during second-line therapy (PFS2), defined as time from reinduction of second-line therapy to disease progression or death from any cause, whichever occurs first [\u00a0Time\u00a0Frame:\u00a0approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to PFS2, defined as time from randomization to first occurrence of disease progression after reintroduction of second-line therapy [\u00a0Time\u00a0Frame:\u00a0approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival, defined as time from randomization to death of any cause [\u00a0Time\u00a0Frame:\u00a0approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Liver resection rate: Proportion of patients who undergo liver metastases resections [\u00a0Time\u00a0Frame:\u00a0approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates of conversion from unresectable to resectable disease (liver-limited and non-liver-limited disease) [\u00a0Time\u00a0Frame:\u00a0approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety: Incidence of adverse events [\u00a0Time\u00a0Frame:\u00a0approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal "], "OOOM": ["Not Provided"], "LUD": ["July 7, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01765582"], "EPCD": ["December 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["STEAM (SEQUENTIAL TRIPLET AND AVASTIN MAINTENANCE): FOLFOXIRI/BEVACIZUMAB REGIMENS (CONCURRENT AND SEQUENTIAL) VS. FOLFOX/BEVACIZUMAB IN FIRST-LINE METASTATIC COLORECTAL "], "COOM": ["Not Provided"], "SD": ["January 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01673022"], "CPOM": ["Estimate the sensitivity of the sentinel lymph node [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 22, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01673022?rank=162&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging"], "OOOM": ["Not Provided"], "LUD": ["April 22, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01673022"], "EPCD": ["May 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging for Detecting Metastatic Endometrial and Cervical "], "COOM": ["Not Provided"], "SD": ["May 2012"]},
{"OPOM": ["Time to Treatment Failure (TTF) [\u00a0Time\u00a0Frame:\u00a0up to 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01857817"], "CPOM": ["Change in prostate specific antigen (PSA) [\u00a0Time\u00a0Frame:\u00a0baseline (Day 1 Cycle 1) to 12 weeks (Day 1, Cycle 4)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 15, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01857817?rank=165&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">PSA progression [\u00a0Time\u00a0Frame:\u00a0baseline to 12 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">PSA doubling time (PSADT) [\u00a0Time\u00a0Frame:\u00a0baseline and every month during treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in self-reported performance (EQ-5D), pain (visual analog scale [VAS] and opiate usage) [\u00a0Time\u00a0Frame:\u00a0Day 1 Cycle 1, on Day 1 of each subsequent 28-day cycle, and on end of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to symptom progression (TTSP) [\u00a0Time\u00a0Frame:\u00a0Day 1 Cycle 1 and Day 1 of each subsequent 28-day cycle\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in correlative biomarkers [\u00a0Time\u00a0Frame:\u00a0Day 1 Cycle 1, on Day 1 of each subsequent 28-day cycle, and on end of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate "], "OOOM": ["Not Provided"], "LUD": ["July 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Patient Reported Outcome [Functional Assessment of Cancer Therapy-General (FACT G)] [\u00a0Time\u00a0Frame:\u00a0baseline and every 28 days for 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Performance (Karnofsky Performance Score, KPS) [\u00a0Time\u00a0Frame:\u00a0baseline and every 28 days for 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease progression assessed by prostate-specific antigen (PSA), imaging or death [\u00a0Time\u00a0Frame:\u00a0up to 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) in participants [\u00a0Time\u00a0Frame:\u00a0up to 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0up to 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to Symptom Progression (TTSP) [\u00a0Time\u00a0Frame:\u00a0up to 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in self-reported performance (EQ-5D), pain [visual analog scale (VAS) and opiate usage] [\u00a0Time\u00a0Frame:\u00a0baseline and every 28 days for 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in correlative biomarkers [e.g., C-reactive protein (CRP), interleukin-6 (IL-6), urine collagen-type I N- telopeptide (NTx)] [\u00a0Time\u00a0Frame:\u00a0baseline and every 28 days for 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01857817"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate "], "COOM": ["Not Provided"], "SD": ["June 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01571284"], "CPOM": [], "FRD": ["April 3, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01571284?rank=161&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Health-Related Quality of Life (HRQL) assessed by using changes from baseline in scores derived from the 3 HRQL questionnaires [\u00a0Time\u00a0Frame:\u00a0Every 4 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal ", " Previously Treated With an Oxaliplatin-Based Regimen"], "OOOM": ["Not Provided"], "LUD": ["July 31, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01571284"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal ", " (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen"], "COOM": ["Not Provided"], "SD": ["May 2012"]},
{"OPOM": ["Progression-free Survival [\u00a0Time\u00a0Frame:\u00a0Up to approximately 49 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01491737"], "CPOM": ["Progression-free Survival [\u00a0Time\u00a0Frame:\u00a0Up to approximately 33 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 6, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01491737?rank=166&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a0Up to approximately 49 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate [\u00a0Time\u00a0Frame:\u00a0Up to approximately 49 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinical Benefit Rate [\u00a0Time\u00a0Frame:\u00a0Up to approximately 49 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response [\u00a0Time\u00a0Frame:\u00a0Up to approximately 49 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to Response [\u00a0Time\u00a0Frame:\u00a0Up to approximately 49 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Safety: Incidence of Adverse Events [\u00a0Time\u00a0Frame:\u00a0Up to approximately 49 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of Life: EQ-5D Questionnaire [\u00a0Time\u00a0Frame:\u00a0Up to approximately 49 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast "], "OOOM": ["Not Provided"], "LUD": ["July 14, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01491737"], "EPCD": ["May 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Two-arm, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab Plus an Aromatase Inhibitor in First Line Patients With HER2-positive and Hormone Receptor-positive Advanced (Metastatic or Locally Advanced) Breast ", "."], "COOM": ["Not Provided"], "SD": ["February 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00978458"], "CPOM": [], "FRD": ["September 16, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00978458?rank=163&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Quality of life as assessed by the FACT-BR questionnaire at baseline, annually until disease progression, and at the time of disease progression [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Neurocognitive functioning as assessed at baseline, annually until disease progression, and at the time of disease progression [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of pre-treatment 1p and 19q levels in tumor tissue samples with PFS and OS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma"], "OOOM": ["Not Provided"], "LUD": ["December 4, 2012"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT00978458"], "EPCD": ["May 2026 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas"], "COOM": ["Not Provided"], "SD": ["September 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02027428"], "CPOM": ["Progression free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Approximately 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 2, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02027428?rank=168&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Adverse Events [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Number of participants with adverse events</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Number of participants who survive</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall response rate [\u00a0Time\u00a0Frame:\u00a0Approximately 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The percentage of patients who achieve an overall response according to Response Evaluation Criteria in Solid Tumors RECIST 1.1 guidelines</div></li>\n</ul></td>"], "BT": ["Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["July 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02027428"], "EPCD": ["May 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane\u00ae) as Maintenance Treatment After Induction With Nab-Paclitaxel (Abraxane\u00ae) Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung ", " (NSCLC)"], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01962168"], "CPOM": ["Freedom from symptomatic recurrent biliary obstruction requiring reintervention [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 9, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01962168?rank=169&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Technical success [\u00a0Time\u00a0Frame:\u00a0Immediately following completion of the stent placement procedure\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Technical success is defined as a stent successfully delivered and placed at its intended location at the end of the procedure.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of device-related adverse events [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Ease of use [\u00a0Time\u00a0Frame:\u00a0Immediately following completion of the stent placement procedure\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Ease of use will be evaluated on a five point scale ranging from very easy to very difficult.</div></li>\n</ul></td>"], "BT": ["Evolution\u00ae Biliary Stent System Clinical Study"], "OOOM": ["Not Provided"], "LUD": ["July 22, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01962168"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Palliation of Biliary ", " With the Cook Evolution\u00ae Biliary Stent System"], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02141295"], "CPOM": ["Progression-free survival (PFS) based on response evaluation criteria in solid tumors (RECIST) v. 1.1 [\u00a0Time\u00a0Frame:\u00a0Up to 28 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 15, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02141295?rank=164&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) as per RECIST v. 1.1 [\u00a0Time\u00a0Frame:\u00a0Up to 28 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of response [\u00a0Time\u00a0Frame:\u00a0Up to 28 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival [\u00a0Time\u00a0Frame:\u00a0Up to 28 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events [\u00a0Time\u00a0Frame:\u00a0Up to 28 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the concentration-time curve (AUC) of RO5520985 [\u00a0Time\u00a0Frame:\u00a0Up to 28 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal ", " (McCAVE)"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02141295"], "EPCD": ["December 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO5520985 PLUS FOLFOX VERSUS BEVACIZUMAB PLUS FOLFOX IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL "], "COOM": ["Not Provided"], "SD": ["June 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01722292"], "CPOM": [], "FRD": ["November 2, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01722292?rank=167&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Phase 1b and 2: Pharmacokinetics: Maximum Concentration (Cmax) of LY2940680, LSN2941091, carboplatin, and etoposide at the Recommended Dose [\u00a0Time\u00a0Frame:\u00a0Predose up to 24 Hours Postdose\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase 1b and 2: Pharmacokinetics: Area Under the Curve (AUC) of LY2940680, LSN2941091, carboplatin, and etoposide at the Recommended Dose [\u00a0Time\u00a0Frame:\u00a0Predose up to 24 Hours Postdose\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase 1b: Number of Participants with a Complete or Partial Tumor Response (Overall Response Rate) [\u00a0Time\u00a0Frame:\u00a0Baseline to Study Completion (Estimated as 38 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase 1b: Expression Levels of Gli1 in Skin Cells at the Recommended Dose [\u00a0Time\u00a0Frame:\u00a0Baseline, Cycle 2 Day 1, Cycle 7 Day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase 2: Overall Survival [\u00a0Time\u00a0Frame:\u00a0Randomization to Study Completion (Estimated as 38 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase 2: Percent Change in Tumor Size (CTS) [\u00a0Time\u00a0Frame:\u00a0Randomization to End of Cycle 2 (Estimated as 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase 2: Number of Participants with a Complete or Partial Tumor Response  (Overall Response Rate) [\u00a0Time\u00a0Frame:\u00a0Randomization to Study Completion (Estimated as 38 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase 1b and 2: Pharmacokinetics: Time to Maximal Concentration (Tmax) of LY2940680, LSN2941091, carboplatin, and etoposide at the Recommended Dose [\u00a0Time\u00a0Frame:\u00a0Predose up to 24 Hours Postdose\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of LY2940680 in Small Cell Lung "], "OOOM": ["Not Provided"], "LUD": ["May 16, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01722292"], "EPCD": ["August 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung "], "COOM": ["Not Provided"], "SD": ["January 2013"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT00973427"], "CPOM": ["Not Provided"], "FRD": ["September 8, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00973427?rank=174&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["DNA Chip Based Prognosis of Lung "], "OOOM": ["Not Provided"], "LUD": ["June 8, 2011"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00973427"], "EPCD": ["December 2011 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["DNA Chip Based Prognosis of Lung "], "COOM": ["Not Provided"], "SD": ["June 2008"]},
{"OPOM": ["Radiological progression-free survival (rPFS) [\u00a0Time\u00a0Frame:\u00a0From randomization to radiological disease progression or death from any cause, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT02034552"], "CPOM": ["Patient Bone Scan Response [\u00a0Time\u00a0Frame:\u00a0At 24 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 16, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02034552?rank=175&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">radiological progression-free survival (rPFS) [\u00a0Time\u00a0Frame:\u00a0from randomization to radiological disease progression or death from any cause, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">symptomatic skeletal event-free survival (SSE-FS) [\u00a0Time\u00a0Frame:\u00a0From randomization to the earlier SSE or death, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to first symptomatic skeletal event(SSE) [\u00a0Time\u00a0Frame:\u00a0From randomization to first SSE or death, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0From randomization to the date of radiological disease progression, up to 7.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">time to radiological bone progression by treatment group [\u00a0Time\u00a0Frame:\u00a0time to radiological bone progression up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with treatment-emergent adverse events as a measure of safety and tolerability [\u00a0Time\u00a0Frame:\u00a0Up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with serious adverse events as a measure of safety and tolerability [\u00a0Time\u00a0Frame:\u00a0Up to 7.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate ", " (CRPC)"], "OOOM": ["Not Provided"], "LUD": ["July 24, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to first symptomatic skeletal event(SSE) [\u00a0Time\u00a0Frame:\u00a0From ransomization to the first SSE, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Symptomatic skeletal event-free survival [\u00a0Time\u00a0Frame:\u00a0From randomization to the earlier of first SSE or death, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0From randomization to the date of radiological disease progression, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to radiological bone progression [\u00a0Time\u00a0Frame:\u00a0From randomization to the date of radiological bone progression, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to radiological progression [\u00a0Time\u00a0Frame:\u00a0From randomization to the date of radiological progression, up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with treatment-emergent adverse events as a measure of safety and tolerability [\u00a0Time\u00a0Frame:\u00a0Up to 30 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with serious adverse events as a measure of safety and tolerability [\u00a0Time\u00a0Frame:\u00a0Up to 7.5 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT02034552"], "EPCD": ["June 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate ", " Who Have Bone Metastases"], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00988559"], "CPOM": ["To evaluate feasibility and toxicity in women with CIN2/3 caused by HPV16 [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["October 1, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00988559?rank=177&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">To compare immunogenicity of three different routes of administration: intradermal (ID), intramuscular (IM), and intralesional (IL) [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</td>"], "BT": ["Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial ", " (CIN2/3)"], "OOOM": ["Not Provided"], "LUD": ["March 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT00988559"], "EPCD": ["September 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Pilot Study of pnGVL4a-CRT/E7 (Detox) for the Treatment of Patients With HPV16+ Cervical Intraepithelial ", " 2/3 (CIN2/3)"], "COOM": ["Not Provided"], "SD": ["September 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01712009"], "CPOM": ["Bone pain (all grade) in cycle 1 [\u00a0Time\u00a0Frame:\u00a0Will be assessed 30 days after all subjects complete chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 19, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01712009?rank=172&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Bone pain (all grade) by cycle (2-4) and across cycles [\u00a0Time\u00a0Frame:\u00a0Will be assessed 30 days after all subjects complete chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Bone pain (all grade) by cycle (2-4) and across cycles (up to and including 4 cycles)</div></li>\n<li style=\"margin:1ex 0.5ex\">Severe (grade 3/4) bone pain by cycle and across cycles [\u00a0Time\u00a0Frame:\u00a0Will be assessed 30 days after all subjects complete chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Severe (grade 3/4) bone pain by cycle and across cycles (up to and including 4 cycles)</div></li>\n<li style=\"margin:1ex 0.5ex\">Subject reported bone pain [\u00a0Time\u00a0Frame:\u00a0Will be assessed 30 days after all subjects complete chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Subject-reported bone pain by cycle and across cycles (up to and including 4 cycles)</div></li>\n<li style=\"margin:1ex 0.5ex\">Maximum Subject Reported bone pain [\u00a0Time\u00a0Frame:\u00a0Will be assessed 30 days after all subjects complete chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Maximum subject-reported bone pain by cycle and across cycles (up to and including 4 cycles)</div></li>\n<li style=\"margin:1ex 0.5ex\">Area under the Curve for subject-reported bone pain [\u00a0Time\u00a0Frame:\u00a0Will be assessed 30 days after all subjects complete chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">AUC for subject-reported bone pain during by cycle and across all cycles (up to and including 4)</div></li>\n<li style=\"margin:1ex 0.5ex\">Adverse Event and Serious Adverse Events [\u00a0Time\u00a0Frame:\u00a0Will be assessed 30 days after all subjects complete chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">AEs and Serious Adverse Events (SAEs) related to pegfilgrastim, naproxen, or loratadine</div></li>\n<li style=\"margin:1ex 0.5ex\">Severity of Adverse Events [\u00a0Time\u00a0Frame:\u00a0Will be assessed 30 days after all subjects complete chemotherapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Severity of AEs related to pegfilgrastim, naproxen, or loratadine</div></li>\n</ul></td>"], "BT": ["NOLAN: Naproxen or Loratadine and Neulasta"], "OOOM": ["Not Provided"], "LUD": ["July 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01712009"], "EPCD": ["April 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast ", " Subjects Receiving Chemotherapy and Pegfilgrastim"], "COOM": ["Not Provided"], "SD": ["November 2012"]},
{"OPOM": ["Overall survival of patients treated with adjuvant ipilimumab  versus  high-dose recombinant interferon alfa-2b [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01274338"], "CPOM": [], "FRD": ["January 8, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01274338?rank=170&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of toxicity assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 70 days after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be summarized by treatment group and NCI CTCAE worst grade. Toxicity incidence rate and 95% confidence interval for each type will be presented.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in global quality of life assessed using the FACT-G [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The two-sample t-test will be used to compare continuous measurements and Chi-square test will be used to compare the categorical outcomes between the two treatment groups. Longitudinal regression models will also be used to address the overall change over time during which the QOL data is collected.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in health-related domains of quality of life assessed using symptom and functioning subscales [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The two-sample t-test will be used to compare continuous measurements and Chi-square test will be used to compare the categorical outcomes between the two treatment groups. Longitudinal regression models will also be used to address the overall change over time during which the QOL data is collected.</div></li>\n</ul></td>"], "BT": ["Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery"], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Recurrence-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity of adjuvant ipilimumab  versus  high-dose recombinant interferon alfa-2b [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Global quality of life [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01274338"], "EPCD": ["May 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma"], "COOM": ["Not Provided"], "SD": ["May 2011"]},
{"OPOM": ["Part 1 maximum tolerated dose of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 1 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01703481"], "CPOM": ["Part 1: Maximum tolerated dose of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 1 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 22, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01703481?rank=171&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Maximum observed plasma concentration of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time of maximum observed plasma concentration of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the plasma concentration-time curve from time 0 to time 24 hours of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Half life of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Apparent volume of distribution at steady-state of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Total clearance of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Accumulation index of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with best overall response of complete response (CR) [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Complete response is disappearance of all target lesions for a period of at least one month. This will be considered for evaluation of objective response rate.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with best overall response of partial response (PR) [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Partial response is at least a 30% decrease in the sum of the longest diameter of measures of target lesions. This will be considered for evaluation of objective response rate.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with best overall response of stable disease (SD) [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progression of disease.</div></li>\n<li style=\"margin:1ex 0.5ex\">The number of participants affected by an adverse event [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Progression free survival is the time period from start of study medication till the disease progression or death, whichever occurs first.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of objective response [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Duration of objective response is time interval from the first date that criteria for complete response or partial response are met to the first date of progression of disease.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with best overall response of progressive disease (PD) [\u00a0Time\u00a0Frame:\u00a0Up to Part 3 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Progressive disease is a 20 percentage or greater increase in the sum of the longest diameter of measured lesions (target lesions), taking as reference the smallest sum of longest diameter recorded since the treatment started or the appearance of one or more new lesions</div></li>\n</ul></td>"], "BT": ["A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid ", " or Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Maximum observed plasma concentration of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time of maximum observed plasma concentration of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the plasma concentration-time curve from time 0 to time 24 hours of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Half life of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Apparent volume of distribution at steady-state of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Total clearance of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Accumulation index of JNJ-42756493 [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with complete response (CR) [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with partial response (PR) [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with stable disease (SD) [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">The number of participants affected by an adverse event [\u00a0Time\u00a0Frame:\u00a0Up to Part 2 Day 84 (Cycle 4, Day 21)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patients with change in tissue pFGFR marker during treatment relative to pre-treatment baseline [\u00a0Time\u00a0Frame:\u00a0Screening and Day 21, Cycle 1 (+ or - 2 days)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patients with change in tissue pERK marker during treatment relative to pre-treatment baseline [\u00a0Time\u00a0Frame:\u00a0Screening and Day 21, Cycle 1 (+ or - 2 days)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Patients with change in tissue pS6 marker during treatment relative to pre-treatment baseline [\u00a0Time\u00a0Frame:\u00a0Screening and Day 21, Cycle 1 (+ or - 2 days)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01703481"], "EPCD": ["July 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid ", " or Lymphoma"], "COOM": ["Not Provided"], "SD": ["June 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01900652"], "CPOM": ["Proportion of Participants Exhibiting a Confirmed Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) [\u00a0Time\u00a0Frame:\u00a0Baseline to Objective Disease Progression or Start of New Anticancer Therapy (Estimated up to 15 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 12, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01900652?rank=178&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Baseline to Objective Disease Progression or Death Due to Any Cause (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to Progressive Disease (TTPD) [\u00a0Time\u00a0Frame:\u00a0Baseline to Objective Disease Progression (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in Tumor Size (CTS) [\u00a0Time\u00a0Frame:\u00a0Baseline to Measurement with Smallest Tumor Size (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Proportion of Participants Exhibiting a Stable Disease (SD) or a confirmed CR or PR (Disease Control Rate [DCR]) [\u00a0Time\u00a0Frame:\u00a0Baseline to Objective Disease Progression or Participant Stops Study (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (DoR) [\u00a0Time\u00a0Frame:\u00a0Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0Baseline to Death Due to Any Cause (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ) C30 (QLQ-C30) and Lung Cancer 13 (QLQ-LC13) [\u00a0Time\u00a0Frame:\u00a0Baseline, Objective Disease Progression or Participants Stops Study (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from Baseline in EuroQol 5-Dimensional Scale (EQ-5D) [\u00a0Time\u00a0Frame:\u00a0Baseline, Objective Disease Progression or Participants Stops Study (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics (PK):  Area Under the Concentration Time Curve During a Dosing Interval (AUCtau) of LY2875358 [\u00a0Time\u00a0Frame:\u00a0Cycle 1 through Cycle 4 (28 Day Cycle)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Proportion of Participants with Anti-LY2875358 Antibody Response [\u00a0Time\u00a0Frame:\u00a0Baseline through 30 Day Follow Up (Estimated up to 24 Months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["A Study of LY2875358 in Non Small Cell Lung ", " (NSCLC) Participants"], "OOOM": ["Not Provided"], "LUD": ["July 29, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01900652"], "EPCD": ["February 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib"], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": ["The primary endpoint is death from any cause or incident, dementia or persistent physical disability. [\u00a0Time\u00a0Frame:\u00a0every 3-6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT01038583"], "CPOM": ["The primary endpoint is death from any cause or incident, dementia or persistent physical disability. [\u00a0Time\u00a0Frame:\u00a0every 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["December 21, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01038583?rank=179&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">All-cause mortality [\u00a0Time\u00a0Frame:\u00a0every 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Fatal and non fatal cardiovascular events including a) coronary heart disease death, b) non-fatal MI, c) fatal and non-fatal stroke and d) any hospitalization for heart failure [\u00a0Time\u00a0Frame:\u00a0every 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Fatal and non-fatal cancer, excluding non-melanoma skin cancer [\u00a0Time\u00a0Frame:\u00a0every 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Dementia [\u00a0Time\u00a0Frame:\u00a0every 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Mild Cognitive Impairment (MCI; assessed using the Modified Mini-Mental State Examination or 3MS 70 and other cognitive function measures - see below) [\u00a0Time\u00a0Frame:\u00a0every 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Physical disability [\u00a0Time\u00a0Frame:\u00a0every 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Major hemorrhagic events [\u00a0Time\u00a0Frame:\u00a0every 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Aspirin in Reducing Events in the Elderly"], "OOOM": ["Not Provided"], "LUD": ["May 16, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">All-cause mortality [\u00a0Time\u00a0Frame:\u00a0every 3-6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Fatal and non fatal cardiovascular events including a) coronary heart disease death, b) non-fatal MI, c) fatal and non-fatal stroke and d) any hospitalization for heart failure [\u00a0Time\u00a0Frame:\u00a0every 3-6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Fatal and non-fatal cancer, excluding non-melanoma skin cancer [\u00a0Time\u00a0Frame:\u00a0every 3-6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Dementia [\u00a0Time\u00a0Frame:\u00a0every 3-6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Mild Cognitive Impairment (MCI; assessed using the Modified Mini-Mental State Examination or 3MS 70 and other cognitive function measures - see below) [\u00a0Time\u00a0Frame:\u00a0every 3-6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Physical disability [\u00a0Time\u00a0Frame:\u00a0every 3-6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Major hemorrhagic events [\u00a0Time\u00a0Frame:\u00a0every 3-6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01038583"], "EPCD": ["January 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Aspirin in Reducing Events in the Elderly"], "COOM": ["Not Provided"], "SD": ["January 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01520220"], "CPOM": [], "FRD": ["January 10, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01520220?rank=180&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Pharmacokinetics of LY2784544:  Maximum concentration (Cmax) [\u00a0Time\u00a0Frame:\u00a0Cycle 1 in Part A and Part B (28 day cycles)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics of LY2784544:  Area under the concentration-time curve (AUC) [\u00a0Time\u00a0Frame:\u00a0Cycle  1 in Part A  and Part B (28 day cycles)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">International Working Group (IWG) response [\u00a0Time\u00a0Frame:\u00a0Baseline through last Cycle in Part A and Part B (28 day cycles)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Dynamic International Prognostic Scoring System (DIPSS) Plus [\u00a0Time\u00a0Frame:\u00a0Baseline through last Cycle in Part A and Part B (28 day cycles)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in symptom burden as assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) [\u00a0Time\u00a0Frame:\u00a0Baseline, Last Cycle in Part A and Part B\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in Myeloproliferative Neoplasm (MPN) Physician Symptom Assessment [\u00a0Time\u00a0Frame:\u00a0Baseline, Last Cycle in Part A and Part B\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative "], "OOOM": ["Not Provided"], "LUD": ["July 18, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Pharmacokinetics of LY2784544:  Maximum concentration (Cmax) [\u00a0Time\u00a0Frame:\u00a0Cycles 1 and 2 in Part A (28 day cycles)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics of LY2784544:  Area under the concentration-time curve (AUC) [\u00a0Time\u00a0Frame:\u00a0Cycles 1 and 2 in Part A (28 day cycles)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">International Working Group (IWG) response [\u00a0Time\u00a0Frame:\u00a0Baseline through last Cycle in Part A and Part B (28 day cycles)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Dynamic International Prognostic Scoring System (DIPSS) Plus [\u00a0Time\u00a0Frame:\u00a0Baseline through last Cycle in Part A and Part B (28 day cycles)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in symptom burden as assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) [\u00a0Time\u00a0Frame:\u00a0Baseline, Last Cycle in Part A and Part B\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in Myeloproliferative Neoplasm (MPN) Physician Symptom Assessment [\u00a0Time\u00a0Frame:\u00a0Baseline, Last Cycle in Part A and Part B\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01520220"], "EPCD": ["March 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative "], "COOM": ["Not Provided"], "SD": ["June 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01896531"], "CPOM": ["Progression-free survival (RECIST v1.1 criteria) [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 8, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01896531?rank=176&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Confirmed objective tumor response in patients with measurable soft tissue disease at baseline [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of confirmed objective response in patients with measurable soft tissue disease at baseline [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction "], "OOOM": ["Not Provided"], "LUD": ["July 21, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01896531"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Phase II, Placebo Controlled Study of GDC-0068, an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma"], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": ["A Photodynamic Therapy (PDT) research repository and de-identified registry [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01842555"], "CPOM": ["A Photodynamic Therapy (PDT) research repository and de-identified registry [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 18, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01842555?rank=173&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Survival following palliative and non-palliative PDT [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">calculated by date of PDT treatment and date of death (where applicable)</div></li>\n<li style=\"margin:1ex 0.5ex\">Short and long term efficacy of PDT in presenting symptom improvement [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Quality of Life Score before and after PDT</div></li>\n<li style=\"margin:1ex 0.5ex\">Complications after PDT [\u00a0Time\u00a0Frame:\u00a0up to 3 years after\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">30-day mortality (yes/no), length of stay in hospital (number of days), assessment of PDT-related complications (ex: phototoxic reaction (yes/no), urgent re-bronchoscopy (yes/no))</div></li>\n</ul></td>"], "BT": ["Photodynamic Therapy (PDT) Oncology Registry"], "OOOM": ["Not Provided"], "LUD": ["December 13, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Survival following palliative and non-palliative PDT [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">calculated by date of PDT treatment and date of death (where applicable)</div></li>\n<li style=\"margin:1ex 0.5ex\">Short and long term efficacy of PDT in presenting symptom improvement [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Quality of Life Score before and after PDT</div></li>\n<li style=\"margin:1ex 0.5ex\">Complications after PDT [\u00a0Time\u00a0Frame:\u00a0up to 3 years after\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">30-day mortality (yes/no), length of stay in hospital (number of days), asssessment of PDT-related complications (ex: phototoxic reaction (yes/no), urgent re-bronchoscopy (yes/no))</div></li>\n</ul></td>"], "record_id": ["NCT01842555"], "EPCD": ["November 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Photodynamic Therapy (PDT) Oncology Registry"], "COOM": ["Not Provided"], "SD": ["November 2012"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT00026312"], "CPOM": ["EFS [\u00a0Time\u00a0Frame:\u00a0From study enrollment until the first occurrence of an event or until last contact with the patient if no event occurs, assessed up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 9, 2001"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00026312?rank=181&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0From study enrollment until death or until last contact with the patient if the patient dose not die, assessed up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier curves will be generated and log rank tests will be performed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in MRD [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A descriptive analysis of the change from baseline of MRD will be performed. Also, a Wilcoxon rank-sum test will be performed to compare the median change from baseline of MRD between the two treatment arms. A multivariate Cox proportional hazards regression model will test to see if the change in MRD burden is associated with EFS or OS.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in tumor biology [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A multivariate Cox proportional hazards regression model will test to see if the Ch14.18 serum level, HACA titer, effector cell function, or serum marker for effector cell activation are associated with EFS or OS.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of toxicities assessed using Common Terminology Criteria for Adverse Events version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive analyses of toxicity will be performed over all patients.</div></li>\n<li style=\"margin:1ex 0.5ex\">Levels of ADCC [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be descriptively compared.</div></li>\n<li style=\"margin:1ex 0.5ex\">Average level of HACA [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The average level of HACA at each collection time point during immunotherapy will be calculated.</div></li>\n<li style=\"margin:1ex 0.5ex\">Historical data for the analogous patients [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A historical comparison will be made. This comparison will be a descriptive one only.</div></li>\n<li style=\"margin:1ex 0.5ex\">13-cis-retinoic-acid pharmacokinetic parameters [\u00a0Time\u00a0Frame:\u00a0At 4 hours after administration on day 14 of course 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine if there is a relationship of the peak serum concentration level with EFS, the term for this level will be tested in a Cox proportional hazards model. To determine if there is a relationship of the peak serum concentration level with toxicity rates, Kendall's Tau statistic will be calculated.</div></li>\n<li style=\"margin:1ex 0.5ex\">Presence of naturally occurring anti-glycan antibodies [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A Fisher's exact test will be performed to determine if the presence of naturally occurring anti-glycan antibodies correlates with allergic reactions. A Wilcoxon test will be performed to determine if the presence of naturally occurring anti-glycan antibodies correlates with blood levels of ch14.18.</div></li>\n<li style=\"margin:1ex 0.5ex\">Genotype of Kir/Kir-Ligand [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier plots of EFS will be generated for the three genotype subgroups of FcR as well as for the three genotype subgroups of Kir/Kir-Ligand. In addition, a log rank test comparison will be made in a pairwise fashion of each of the genotypes within FcR and within Kir/Kir-Ligand.</div></li>\n<li style=\"margin:1ex 0.5ex\">EFS of patients from the non-randomized portion of the trial [\u00a0Time\u00a0Frame:\u00a0From study enrollment until the first occurrence of an event or until last contact with the patient if no event occurs, assessed up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier curves of EFS and OS will be generated, including 95% confidence intervals on the curves.</div></li>\n<li style=\"margin:1ex 0.5ex\">OS of patients from the non-randomized portion of the trial [\u00a0Time\u00a0Frame:\u00a0From study enrollment until death or until last contact with the patient if the patient dose not die, assessed up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier curves of EFS and OS will be generated, including 95% confidence intervals on the curves.</div></li>\n<li style=\"margin:1ex 0.5ex\">Cardiac repolarization [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">In general, descriptive summaries will include n, mean, standard deviation, median, minimum, maximum and 90% confidence intervals for continuous variables, and n and percent for categorical variables. Summaries will present data by assessment time when appropriate.</div></li>\n<li style=\"margin:1ex 0.5ex\">Genotype of FcR [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier plots of EFS will be generated for the three genotype subgroups of FcR as well as for the three genotype subgroups of Kir/Kir-Ligand. In addition, a log rank test comparison will be made in a pairwise fashion of each of the genotypes within FcR and within Kir/Kir-Ligand.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of courses of therapy delivered [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A Wilcoxon test will be used to compare the number of courses of therapy delivered.</div></li>\n</ul></td>"], "BT": ["Isotretinoin With or Without Monoclonal Antibody Ch14.18, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00026312"], "EPCD": ["December 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue"], "COOM": ["Not Provided"], "SD": ["October 2001"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01262651"], "CPOM": ["The primary endpoint is the percent improvement from baseline to the end of treatment in NRS average pain score. [\u00a0Time\u00a0Frame:\u00a05 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 16, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01262651?rank=185&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Change from baseline in mean NRS average pain [\u00a0Time\u00a0Frame:\u00a05 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in mean NRS worst pain [\u00a0Time\u00a0Frame:\u00a05 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in mean Sleep Disruption NRS [\u00a0Time\u00a0Frame:\u00a05 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study of Sativex\u00ae for Relieving Persistent Pain in Patients With Advanced "], "OOOM": ["Not Provided"], "LUD": ["July 16, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01262651"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex\u00ae in Relieving Persistent Pain in Patients With Advanced ", ", Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy."], "COOM": ["Not Provided"], "SD": ["December 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01096368"], "CPOM": [], "FRD": ["March 30, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01096368?rank=184&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">EFS and OS of children with incompletely resected ependymoma who are unable to achieve a complete response (CR) by  post-operative induction chemotherapy or by second surgery [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Kaplan-Meier curves will be used to estimate the EFS and OS for patients who were non-randomly assigned to receive maintenance chemotherapy after incomplete resection</div></li>\n<li style=\"margin:1ex 0.5ex\">EFS and OS of children with supratentorial classic ependymoma who achieve a complete resection at first or second surgery or children who achieve a CR after induction chemotherapy assigned to observation [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using Kaplan-Meier curves for patients with supratentorial classic disease that achieve complete resection or CR to induction chemotherapy and are assigned to observation only.</div></li>\n<li style=\"margin:1ex 0.5ex\">Neurologic, neuropsychological, and endocrine long-term sequelae of surgery, conformal radiotherapy, and maintenance chemotherapy [\u00a0Time\u00a0Frame:\u00a0At 9, 30, and 60 months post diagnosis\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Gene expression signatures and genomic alterations in pediatric ependymoma [\u00a0Time\u00a0Frame:\u00a0At the time of first or second surgery\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma"], "OOOM": ["Not Provided"], "LUD": ["February 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">EFS and OS of children with incompletely resected ependymoma who are unable to achieve a complete response (CR) by  post-operative induction chemotherapy or by  second surgery [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">EFS and OS of children with supratentorial classic ependymoma who achieve a complete resection at first or second resection or children who achieve a CR to short-course induction chemotherapy following first surgery [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Neurologic, neuropsychological, and endocrine long-term sequelae of surgery, cRT, and VCEC as compared to those patients treated on COG-ACNS0121 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Gene expression signatures and genomic alterations in pediatric ependymoma [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prognostic molecular signatures and genomic alterations in ependymomas [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01096368"], "EPCD": ["March 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years"], "COOM": ["Not Provided"], "SD": ["March 2010"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT01351545"], "CPOM": ["Not Provided"], "FRD": ["May 9, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01351545?rank=189&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)"], "OOOM": ["Not Provided"], "LUD": ["July 18, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01351545"], "EPCD": ["Not Provided"], "OT": ["A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic ", " and Other Indications"], "COOM": ["Not Provided"], "SD": ["October 2011"]},
{"OPOM": ["To compare Progression Free Survival  (PFS) of nilotinib and imatinib when used as initial therapy in patents with unresectable and/ or metastatic GIST. [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00785785"], "CPOM": ["To compare Progression Free Survival  (PFS) of nilotinib and imatinib when used as initial therapy in patents with unresectable and/ or metastatic GIST. [\u00a0Time\u00a0Frame:\u00a0throughout the study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 4, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00785785?rank=186&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">To compare disease control rate (DCR) of nilotinib and imatinib [\u00a0Time\u00a0Frame:\u00a0throughout the study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To compare time to treatment failure (TTF) of nilotinib and imatinib [\u00a0Time\u00a0Frame:\u00a0throughout the study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To compare overall survival (OS) of nilotinib and imatinib [\u00a0Time\u00a0Frame:\u00a0throughout the study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To compare time to progression (TTP), response rate (RR), time to tumor response and assess duration of response of nilotinib and imatinib [\u00a0Time\u00a0Frame:\u00a0throughout the study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To compare safety and tolerability of nilotinib and imatinib [\u00a0Time\u00a0Frame:\u00a0at month 1 and then every 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["A Study of Nilotinib Versus Imatinib in GIST Patients"], "OOOM": ["Not Provided"], "LUD": ["March 13, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">To compare disease control rate (DCR) of nilotinib and imatinib [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To compare time to treatment failure (TTF) of nilotinib and imatinib [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To compare overall survival (OS) of nilotinib and imatinib [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00785785"], "EPCD": ["May 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Open Label, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib in Adult Patients With Unresectable or Metastatic Gastrointestinal Stromal ", " (GIST)"], "COOM": ["Not Provided"], "SD": ["March 2009"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02092467"], "CPOM": [], "FRD": ["March 3, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02092467?rank=188&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Opportunistic infections [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adjudicated, including tuberculosis</div></li>\n<li style=\"margin:1ex 0.5ex\">Hepatic events [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adjudicated</div></li>\n<li style=\"margin:1ex 0.5ex\">Cardiovascular events other than MACE [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adjudicated</div></li>\n<li style=\"margin:1ex 0.5ex\">All cause mortality [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adjudicated</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease Activity Score Based on 28-joints Count (DAS28) [\u00a0Time\u00a0Frame:\u00a0Month 3, 6, 9, 12, 24, 36, 48, 60\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 \u22643.2 = low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants With an American College of Rheumatology 20% (ACR20) Response [\u00a0Time\u00a0Frame:\u00a0Month 3, 6, 9, 12, 24, 36, 48, 60\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ACR20 response: greater than or equal to (\u2265) 20 percent (%) improvement in tender joint count; \u2265 20% improvement in swollen joint count; and \u2265 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</div></li>\n<li style=\"margin:1ex 0.5ex\">Clinical Disease Activity Index (CDAI) [\u00a0Time\u00a0Frame:\u00a0Month 3, 6, 9, 12, 24, 36, 48, 60\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Simplified Disease Activity Index (SDAI) [\u00a0Time\u00a0Frame:\u00a0Month 3, 6, 9, 12, 24, 36, 48, 60\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">ACR-EULAR Boolean remission [\u00a0Time\u00a0Frame:\u00a0Month 3, 6, 9, 12, 24, 36, 48, 60\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Must have all of the following: &lt; or = 1 tender joint count, &lt; or = 1 swollen joint count, CRP &lt; or = 1 mg/dL, patient global assessment &lt; or = 1 on 0-10 scale</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response [\u00a0Time\u00a0Frame:\u00a0Month 3, 6, 9, 12, 24, 36, 48, 60\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ACR50 response: greater than or equal to (\u2265) 50 percent (%) improvement in tender or swollen joint counts and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response [\u00a0Time\u00a0Frame:\u00a0Month 3, 6, 9, 12, 24, 36, 48, 60\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ACR70 response: greater than or equal to (\u2265) 70 percent (%) improvement in tender or swollen joint counts and 70% improvement in 3 of the following 5 criteria: 1) physician's global assessment of disease activity, 2) subject's assessment of disease activity, 3) subject's assessment of pain, 4) subject's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein at each visit.</div></li>\n<li style=\"margin:1ex 0.5ex\">Health Assessment Questionnaire-Disability Index (HAQ-DI) [\u00a0Time\u00a0Frame:\u00a0Month 3, 6, 9, 12, 24, 36, 48, 60\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Safety Study Of Tofacitinib Versus ", " Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis"], "OOOM": ["Not Provided"], "LUD": ["July 8, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02092467"], "EPCD": ["April 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A ", " Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis"], "COOM": ["Not Provided"], "SD": ["March 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01191814"], "CPOM": ["Complications related to stent dysfunction [\u00a0Time\u00a0Frame:\u00a030 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["August 12, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01191814?rank=191&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Procedural complications [\u00a0Time\u00a0Frame:\u00a030 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Complications related to the procedure which includes pancreatitis, perforation or hemorrhage.</div></td>"], "BT": ["Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression"], "OOOM": ["Not Provided"], "LUD": ["November 19, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01191814"], "EPCD": ["July 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Not Provided"], "COOM": ["Not Provided"], "SD": ["July 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02048813"], "CPOM": [], "FRD": ["January 27, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02048813?rank=190&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0Time from randomization until death due to any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A stratified logrank test applied to all patients as randomized will be the primary analysis for OS, with age, ECOG performance status, disease stage, and baseline cytogenetic abnormalities as stratification factors. The same analysis applied to eligible patients only will also be performed as a sensitivity analysis. Cox proportional hazards models will be used to assess possible effects of clinical and biological characteristics on outcome, including age, gender, disease stage, cytogenetic abnormalities, ECOG performance status, and important mutations.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of toxicity, defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment, graded according to NCI Common Terminology for Adverse Events version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. In addition, all adverse event data that is graded as 3, 4, or 5 will be reviewed and classified as either \"unrelated or unlikely to be related\" to study treatment in the event of an actual relationship developing.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in FACT-Leu TOI score [\u00a0Time\u00a0Frame:\u00a0Baseline to 3 months after beginning therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The change in FACT-Leu TOI score will be compared between arm A and arm B to assess the short-term effect of the two therapies on QOL.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in FACT-Leu TOI score [\u00a0Time\u00a0Frame:\u00a0Baseline to 6 months after beginning therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The change in FACT-Leu TOI score from the time of randomization to 6 months after beginning therapy will be compared between the two treatment arms in order to provide additional information regarding the toxicity of the different regimens.</div></li>\n<li style=\"margin:1ex 0.5ex\">Impact of CLL on QOL [\u00a0Time\u00a0Frame:\u00a0Baseline\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The social well-being and emotional well-being components of the FACT-General (G) will be administered at study entry. The entire FACT-Leukemia instrument (FACT-G and the leukemia subscale) at baseline will be analyzed using descriptive statistics to assess the impact of CLL on QOL independent of treatment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Adherence to prescription assessed by the Moriskey Adherence Scale (Arm A only) [\u00a0Time\u00a0Frame:\u00a0Up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive statistics will be used to summarize trend in adherence to prescription.</div></li>\n</ul></td>"], "BT": ["Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02048813"], "EPCD": ["April 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)"], "COOM": ["Not Provided"], "SD": ["February 2014"]},
{"OPOM": ["Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0The outcome of PFS will be measured montly for an estimate of 22 months after the first 50 patients are enrolled.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01774851"], "CPOM": ["Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a030 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 10, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01774851?rank=182&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach"], "OOOM": ["Not Provided"], "LUD": ["July 25, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01774851"], "EPCD": ["July 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy"], "COOM": ["Not Provided"], "SD": ["January 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01394978"], "CPOM": ["Safety endpoints [\u00a0Time\u00a0Frame:\u00a090 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["July 13, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01394978?rank=192&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["NeoMend ProGEL\u2122 Pleural Air Leak Sealant Post-Approval Study"], "OOOM": ["Not Provided"], "LUD": ["July 23, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01394978"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["AirTight: A Prospective Controlled Post-Approval Study of NeoMend ProGEL\u2122 Pleural Air Leak Sealant in the Treatment of Visible Pleural Air Leaks After Standard Pleural Closure"], "COOM": ["Not Provided"], "SD": ["June 2011"]},
{"OPOM": ["Progression-free survival rate [\u00a0Time\u00a0Frame:\u00a06 months post-Day 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT01498328"], "CPOM": [], "FRD": ["December 21, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01498328?rank=193&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and Tolerability [\u00a0Time\u00a0Frame:\u00a0Until 28 days or initiation of other anti-cancer treatment, whichever is first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety and tolerability will be evaluated by comparing the treatment regimens in regards to vital sign measurements, physical and neurological examinations, adverse events reporting, and Karnofsky performance status</div></li>\n<li style=\"margin:1ex 0.5ex\">Anti-tumor activity [\u00a0Time\u00a0Frame:\u00a0During treatment and every 8 weeks through follow up\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Evaluated by comparing the treatment regimens for anti-tumor activity, including objective response rate, overall progression free survival (PFS), and overall survival (OS) for Groups 1 and 2; and PFS6, overall PFS, and OS for Group 2C.</div></li>\n<li style=\"margin:1ex 0.5ex\">EGFRvIII-specific immune response [\u00a0Time\u00a0Frame:\u00a0Several times during the first month of treatment and then approximately every 8 weeks until treatment is stopped.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Characterize the EGFRvIII specific immune response to rindopepimut.</div></li>\n</ul></td>"], "BT": ["A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma"], "OOOM": ["Not Provided"], "LUD": ["July 8, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and Tolerability [\u00a0Time\u00a0Frame:\u00a0Until 28 days or initiation of other anti-cancer treatment, whichever is first\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety and tolerability will be evaluated by comparing the treatment regimens in regards to vital sign measurements, physical and neurological examinations, adverse events reporting, and Karnofsky performance status</div></li>\n<li style=\"margin:1ex 0.5ex\">Anti-tumor activity [\u00a0Time\u00a0Frame:\u00a0During treatment and every 8 weeks through follow up\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Evaluated by comparing the treatment regimens for anti-tumor activity, including objective response rate, overall progression free survival, and overall survival (OS).</div></li>\n<li style=\"margin:1ex 0.5ex\">EGFRvIII-specific immune response [\u00a0Time\u00a0Frame:\u00a0Several times during the first month of treatment and then approximately every 8 weeks until treatment is stopped.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Characterize the EGFRvIII specific immune response to rindopepimut.</div></li>\n</ul></td>"], "record_id": ["NCT01498328"], "EPCD": ["June 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma"], "COOM": ["Not Provided"], "SD": ["December 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02013128"], "CPOM": ["To evaluate the safety of ublituximab in combination with ibrutinib in patients with select B-cell malignancies [\u00a0Time\u00a0Frame:\u00a028 days (1 cycle of therapy)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 11, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02013128?rank=197&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Overall Response Rate [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the overall response rate (ORR) in patients with hematologic malignancies treated with Ublituximab in combination with Ibrutinib</div></td>"], "BT": ["Ublituximab + Ibrutinib in Select B-cell "], "OOOM": ["Not Provided"], "LUD": ["March 24, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02013128"], "EPCD": ["September 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell "], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death or, otherwise, the last follow-up date on which the patient was reported alive, assessed up to13 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01730950"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0From randomization to the date of death or the last follow-up. Analysis occurs after XX deaths have bee reported.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 15, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01730950?rank=194&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response [\u00a0Time\u00a0Frame:\u00a0Analysis occurs at the same time as the primary outcome analysis.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using an exact binomial distribution together with 95% confidence interval. The difference between the two groups will be tested using a chi square test.</div></li>\n<li style=\"margin:1ex 0.5ex\">6-month Progression-free survival (PFS) rate [\u00a0Time\u00a0Frame:\u00a0Up to 6-months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using an exact binomial distribution together with 95% confidence interval. The difference between the two groups will be teated using a chi square test.</div></li>\n<li style=\"margin:1ex 0.5ex\">PFS [\u00a0Time\u00a0Frame:\u00a0Analysis occurs at the same time as the primary outcome analysis.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Progression-free survival rates will be estimated using the Kaplan-Meier method (Kaplan 1958), and differences between treatment arms will be tested in the log-rank test (Mantel 1966). Multivariate analyses with the Cox proportional hazard model (Cox 1972) for PFS will be performed with the stratification variables as fixed variables to assess the treatment effect adjusting patient-specific risk factors.</div></li>\n<li style=\"margin:1ex 0.5ex\">Grade 3+ acute or delayed CNS toxicity rate [\u00a0Time\u00a0Frame:\u00a0Analysis occurs at the same time as the primary outcome analysis.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using an exact binomial distribution together with 95% confidence interval. The difference between the two groups will be tested using a chi square test.</div></li>\n</ul></td>"], "BT": ["Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma"], "OOOM": ["Not Provided"], "LUD": ["May 19, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using an exact binomial distribution together with 95% confidence interval. The difference between the 2 groups will be tested using a chi square test.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Up to 6-month\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Progression-free survival rates will be estimated using the Kaplan-Meier method (Kaplan 1958), and differences between treatment arms will be tested in the log-rank test (Mantel 1966). Multivariate analyses with the Cox proportional hazard model (Cox 1972) for PFS will be performed with the stratification variables as fixed variables to assess the treatment effect adjusting patient-specific risk factors.</div></li>\n<li style=\"margin:1ex 0.5ex\">PFS [\u00a0Time\u00a0Frame:\u00a0From randomization to progression or death, whichever occurs first, assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Progression-free survival rates will be estimated using the Kaplan-Meier method (Kaplan 1958), and differences between treatment arms will be tested in the log-rank test (Mantel 1966). Multivariate analyses with the Cox proportional hazard model (Cox 1972) for PFS will be performed with the stratification variables as fixed variables to assess the treatment effect adjusting patient-specific risk factors.</div></li>\n<li style=\"margin:1ex 0.5ex\">Treatment adverse events according to CTCAE v. 4.0 [\u00a0Time\u00a0Frame:\u00a02 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Grade 3 acute or delayed CNS toxicity [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using an exact binomial distribution together with 95% confidence interval.</div></li>\n</ul></td>"], "record_id": ["NCT01730950"], "EPCD": ["July 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VERSUS BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA"], "COOM": ["Not Provided"], "SD": ["December 2012"]},
{"OPOM": ["The primary objective is to estimate the rate of inadequate response to laxatives (LIR) in a cohort of patients with OIC. [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01928953"], "CPOM": ["Rate of LIR among the OIC population [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 22, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01928953?rank=195&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Rate of inadequate response to first and second-line laxative treatment for OIC (1x LIR and 2x LIR). [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Baseline demographic and clinical characteristics of patients with OIC (prior health status, comorbidities, GI symptoms, and concomitant medications). [\u00a0Time\u00a0Frame:\u00a012months retrospectively\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Drug utilization and self-management of OIC at baseline and changes from baseline over the 24-week follow-up period. [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Healthcare resource utilization profiles pre- and post-baseline [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cost of illness related to the diagnosis, treatment, and general management of OIC (including laxative use) and events attributed to OIC, including both direct and indirect costs. [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Baseline constipation-associated GI symptoms and changes from baseline over the 24-week follow-up period (PAC-SYM and additional symptom questions). [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Baseline health-related quality of life (PAC-QOL and EQ-5D) and changes from baseline over the 24-week follow-up period (PAC-QOL). [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Loss of productivity (WPAI-SHP score) at baseline and changes from baseline over the 24-week follow-up period. [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Persistence on opioid therapy at baseline and changes from baseline over the 24-week follow-up period [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Treatment satisfaction with laxative use at baseline and changes from baseline over the 24-week follow-up period, for all patients taking laxatives. [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Physician-reported awareness of OIC and symptoms, and understanding of patient reported impact of OIC at baseline. [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Longitudinal Study of Patients With Opioid-Induced Constipation"], "OOOM": ["Not Provided"], "LUD": ["February 27, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">To estimate the rate of inadequate response to first and second-line laxative treatment for OIC (1x LIR and 2x LIR) in patients with OIC [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To describe the baseline demographic and clinical characteristics, including prior health status, comorbidities, constipation-related GI symptoms, and concomitant medications of patients with OIC [\u00a0Time\u00a0Frame:\u00a012months retrospectively\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To describe drug utilization and self-management of OIC [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To describe the healthcare resource utilization and estimate costs associated with the diagnosis, treatment, and general management of OIC (including laxative use) and events attributed to OIC, including both direct and indirect costs [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To describe patient-reported impact of OIC on health-related quality of life, productivity, and pain management [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To describe patient-reported treatment satisfaction with laxative use; [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">To describe physician-reported awareness of OIC and symptoms, and understanding of patient-reported impact of OIC [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01928953"], "EPCD": ["April 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Longitudinal Study of Patients With Opioid-Induced Constipation"], "COOM": ["Not Provided"], "SD": ["October 2012"]},
{"OPOM": ["EFS at 3 years [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01595048"], "CPOM": ["EFS [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["May 8, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01595048?rank=183&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Survival [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated by the Kaplan-Meier method and the 95% confidence intervals (95% CI) of the actuarial rates calculated by the Rothman method.</div></li>\n<li style=\"margin:1ex 0.5ex\">Complete remission rate compared between arms by logistic regression [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared between arms by logistic regression.</div></li>\n<li style=\"margin:1ex 0.5ex\">Acute and long-term toxicity as assessed by the National Cancer Institute Common Terminology Criteria version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Immune reconstitution as assessed by Ig (G, A, and M) levels and lymphocyte counts [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia"], "OOOM": ["Not Provided"], "LUD": ["February 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Survival estimated by the Kaplan-Meier method and the 95% confidence intervals (95% CI) of the actuarial rates calculated by the Rothman method [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Complete remission rate compared between arms by logistic regression [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Acute and long-term toxicity as assessed by the National Cancer Institute Common Terminology Criteria  version 4.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Immune reconstitution as assessed by Ig (G, A, and M) levels and lymphocyte counts [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01595048"], "EPCD": ["December 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients"], "COOM": ["Not Provided"], "SD": ["June 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01889797"], "CPOM": ["Complete Response (CR) Rate [\u00a0Time\u00a0Frame:\u00a0Re-staging (week 12, 13 or 14) and during follow-up if physician feels patient is subsequently in CR for up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 26, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01889797?rank=196&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">PET Response Rate [\u00a0Time\u00a0Frame:\u00a0Re-staging (week 12, 13 or 14)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PET response rate [PET-documented CR + Partial Response (PR)] based on PET scan results.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate [\u00a0Time\u00a0Frame:\u00a0Baseline and Re-staging (week 12, 13 or 14)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Overall response rate (CR + PR by Cheson criteria) at re-staging (including bone marrow biopsy if CR suspected) by PET and Neck, Chest, Abdomen and Pelvic Computed Tomography (CT) scan.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to Next Treatment [\u00a0Time\u00a0Frame:\u00a0Every 3 months for 2 years, then every 6 months for up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Next treatment is defined as any monoclonal antibody treatment, immunological therapy (such as vaccines), chemotherapy, radiotherapy, or radioimmunotherapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Every 3 months for 2 years, then every 6 months for up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">CT scan every 6 months until progression. Compare PFS in each treatment arm.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants with Adverse Events as a Measure of Safety and Tolerability [\u00a0Time\u00a0Frame:\u00a0Weekly x 4 weeks and Re-Staging (week 12, 13 or 14)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adverse event rates, exposure and laboratory data by treatment arm.</div></li>\n</ul></td>"], "BT": ["Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low ", " Burden Indolent Non-Hodgkin's Lymphoma"], "OOOM": [], "LUD": ["June 26, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01889797"], "EPCD": ["August 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low ", " Burden Indolent Non-Hodgkin's Lymphoma"], "COOM": [], "SD": ["December 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00897325"], "CPOM": ["Banking of tumor cells and germline DNA [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00897325?rank=198&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["November 3, 2012"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00897325"], "EPCD": ["Not Provided"], "OT": ["A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens"], "COOM": ["Not Provided"], "SD": ["September 2006"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00897767"], "CPOM": [], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00897767?rank=199&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial"], "OOOM": ["Not Provided"], "LUD": ["December 5, 2012"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00897767"], "EPCD": ["Not Provided"], "OT": ["Ancillary Laboratory Protocol For the Collection of Diagnostic Material On Patients Considered For ECOG Treatment Trials For Leukemia Or Related Hematologic Disorders"], "COOM": ["Not Provided"], "SD": ["July 2004"]},
{"OPOM": ["Progression Free Survival [\u00a0Time\u00a0Frame:\u00a0up to 48 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01799889"], "CPOM": ["Progression Free Survival [\u00a0Time\u00a0Frame:\u00a0Up to 24 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["February 13, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01799889?rank=200&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of abnormal laboratory data and adverse events [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">This composite endpoint is to assess the safety and tolerability profile of GS-9973. Safety will be assessed by grading of laboratory values and adverse events according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Objective response rate (ORR) will be determined from the participants' best response during GS-9973 therapy and will include complete response (CR) and partial response (PR) (or very good partial response [VGPR] or minor response [MR] for subjects with LPL/WM).</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of response [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Duration of response (DOR) is defined as time from the first response (CR or PR [or VGPR or MR for participants with LPL/WM]) is achieved until the earlier of the first documentation of definitive disease progression or death from any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to response [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to response (TTR) is defined as time from the first dose of GS-9973 to the first time the response (CR or PR [or VGPR or MR for subjects with LPL/WM]) is achieved.</div></li>\n</ul></td>"], "BT": ["A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic "], "OOOM": ["Exploratory endpoints [\u00a0Time\u00a0Frame:\u00a0up to 48 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Safety and Tolerability [\u00a0Time\u00a0Frame:\u00a0up to 48 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Safety: all abnormal laboratory data, adverse events (AEs) and treatment-emergent AEs. Safety will be assessed by grading of laboratory values and AEs according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</div></li>\n<li style=\"margin:1ex 0.5ex\">Efficacy [\u00a0Time\u00a0Frame:\u00a0up to 48 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><ul style=\"margin-top:1ex; margin-bottom:1ex;\"><li style=\"margin-top:0.7ex;\">Objective response rate (ORR). ORR will be determined from the subjects' best response during GS-9973 therapy and will include complete response (CR) and partial response (PR).</li>\n<li style=\"margin-top:0.7ex;\">Disease control rate (DCR). DCR will be defined as from the subjects' best response during GS-9973 therapy and will include stable disease (SD) lasting at least 16 weeks, CR, and PR.</li>\n<li style=\"margin-top:0.7ex;\">Duration of response (DOR). DOR will be defined as time from the first response is achieved until the earlier of the first documentation of definitive disease progression or death from any cause.</li>\n<li style=\"margin-top:0.7ex;\">Time to response (TTR). TTR will be defined as time from the first dose of GS-9973 to the first time the response (CR or PR) is achieved.</li>\n</ul></div></li>\n</ul></td>"], "record_id": ["NCT01799889"], "EPCD": ["June 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic "], "COOM": ["Not Provided"], "SD": ["March 2013"]},
{"OPOM": ["Development of proven or probable invasive fungal infections (IFI) defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01307579"], "CPOM": ["Time to development of proven or probable IFI, defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) [\u00a0Time\u00a0Frame:\u00a0Assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 1, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01307579?rank=187&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to development of proven or probably invasive aspergillosis (IA), defined according to the criteria developed by the EORTC/MSG [\u00a0Time\u00a0Frame:\u00a0Assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Evaluated using Kaplan-Meier analyses. Log rank test will be used to assess if there is any benefit associated with caspofungin acetate compared to fluconazole. Gray's test will be used to compare the cumulative incidence function between the 2 arms. Summary statistics such as means, standard deviations, medians, and ranges will be produced.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to death due to any cause [\u00a0Time\u00a0Frame:\u00a0Assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Standard survival analyses will be performed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Total days of empiric antifungal therapy while a patient is receiving prophylaxis [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared between the 2 arms using t-test or Wilcoxon rank sum test.</div></li>\n<li style=\"margin:1ex 0.5ex\">Sensitivity, specificity, positive predictive value, and negative predictive value of the galactomannan and beta-D glucan assays for the diagnosis of IFI or IA alone [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Determined using standard formulas and EORTC/MSG criteria as the gold standard. Calculated using STATA statistical software version 11.0.</div></li>\n<li style=\"margin:1ex 0.5ex\">Results of the genotyping assays for single nucleotide polymorphism analysis [\u00a0Time\u00a0Frame:\u00a0At the end of course 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Impact of candidate gene SNPs will be determined using the log rank test.</div></li>\n</ul></td>"], "BT": ["Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy"], "OOOM": ["Not Provided"], "LUD": ["June 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Development of proven or probably invasive aspergillosis (IA) defined according to the criteria developed by the EORTC/MSG [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Death due to any cause [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Need for empiric antifungal therapy defined as the institution of antifungal therapy while a patient is receiving prophylaxis [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Results from galactomannan and beta-D glucan assays for the diagnosis of IFI or IA alone [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Results of the genotyping assays for single nucleotide polymorphism analysis [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01307579"], "EPCD": ["October 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)"], "COOM": ["Not Provided"], "SD": ["April 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00899275"], "CPOM": [], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00899275?rank=201&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Samples of Blood and ", " Tissue From Patients With Osteosarcoma"], "OOOM": ["Not Provided"], "LUD": ["November 22, 2012"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00899275"], "EPCD": ["Not Provided"], "OT": ["A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens"], "COOM": ["Not Provided"], "SD": ["February 2008"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02006485"], "CPOM": ["Maximum Tolerated Dose acceptable for participants [\u00a0Time\u00a0Frame:\u00a028 days (1 cycle of therapy)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 5, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02006485?rank=205&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Overall Response Rate [\u00a0Time\u00a0Frame:\u00a0Up to 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the overall response rate (ORR) in patients with hematologic malignancies treated with Ublituximab in combination with TGR-1202</div></td>"], "BT": ["Ublituximab in Combination With TGR-1202 in Patients With B-cell "], "OOOM": ["Not Provided"], "LUD": ["January 25, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02006485"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor, in Patients With B-cell ", "."], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01979536"], "CPOM": [], "FRD": ["November 4, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01979536?rank=204&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Changes on levels of MRD [\u00a0Time\u00a0Frame:\u00a0Baseline up to day 21 (course 1)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Analyzed using the log-rank test.</div></td>"], "BT": ["Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01979536"], "EPCD": ["September 2020 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)"], "COOM": ["Not Provided"], "SD": ["November 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01404702"], "CPOM": ["Evaluate the safety and toxicity of zoledronic acid and aldesleukin [\u00a0Time\u00a0Frame:\u00a01.5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["July 13, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01404702?rank=209&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Evaluate the biologic function of autologous expanded/activated gamma delta T cells in neuroblastoma patients receiving therapy with zoledronic acid and aldesleukin [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The ability of gamma-delta T cells derived from patients' peripheral blood to kill NB cells in vitro will be quantified by standard tumor cytotoxicity assays.</div></li>\n<li style=\"margin:1ex 0.5ex\">uoEvaluate immune phenotype of in vivo expanded/activated autologous gamma delta T cells [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Peripheral blood mononuclear cells will be immunophenotyped by standard conjugation of fluorescent monoclonal antibodies in order to quantify and phenotype patient lymphocytes using flow cytometry.</div></li>\n<li style=\"margin:1ex 0.5ex\">To document tumor response in patients with measurable disease. [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Tumor response and progression will be assessed and documented utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</div></li>\n<li style=\"margin:1ex 0.5ex\">Determine the ability of in vivo expanded/activated gamma delta T cells to infiltrate neuroblastoma tissue using immunohistochemical techniques when post-therapy specimens are available. [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Patients with known or suspected bone marrow metastasis will undergo bilateral bone marrow biopsies at the beginning and end of the first course of therapy.  This tissue will be fixed and processed per protocol (Appendix I) and  infiltrating lymphocytes per hpf will be documented under standard microscopy.</div></li>\n</ul></td>"], "BT": ["Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma"], "OOOM": ["Not Provided"], "LUD": ["May 9, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Evaluate the biologic function of autologous expanded/activated gamma delta T cells in neuroblastoma patients receiving therapy with zoledronic acid and aldesleukin [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The ability of gamma-delta T cells derived from patients' peripheral blood to kill NB cells in vitro will be quantified by standard tumor cytotoxicity assays.</div></li>\n<li style=\"margin:1ex 0.5ex\">Evaluate immune phenotype of in vivo expanded/activated autologous gamma delta T cells [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Peripheral blood mononuclear cells will be immunophenotyped by standard conjugation of flourescent monocloncal antibodies in order to quantify and phenotype patient lymphocytes using flow cytometry.</div></li>\n<li style=\"margin:1ex 0.5ex\">To document tumor response in patients with measurable disease. [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Tumor response and progression will be assessed and documented utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</div></li>\n<li style=\"margin:1ex 0.5ex\">Determine the ability of in vivo expanded/activated gamma delta T cells to infiltrate neuroblastoma tissue using immunohistochemical techniques when post-therapy specimens are available. [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Patients with known or suspected bone marrow metastasis will undergo bilateral bone marrow biopsies at the beginning and end of the first course of therapy.  This tissue will be fixed and processed per protocol (Appendix I) and  infiltrating lymphocytes per hpf will be documented under standard microscopy.</div></li>\n</ul></td>"], "record_id": ["NCT01404702"], "EPCD": ["August 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion \u03b3\u03b4 T-Cells"], "COOM": ["Not Provided"], "SD": ["August 2011"]},
{"OPOM": ["Improvement in PFS with high-dose recombinant interferon alfa-2b [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01708941"], "CPOM": ["Progression-free survival [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 15, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01708941?rank=206&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Regimen limiting serious adverse events (AEs), defined as grade 3 or higher immune mediated AE that require steroids or immunosuppressive therapy according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The regimen limiting serious adverse events rate will be evaluated for each treatment arm.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS data will be described for each treatment arm using the Kaplan-Meier method. OS will also be assessed for ipilimumab 10 mg/kg in comparison to ipilimumab 3 mg/kg.</div></li>\n<li style=\"margin:1ex 0.5ex\">Response rate by RECIST and by immune-related response criteria [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Response rate will also be assessed for ipilimumab 10 mg/kg in comparison to ipilimumab 3 mg/kg.</div></li>\n<li style=\"margin:1ex 0.5ex\">PFS for ipilimumab 10 mg/kg treatment in comparison to ipilimumab 3 mg/kg [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Regimen limiting serious adverse events (AE), defined as grade 3 or higher immune mediated AE that require steroids or immunosuppressive therapy according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 [\u00a0Time\u00a0Frame:\u00a06 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">OS (within the constraints of the sample size) for HDI versus no HDI [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS data will be described for each treatment arm using the Kaplan-Meier method.</div></li>\n<li style=\"margin:1ex 0.5ex\">Response rate by RECIST and by immune-related response criteria (irRC) [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">PFS for ipilimumab 10 mg/kg treatment in comparison to ipilimumab 3 mg/kg [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01708941"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma"], "COOM": ["Not Provided"], "SD": ["January 2013"]},
{"OPOM": ["Phase 1: Safety and tolerability as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events during cycle 1 [\u00a0Time\u00a0Frame:\u00a0Measured every 3 weeks until progression.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "CH": ["/ct2/archive/NCT01905813"], "CPOM": ["Safety and tolerability of INCB040093 as monotherapy  and when given in combination with INCB039110 as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events during cycle 1 [\u00a0Time\u00a0Frame:\u00a0Measured every 3 weeks until progression.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["June 19, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01905813?rank=202&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Preliminary efficacy as assessed by Overall Response Rate (ORR) as measured by published criteria for Hodgkin's/non-Hodgkin's lymphoma (Cheson et al 2007 and Owen et al 2013) and Chronic Lymphocytic Leukemia (CLL) (Cheson et el 2012) [\u00a0Time\u00a0Frame:\u00a0Every 12 weeks (4 cycles) until progression.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetic (PK) collections. [\u00a0Time\u00a0Frame:\u00a0Measured for each patient at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 1 Day 15\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Plasma concentrations of each INCB040093 and INCB039110 will be used to estimate peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC).</div></li>\n</ul></td>"], "BT": ["Study of INCB040093 in Subjects With Previously Treated B-Cell "], "OOOM": ["Not Provided"], "LUD": ["May 14, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Preliminary efficacy as assessed by Overall Response Rate (ORR) as measured by published criteria for lymphoma and Chronic Lymphocytic Leukemia (CLL) (Cheson et el 2007). [\u00a0Time\u00a0Frame:\u00a0Every 12 weeks (4 cycles) until progression.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetic (PK) collections. [\u00a0Time\u00a0Frame:\u00a0Measured for each patient 1 time at Cycle 1 Day 15.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Plasma concentrations of INCB040093 will be used to estimate peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC).</div></li>\n</ul></td>"], "record_id": ["NCT01905813"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell "], "COOM": ["Not Provided"], "SD": ["June 2013"]},
{"OPOM": ["To evaluate the use of Bioelectrical Impedance Analysis as a clinical assessment tool in Glioblastoma Multiforme patients [\u00a0Time\u00a0Frame:\u00a0Participants will be followed every 3 months up to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01770626"], "CPOM": ["To evaluate the use of Bioelectrical Impedance Analysis as a clinical assessment tool in Glioblastoma Multiforme patients [\u00a0Time\u00a0Frame:\u00a0Participants will be followed every 3 months up to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 20, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01770626?rank=212&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">To compare estimated caloric needs determined by BIA and Harris Benedict Equation to Resting Energy Expenditure from Indirect Calorimetry [\u00a0Time\u00a0Frame:\u00a0At initial visit until end of study.Participants will be followed for duration average of every 3 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Age, sex, and body composition are the prime influences on resting energy expenditure (REE), the energy used by an individual when fasted and at rest. The largest component of total energy expenditure (TEE) is REE.</div></td>"], "BT": ["A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients"], "OOOM": ["Not Provided"], "LUD": ["July 31, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01770626"], "EPCD": ["May 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Pilot Study to Determine the Effectiveness of Bioelectrical Impedance Analysis as a Clinical Assessment Tool of Nutrition Status in Glioblastoma Multiforme Patients (The BEAM Study [BIA Effectiveness as Assessment Tool for Glioblastoma Multiforme (GBM) Patients])"], "COOM": ["Not Provided"], "SD": ["April 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01204203"], "CPOM": ["Evaluation of the tumor response rate following zoledronic acid [\u00a0Time\u00a0Frame:\u00a0CT and/or PET scans will be performed to measure tumor size approximately every 56 days until there is tumor growth\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["September 15, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01204203?rank=213&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Evaluation of the duration of tumor response [\u00a0Time\u00a0Frame:\u00a0Assessments approximately every 8 weeks for the patient's life\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The patient's medical condition will be followed for the rest of their lives with continued CT scans being performed every 8 weeks to document tumor growth while off of the study medication.</div></td>"], "BT": ["Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)"], "OOOM": ["Not Provided"], "LUD": ["January 16, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01204203"], "EPCD": ["June 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma"], "COOM": ["Not Provided"], "SD": ["June 2009"]},
{"OPOM": ["PFS [\u00a0Time\u00a0Frame:\u00a0Time from study entry to the time of documented disease progression or death, assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01886872"], "CPOM": ["PFS [\u00a0Time\u00a0Frame:\u00a0Time from study entry to the time of documented disease progression or death, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 24, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01886872?rank=207&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0From the date of registration to the date of death, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kaplan-Meier method will be used to estimate OS distributions in this CLL population.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to progression [\u00a0Time\u00a0Frame:\u00a0From the date of registration to the date of disease progression, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kaplan-Meier method will be used to estimate time to progression distributions in this CLL population.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of response (CR, nPR, and PR) [\u00a0Time\u00a0Frame:\u00a0From the date at which the patient's objective status is first noted to be a response to the date that progression or death is documented (if one has occurred) or to the date of last follow-up, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kaplan-Meier method will be used to estimate the duration of response in the CLL population.</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients achieving any response to treatment (ORR [PR +nPR+ CR]) [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using the number of patients with the type of response of interest divided by the total number of patients randomized to that treatment arm. Corresponding exact binomial 95% confidence intervals for true response rates will be calculated.</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients achieving a biopsy-proven CR [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using the number of patients with the type of response of interest divided by the total number of patients randomized to that treatment arm. Corresponding exact binomial 95% confidence intervals for true response rates will be calculated</div></li>\n<li style=\"margin:1ex 0.5ex\">Complete and nPR rate [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using the number of patients with the type of response of interest divided by the total number of patients randomized to that treatment arm. Corresponding exact binomial 95% confidence intervals for true response rates will be calculated</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients who attain MRD negative status [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated using the number of patients who achieve minimal residual disease divided by the total number randomized to that treatment arm. Corresponding exact binomial 95% confidence intervals for MRD rates will be calculated.</div></li>\n<li style=\"margin:1ex 0.5ex\">Toxicity, calculated according to the frequency and severity of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients who experience grade 3 or higher non-hematologic toxicities [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Tolerability assessed by the number of patients requiring dose modifications and/or dose delays [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Tolerability measures will be assessed within each of the treatment arms.</div></li>\n<li style=\"margin:1ex 0.5ex\">Proportion of patients who go off treatment due to adverse reactions or refuse further treatment for lesser toxicities that inhibit their willingness to continue participation [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Tolerability measures will be assessed within each of the treatment arms.</div></li>\n<li style=\"margin:1ex 0.5ex\">Geriatric functional status (optional) [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed using assessed by the Older Americans' Resources and Services Multidimensional Functional Assessment Questionnaire, Activities of Daily Living, Medical Outcomes Study physical functioning, Karnofsky performance status rated by a health care professional, Karnofsky performance status rated by the patient, timed \"Up and Go\", and number of falls in the last six months.</div></li>\n<li style=\"margin:1ex 0.5ex\">Quality of life [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed using the Geriatric Assessment Survey.</div></li>\n</ul></td>"], "BT": ["Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kaplan-Meier method will be used to estimate OS distributions in this CLL population.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to progression [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kaplan-Meier method will be used to estimate time to progression distributions in this CLL population.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of response (CR, nPR, and PR) [\u00a0Time\u00a0Frame:\u00a0From the date at which the patient's objective status is first noted to be a response to the date that progression or death is documented (if one has occurred) or to the date of last follow-up, assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Kaplan-Meier method will be used to estimate the duration of response in the CLL population.</div></li>\n<li style=\"margin:1ex 0.5ex\">ORR (PR +nPR+ CR) [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in MRD status [\u00a0Time\u00a0Frame:\u00a0Baseline to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Hazard ratios and 95% confidence intervals for MRD negative versus positive patients will be calculated for PFS and OS.</div></li>\n<li style=\"margin:1ex 0.5ex\">Frequency and severity of adverse events and tolerability per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 2 years post-treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in geriatric functional status [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed using assessed by the Older Americans' Resources and Services Multidimensional Functional Assessment Questionnaire, Activities of Daily Living, Medical Outcomes Study physical functioning, Karnofsky performance status rated by a health care professional, Karnofsky performance status rated by the patient, timed \"Up and Go\", and number of falls in the last six months.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in quality of life [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed by the Self Assessment Measure-Patient Questionnaire, European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Questionnaire, the Health Care Professional Questionnaire, and the Geriatric Quality of Life Outcomes</div></li>\n<li style=\"margin:1ex 0.5ex\">Correlative markers (cytogenetics, FISH abnormalities, IgVH mutational status, ZAP-70 methylation status) related to outcomes or response [\u00a0Time\u00a0Frame:\u00a0Baseline\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The correlative markers will be summarized quantitatively and graphically between treatment arms.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in gene expression profiling, mRNA and miR expression [\u00a0Time\u00a0Frame:\u00a0Baseline to up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relationship between the FCGR3A SNP (rs396991) and response [\u00a0Time\u00a0Frame:\u00a0After 168 days (6 courses) of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The response phenotype will be quantified using MRD negativity status.</div></li>\n</ul></td>"], "record_id": ["NCT01886872"], "EPCD": ["March 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (\u2265 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)"], "COOM": ["Not Provided"], "SD": ["December 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02016729"], "CPOM": [], "FRD": ["November 21, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02016729?rank=210&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Treatment Response [\u00a0Time\u00a0Frame:\u00a036 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Complete response (CR), complete response with incomplete recovery (CRi), and duration response.</div></td>"], "BT": ["A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia"], "OOOM": ["Not Provided"], "LUD": ["July 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02016729"], "EPCD": ["April 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 Alone and in Combination With Trametinib in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia"], "COOM": ["Not Provided"], "SD": ["April 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01871519"], "CPOM": [], "FRD": ["June 4, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01871519?rank=217&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs"], "OOOM": ["Not Provided"], "LUD": ["May 21, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01871519"], "EPCD": ["February 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures"], "COOM": ["Not Provided"], "SD": ["May 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01780662"], "CPOM": [], "FRD": ["January 29, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01780662?rank=203&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Disease response (Part A) [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Reported descriptively.</div></li>\n<li style=\"margin:1ex 0.5ex\">ORR (Part B) [\u00a0Time\u00a0Frame:\u00a0At 12 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity as assessed by NCI CTCAE version 4.0 (Part B) [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["July 22, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01780662"], "EPCD": ["October 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 1/2 Study of Brentuximab Vedotin (SGN35) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma"], "COOM": ["Not Provided"], "SD": ["January 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01950390"], "CPOM": ["Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0Time from randomization to death from any cause, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["September 23, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01950390?rank=208&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) evaluated based on international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [\u00a0Time\u00a0Frame:\u00a0Time from randomization to disease progression or death (whichever occurs first), assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be estimated using the Kaplan-Meier method. PFS distributions will be compared using the log rank test.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events (AE), defined using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria [\u00a0Time\u00a0Frame:\u00a0Up to 90 days after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Toxicity rate for individual AEs, categorized AEs and worst degree AEs will be compared using the Chi-square of Fisher's exact test. Two-sided p-values will be reported for these comparisons.</div></li>\n<li style=\"margin:1ex 0.5ex\">Immune response assessed using the utility of irRC [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">McNemar's test will be used to evaluate the agreement between irRC and RECIST-based clinical response. The landmark analysis will be conducted to evaluate the association between PFS/OS and irRC.</div></li>\n</ul></td>"], "BT": ["Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery"], "OOOM": ["Not Provided"], "LUD": ["July 22, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Progression-free survival (PFS) evaluated based on international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [\u00a0Time\u00a0Frame:\u00a0Time from randomization to disease progression or death (whichever occurs first), assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be estimated using the Kaplan-Meier method. PFS distributions will be compared using the log rank test.</div></li>\n<li style=\"margin:1ex 0.5ex\">Immune response assessed using the utility of irRC [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">McNemar's test will be used to evaluate the agreement between irRC and RECIST-based clinical response. The landmark analysis will be conducted to evaluate the association between PFS/OS and irRC.</div></li>\n</ul></td>"], "record_id": ["NCT01950390"], "EPCD": ["January 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma"], "COOM": ["Not Provided"], "SD": ["September 2013"]},
{"OPOM": ["Progression Free Survival (PFS) time [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00916409"], "CPOM": ["Progression Free Survival (PFS) time [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 5, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00916409?rank=214&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a05 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)"], "OOOM": ["Not Provided"], "LUD": ["July 16, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival (OS) [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival at 6 months (PFS6) [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">1% and 2-year survival [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Radiological response (Macdonald criteria) [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life assessment (EORTC QLQ-C30) [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Adverse events severity and frequency [\u00a0Time\u00a0Frame:\u00a03 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00916409"], "EPCD": ["January 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM."], "COOM": ["Not Provided"], "SD": ["June 2009"]},
{"OPOM": ["Objective response - best overall response (complete or partial response) at any time on the study [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01553149"], "CPOM": ["Objective response - best response [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 10, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01553149?rank=218&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to treatment failure (EFS) [\u00a0Time\u00a0Frame:\u00a0Time from study enrollment to tumor progression, tumor recurrence, death from any cause, or occurrence of a second malignant neoplasm, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Standard survival methods will be used for analysis of EFS. Analyses include log rank tests and the product-limit (Kaplan-Meier) estimate for estimation of EFS probability.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to death (overall survival [OS]) [\u00a0Time\u00a0Frame:\u00a0Time from study enrollment to death from any cause\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Standard survival methods will be used for analysis of OS. Analyses include log rank tests and the product-limit (Kaplan-Meier) estimate for estimation of OS probability.</div></li>\n</ul></td>"], "BT": ["Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma"], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Time to treatment failure (EFS), time from study enrollment to tumor progression, tumor recurrence, death from any cause, or occurrence of a second malignant neoplasm [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to death (Overall survival [OS]) - the time from study enrollment to death from any cause [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity events using Common Terminology Criteria for Adverse Events (CTCAE) version 4 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Correlation of steady-state pharmacokinetic levels of lenalidomide with best response and EFS at the patient dose [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01553149"], "EPCD": ["May 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients With Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas"], "COOM": ["Not Provided"], "SD": ["March 2012"]},
{"OPOM": [], "CH": [], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0Time between randomization and death from any cause, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 11, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02085408?rank=211&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Mortality rate [\u00a0Time\u00a0Frame:\u00a030 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Induction complete response rates [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The induction response (CR + CRi) rates will be compared between the clofarabine arm and the standard treatment arm. At the end of the study, the 95% confidence interval on the difference in the CR + CRi rates (CR + CRi rate of standard treatment - CR + CRi rate of clofarabine) will be computed based on the normal approximation to the difference of two independent binomial proportions.</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease-free survival (DFS) [\u00a0Time\u00a0Frame:\u00a0Time from the second randomization to relapse or death without relapse, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The primary analysis of DFS will use a one-sided log rank test stratified on the induction therapy and on patient age and cytogenetics to determine the effect of decitabine on DFS as a maintenance therapy in comparison with observation.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To evaluate the impact of consolidation with non-ablative conditioning and allogeneic hematopoietic stem cell transplantation with an HLA-identical sibling on overall survival in patients who achieve a 'morphologic leukemia-free state, a one-sided log rank test stratified on age, therapy-related AML, the presence of AHD at the time of diagnosis of AML, and the induction therapy they received will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Epidemiological factors, measured using the Acute Leukemia Epidemiology and Survival in ECOG (ALESE) questionnaire [\u00a0Time\u00a0Frame:\u00a0Baseline\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The proportions of obese patients and patients who had benzene exposure, ever smoked in their lifetime, took aspirin regularly, took acetaminophen regularly, ever lived in rural/farm environments, or had other exposures or lifestyle factors will be calculated separately, along with their 95% confidence intervals.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in the Functional Assessment of Cancer Therapy (FACT)-Leukemia-specific (Leu) Trial Outcome Index (TOI) score [\u00a0Time\u00a0Frame:\u00a0Baseline to 30 days after beginning induction therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive statistics will be provided and Cronbach's alpha will be calculated at each time point to assess reliability. Repeated measures analysis techniques will also be utilized to examine the treatment effect and time effect on FACT-Leu TOI score. For patients randomized to the induction treatments, the longitudinal scores collected from time of randomization, two weeks after beginning induction therapy (at the time of nadir), and at 28-30 days after beginning induction therapy, will be analyzed according to the methods described in Schluchter and Schluchter, Greene and Beck.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score [\u00a0Time\u00a0Frame:\u00a0Baseline to 30 days after beginning induction therapy\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Descriptive statistics will be provided and Cronbach's alpha will be calculated at each time point to assess reliability. Repeated measures analysis techniques will also be utilized to examine the treatment effect and time effect on FACIT Fatigue score. For patients randomized to the induction treatments, the longitudinal scores collected from time of randomization, two weeks after beginning induction therapy (at the time of nadir), and at 28-30 days after beginning induction therapy, will be analyzed according to the methods described in Schluchter and Schluchter, Greene and Beck.</div></li>\n</ul></td>"], "BT": ["Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia"], "OOOM": [], "LUD": ["March 11, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT02085408"], "EPCD": ["February 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age &gt;/= 60 Years)"], "COOM": [], "SD": ["December 2010"]},
{"OPOM": ["Event-free survival"], "CH": ["/ct2/archive/NCT00554788"], "CPOM": ["Failure-free survival (FFS) [\u00a0Time\u00a0Frame:\u00a0At 1 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["November 6, 2007"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00554788?rank=219&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Response rate to the induction phase of the regimen using a modified version of the international criteria for neuroblastoma response [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated and a corresponding 95% confidence interval calculated for all strata combined.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The toxicity-associated death rate and the percentage of patients for whom an adequate yield of stem cells cannot be harvested will be monitored across all treatment groups collectively. Toxicities will be descriptively summarized.</div></li>\n</ul></td>"], "BT": ["Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma"], "OOOM": ["Not Provided"], "LUD": ["March 21, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Response rate</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity</li>\n</ul></td>"], "record_id": ["NCT00554788"], "EPCD": ["February 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma"], "COOM": ["Not Provided"], "SD": ["February 2008"]},
{"OPOM": ["Progression freee survival (PFS) [\u00a0Time\u00a0Frame:\u00a0The final PFS analysis  is expected approximately 16 months after FPFV.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01763164"], "CPOM": ["Progression free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0The final PFS analysis is expected approximately 16 months after FPFV.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 4, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01763164?rank=215&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0Final analysis is expected to occur 21 months after FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare OS between treatment arms. OS is calculated as the time from date of randomization to date of death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR calculated as the proportion of patient with a best overall response of complete response (CR) or partial response (PR). ORR will be calculated for confirmed and unconfirmed responses separately.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to Objective Response (TTR) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">TTR calculated as the time from date of randomization until first documented complete response (CR) or partial response(PR).</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of objective response (DOR) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DOR calculated as the time from the date of first documented CR or PR to the first documented progression or death due to underlying cancer</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease control rate (DCR) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DCR calculated as the proportion of patient with a best overall response of CR, PR or stable disease (SD)</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of patients with adverse events [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of MEK162 in this patient, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), MUGA(Multi Gated Acquisition Scan)/echocardiogram and assessment of physical and ocular examinations graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of patients with serious adverse events [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of MEK162 in this patient, changes in hematology and chemistry values, vital signs, ECGs, MUGA/echocardiogram and assessment of physical and ocular examinations graded according to the NCI CTCAE v4.03</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 10% deterioration in the global health status score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the global health status between the treatments.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in the global health status score of the EORTC QLQ-C30 [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the global health status between the treatment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in the EQ-5D-5L (EuroQol Group standardised instrument for use as a measure of health outcome) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the global health status between the treatment.</div></li>\n</ul></td>"], "BT": ["Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma"], "OOOM": ["Not Provided"], "LUD": ["May 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0Final analysis is expected to occur 21 months after FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare OS between treatment arms. OS is calculated as the time from date of randomization to date of death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR calculated as the proportion of patient with a best overall response of complete response (CR) or partial response (PR). ORR will be calculated for confirmed and unconfirmed responses separately.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to Objective Response (TTR) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">TTR calculated as the time from date of randomization until first documented complete response (CR) or partial response(PR).</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of objective response (DOR) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DOR calculated as the time from the date of first documented CR or PR to the first documented progression or death due to underlying cancer</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease control rate (DCR) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DCR calculated as the proportion of patient with a best overall response of CR, PR or stable disease (SD)</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of patients with adverse events [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of MEK162 in this patient, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), MUGA(Multi Gated Acquisition Scan)/echocardiogram and assessment of physical and ocular examinations graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of patients with serious adverse events [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To assess the safety and tolerability of MEK162 in this patient, changes in hematology and chemistry values, vital signs, ECGs, MUGA/echocardiogram and assessment of physical and ocular examinations graded according to the NCI CTCAE v4.03</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 10% deterioration in the global health status score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the global health status between the treatments.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in the global health status score of the EORTC QLQ-C30 [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the global health status between the treatment.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline in the EQ-5D (EuroQol Group standardised instrument for use as a measure of health outcome) [\u00a0Time\u00a0Frame:\u00a0Approximately 16 months after the FPFV\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To compare the global health status between the treatment.</div></li>\n</ul></td>"], "record_id": ["NCT01763164"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma"], "COOM": ["Not Provided"], "SD": ["July 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01935960"], "CPOM": [], "FRD": ["September 3, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01935960?rank=216&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of toxicity, graded according to the CTCAE version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Patient toxicity will be summarized by the presence or absence of any toxicities, worst CTCAE grade, and strongest investigator defined relationship will all be examined and characterized by dose. Correlations between the different PK measures of retinoid 9cUAB30 and the different measures of toxicity will be estimated with polyserial correlation. To compare toxicities at each dose level to placebo, the Chi-square test will be used for the presence or absence of toxicities, and Wilcoxon rank-sum tests will be used for CTCAE grade and investigator defined relationship data.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in single dose pharmacokinetics,, including Cmax, Tmax, AUC0-lqc, AUC0-infinity, T1/2, and CL [\u00a0Time\u00a0Frame:\u00a0Day 1 to day 36\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The pharmacokinetics of retinoid 9cUAB30 will be compared between day 1 and day 36 using one-sample t-tests, or Wilcoxon signed-rank tests as appropriate in order to evaluate the single vs. steady state levels. An appropriate regression model will be used to explore the relationship of dose with change in PK: logarithmic transformations will be used as necessary.</div></li>\n<li style=\"margin:1ex 0.5ex\">Level of retinoid 9cUA30 in skin biopsies [\u00a0Time\u00a0Frame:\u00a0Up to day 36\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be summarized with descriptive statistics such as mean and standard deviation, and comparison of 9cUAB30 levels among placebo and the dose level cohorts will be made using analysis of variance.</div></li>\n<li style=\"margin:1ex 0.5ex\">Levels of blood and skin biomarkers, such as PCNA, apoptosis indices, differentiation markers, COX-2, ornithine decarboxylase, and matric metalloproteinases 2 and 9 [\u00a0Time\u00a0Frame:\u00a0Up to day 36\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be compared among treatment groups and between in sun-exposed and non-sun-exposed skin (on upper arm) using ordinal regression models.</div></li>\n</ul></td>"], "BT": ["Retinoid 9cUAB30 in Preventing ", " in Healthy Volunteers"], "OOOM": ["Not Provided"], "LUD": ["June 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of toxicity, graded according to the CTCAE version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after completion of study treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Patient toxicity will be summarized by the presence or absence of any toxicities, worst CTCAE grade, and strongest investigator defined relationship will all be examined and characterized by dose. Correlations between the different PK measures of retinoid 9cUAB30 and the different measures of toxicity will be estimated with polyserial correlation. To compare toxicities at each dose level to placebo, the Chi-square test will be used for the presence or absence of toxicities, and Wilcoxon rank-sum tests will be used for CTCAE grade and investigator defined relationship data.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in single dose pharmacokinetics,, including Cmax, Tmax, AUC0-lqc, AUC0-infinity, T1/2, and CL [\u00a0Time\u00a0Frame:\u00a0Day 1 to day 36\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The pharmacokinetics of retinoid 9cUAB30 will be compared between day 1 and day 36 using one-sample t-tests, or Wilcoxon signed-rank tests as appropriate in order to evaluate the single vs. steady state levels. An appropriate regression model will be used to explore the relationship of dose with change in PK: logarithmic transformations will be used as necessary.</div></li>\n<li style=\"margin:1ex 0.5ex\">Level of retinoid 9cUA30 in skin biopsies [\u00a0Time\u00a0Frame:\u00a0Up to day 36\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be summarized with descriptive statistics such as mean and standard deviation, and comparison of 9cUAB30 levels among placebo and the dose level cohorts will be made using analysis of variance.  Analysis of skin biopsies will be exploratory to generate hypotheses, and thus no power analysis is possible at this stage.</div></li>\n<li style=\"margin:1ex 0.5ex\">Level of blood and skin biomarkers, such as PCNA, apoptosis indices, differentiation markers, COX-2, ornithine decarboxylase, and matric metalloproteinases 2 and 9 [\u00a0Time\u00a0Frame:\u00a0Up to day 36\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Will be compared among treatment groups and between in sun-exposed and non-sun-exposed skin (on upper arm) using ordinal regression models.  This analysis will be exploratory in nature and by necessity due to small sample size.</div></li>\n</ul></td>"], "record_id": ["NCT01935960"], "EPCD": ["June 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized, Double-Blind, Phase I Dose-Escalation Study of the Novel Retinoid 9cUAB30"], "COOM": ["Not Provided"], "SD": ["August 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01693068"], "CPOM": ["Progression-free survival (PFS), defined as the first documentation of objective disease progression, according to Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) [\u00a0Time\u00a0Frame:\u00a0every 6 weeks up to Cycle 13, then every 12 weeks up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["September 14, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01693068?rank=220&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response defined as complete or partial tumor response, according to RECIST v.1.1 criteria [\u00a0Time\u00a0Frame:\u00a0every 6 weeks up to Cycle 13, then every 12 weeks up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease control defined as the proportion of subjects with complete response, partial response, or stable disease for more than 3 months, according to RECIST v.1.1 criteria [\u00a0Time\u00a0Frame:\u00a0every 6 weeks up to Cycle 13, then every 12 weeks up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival rate at six months from the time of randomization based upon objective disease progression, according to RECIST v.1.1 criteria [\u00a0Time\u00a0Frame:\u00a0up to 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival defined as the time from randomization to death from any cause [\u00a0Time\u00a0Frame:\u00a0every 6 months up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival rate at 12 months from the time of randomization [\u00a0Time\u00a0Frame:\u00a0up to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in patient-reported Quality of life (assessed by FACT-Melanoma) from baseline assessment to last assessment prior to objective disease progression, according to RECIST v.1.1 [\u00a0Time\u00a0Frame:\u00a0Day 1 of every cycle up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of subjects with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and death [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinically significant changes in safety related to National Cancer Institute- Common Toxicity Criteria Version 4.0 (NCI-CTC v 4.0) and abnormal vital signs [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Plasma concentration of Pimasertib [\u00a0Time\u00a0Frame:\u00a0Day 8 and Day 15 of Cycle 1, and Day 1 of Cycle 2\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Gene products and genetic alterations in tumor biopsies [\u00a0Time\u00a0Frame:\u00a0Day 1 of Cycle 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Predictive markers in plasma [\u00a0Time\u00a0Frame:\u00a0Day 1 of Cycle 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Potential genetic variations in genomic deoxyribonucleic acid (gDNA) obtained from Peripheral Blood Mononuclear Cell (PBMC) associated with differences in pharmacokinetic and profile of pimasertib [\u00a0Time\u00a0Frame:\u00a0Day 1 of Cycle 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma"], "OOOM": ["Not Provided"], "LUD": ["December 5, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective response defined as complete or partial tumor response, according to RECIST v.1.1 criteria [\u00a0Time\u00a0Frame:\u00a0every 6 weeks up to Cycle 13, then every 12 weeks up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Disease control defined as the proportion of subjects with complete response, partial response, or stable disease for more than 3 months, according to RECIST v.1.1 criteria [\u00a0Time\u00a0Frame:\u00a0every 6 weeks up to Cycle 13, then every 12 weeks up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival rate at six months from the time of randomization based upon objective disease progression, according to RECIST v.1.1 criteria [\u00a0Time\u00a0Frame:\u00a0up to 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival defined as the time from randomization to death from any cause [\u00a0Time\u00a0Frame:\u00a0every 6 months up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival rate at 12 months from the time of randomization [\u00a0Time\u00a0Frame:\u00a0up to 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in patient-reported Quality of life (assessed by FACT-Melanoma) from baseline assessment to last assessment prior to objective disease progression, according to RECIST v.1.1 [\u00a0Time\u00a0Frame:\u00a0Day 1 of every cycle up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of subjects with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and death [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Clinically significant changes in safety related to National Cancer Institute- Common Toxicity Criteria Version 4.0 (NCI-CTC v 4.0) and abnormal vital signs [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Plasma pharmacokinetic parameters of pimasertib [\u00a0Time\u00a0Frame:\u00a0Day 8 and Day 15 of Cycle 1, and Day 1 of Cycle 2\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Gene products and genetic alterations in tumor biopsies [\u00a0Time\u00a0Frame:\u00a0Day 1 of Cycle 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Predictive markers in plasma [\u00a0Time\u00a0Frame:\u00a0Day 1 of Cycle 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Potential genetic variations in genomic deoxyribonucleic acid (gDNA) obtained from Peripheral Blood Mononuclear Cell (PBMC) associated with differences in pharmacokinetic and profile of pimasertib [\u00a0Time\u00a0Frame:\u00a0Day 1 of Cycle 1\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01693068"], "EPCD": ["April 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma"], "COOM": ["Not Provided"], "SD": ["December 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01190930"], "CPOM": [], "FRD": ["August 27, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01190930?rank=222&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Burden of therapy in AR patients overall at different time points during and at the end of therapy [\u00a0Time\u00a0Frame:\u00a0Up to 30 months after beginning of maintenance (off-therapy time point for boys)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed by the Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), the Child Vulnerability Scale, and by the Behavior Assessment Scales of Children-Second Edition, Parent Rating Scale (BASC-2 PRS). Standardized scores for the sub-scales of the PedsQL 4.0 will be calculated using age and gender specific normative data.</div></li>\n<li style=\"margin:1ex 0.5ex\">Burden of therapy in AR patients randomized to every 4-week vs every 12-week pulses during maintenance therapy [\u00a0Time\u00a0Frame:\u00a0Up to 30 months after beginning of Maintenance (off-therapy time point for boys)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed by the Pediatric Quality of Life Instrument scores, the Child Vulnerability Scale, and emotional symptoms (measured by the BASC-2 PRS), adjusting for age, gender, and family income. Comparison of differences in means (of the continuous measures) between the 2 randomization groups with 2-sample t-tests will be done. If the continuous data are not normally distributed, a non-parametric statistical measure will be used.</div></li>\n</ul></td>"], "BT": ["Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia"], "OOOM": ["Not Provided"], "LUD": ["February 17, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Burden of therapy in AR patients overall at different time points during and at the end of therapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Burden of therapy in AR patients randomized to every 4-week vs every 12-week pulses during maintenance therapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01190930"], "EPCD": ["April 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Treatment of Patients With Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)"], "COOM": ["Not Provided"], "SD": ["August 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00900250"], "CPOM": ["Biologic specimen repository and database [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00900250?rank=223&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["November 22, 2012"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00900250"], "EPCD": ["Not Provided"], "OT": ["Hodgkin Disease (HD) Banking Study"], "COOM": ["Not Provided"], "SD": ["October 2006"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01406756"], "CPOM": [], "FRD": ["July 29, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01406756?rank=221&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR-ALL [\u00a0Time\u00a0Frame:\u00a0Assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Graded using the Version 4.0 Common Terminology Criteria for Adverse Events (CTCAE) of the NCI.</div></li>\n<li style=\"margin:1ex 0.5ex\">Toxicity and tolerability of arms II and III compared to arm I in patients with VHR-ALL [\u00a0Time\u00a0Frame:\u00a0Assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Graded using the Version 4.0 CTCAE of the NCI.</div></li>\n<li style=\"margin:1ex 0.5ex\">Increase of greater than or equal to 65% of 5-year DFS and less than 10% induction mortality in patients with DS and HR-ALL treated with modified Induction and post-Induction therapy regimen with MBFM-IMIDM [\u00a0Time\u00a0Frame:\u00a0At 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity and tolerability of MBFM-IMIDM in children with Down syndrome [\u00a0Time\u00a0Frame:\u00a0Assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Graded using the Version 4.0 CTCAE of the NCI.</div></li>\n<li style=\"margin:1ex 0.5ex\">Percentage of VHR-ALL patients randomized to control versus experimental arms that attain MRD less than or equal to 0.01% upon recovery from consolidation [\u00a0Time\u00a0Frame:\u00a0Week 13-14\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared between control vs experimental arms.</div></li>\n<li style=\"margin:1ex 0.5ex\">OS rate for HR-ALL patients [\u00a0Time\u00a0Frame:\u00a0At 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared informally between arms.</div></li>\n<li style=\"margin:1ex 0.5ex\">OS rate for VHR-ALL patients [\u00a0Time\u00a0Frame:\u00a0At 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared informally between arms.</div></li>\n<li style=\"margin:1ex 0.5ex\">Peripheral blood absolute lymphocyte count in prediction of DFS in children, adolescents, and young adults with HR-ALL [\u00a0Time\u00a0Frame:\u00a0Day 29 of induction\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed using Cox regression analysis. Receive operator characteristic (ROC) curves will be used to determine an optimal cut point in ALC values which separates the HR patients into 2 groups with possibly significantly different outcomes.</div></li>\n<li style=\"margin:1ex 0.5ex\">Incidence and prognostic significance of recently discovered recurrent genomic lesions, including high CRLF2 expression, CRLF2 activating genomic lesions, JAK mutations, and IKZF1 mutations/deletions [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The impact of specific genetic lesion on relapse-free survival (RFS) will be evaluated.</div></li>\n<li style=\"margin:1ex 0.5ex\">Prognostic significance of molecular risk classifiers using Low Density Array (LDA) Taqman cards [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Correlated with levels of MRD.</div></li>\n<li style=\"margin:1ex 0.5ex\">Frequency of occurrence of key adverse events across all patient subgroups of HR-ALL [\u00a0Time\u00a0Frame:\u00a0Assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Graded using the Version 4.0 CTCAE of the NCI.</div></li>\n<li style=\"margin:1ex 0.5ex\">Differences in the burden of therapy between HR-ALL and VHR-ALL when treated on the various arms of this study [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Assessed by comparing the total number of hospital days during specific courses of therapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Comparison of drug delivery of vincristine sulfate, pegaspargase and methotrexate during Induction, Consolidation, DI, and IM II in 16-30 year olds on the control arm of the VHR study to AYAs with ALL on the C10403 adult cooperative group trial [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Comparisons will be essentially descriptive in nature.</div></li>\n</ul></td>"], "BT": ["Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia"], "OOOM": ["Not Provided"], "LUD": ["June 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR-ALL [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity and tolerability of arms II and III compared to arm I in patients with VHR-ALL [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Increase of \u2265 65% of 5-year DFS and &lt; 10% induction mortality in patients with DS and HR-ALL treated with modified Induction and post-Induction therapy regimen with MBFM-IMIDM [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity and tolerability of MBFM-IMIDM in children with Down syndrome [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Percentage of VHR-ALL patients randomized to control versus experimental arms that attain MRD \u2264 0.01% upon recovery from consolidation [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">5-year OS rate for HR-ALL patients [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">4-year OS rate for VHR-ALL patients [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prognostic significance of HR genetic lesions and molecular risk classifiers [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01406756"], "EPCD": ["August 2021 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum"], "COOM": ["Not Provided"], "SD": ["February 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01335399"], "CPOM": ["Progression-free survival (PFS) - Time from randomization to date of first tumor progression or death due to any cause, provided death is not more than 10 weeks after the last tumor assessment. [\u00a0Time\u00a0Frame:\u00a0Every 4 weeks (-1/+3 days) relative to the first dose of study medication.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 13, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01335399?rank=224&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective Response Rate - The percentage of patients who have a partial or complete response to study therapy. [\u00a0Time\u00a0Frame:\u00a0All response endpoints assessed every 4 weeks (-1/+3 days).\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival - The period of time from study entry until the date of death or last known date alive. [\u00a0Time\u00a0Frame:\u00a0Survival will be assessed every 16 weeks in the Follow Up Phase of the trial.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma"], "OOOM": ["Not Provided"], "LUD": ["July 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01335399"], "EPCD": ["May 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma"], "COOM": ["Not Provided"], "SD": ["May 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01041703"], "CPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 31, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01041703?rank=227&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">30-day mortality rate [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Induction complete response rates [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Effect of decitabine as maintenance therapy vs observation on disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Impact of consolidation therapy with non-myeloablative conditioning and allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donor on overall survival in select patients [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Quality of life [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia"], "OOOM": ["Not Provided"], "LUD": ["July 24, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01041703"], "EPCD": ["February 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)"], "COOM": ["Not Provided"], "SD": ["January 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01000753"], "CPOM": [], "FRD": ["October 22, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01000753?rank=225&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma"], "OOOM": ["Not Provided"], "LUD": ["November 16, 2012"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01000753"], "EPCD": ["Not Provided"], "OT": ["Rare And Cutaneous Non-Hodgkin Lymphoma Registry"], "COOM": ["Not Provided"], "SD": ["May 2005"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01593228"], "CPOM": ["Number of participants with incidence of adverse events by NCI-CTCAE version 4.03 [\u00a0Time\u00a0Frame:\u00a0Up to 30 days after last treatment dose\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["April 30, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01593228?rank=229&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial"], "OOOM": ["Not Provided"], "LUD": ["September 14, 2013"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01593228"], "EPCD": ["June 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in ", " Patients Who Have Derived Clinical Benefit From Iniparib Following Completion of a Phase 1, 2 or 3 Parental Study"], "COOM": ["Not Provided"], "SD": ["May 2012"]},
{"OPOM": ["Not Provided"], "CH": ["/ct2/archive/NCT01252797"], "CPOM": ["to investigate the maximum tolerated dose (MTD) of preoperative stereotactic radiosurgery (SRS) for brain metastasis [\u00a0Time\u00a0Frame:\u00a0one year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["November 22, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01252797?rank=226&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">to evaluate acute toxicity, late toxicity, technical feasibility, and to estimate rates of local control and leptomeningeal dissemination with preoperative stereotactic radiosurgery (SRS). [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases(RAD 1002)"], "OOOM": ["Not Provided"], "LUD": ["February 25, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01252797"], "EPCD": ["December 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["RAD 1002: Phase I Dose Escalation/De-escalation Study of Pre-operative Stereotactic Radiosurgery for Brain Metastases"], "COOM": ["Not Provided"], "SD": ["October 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01802333"], "CPOM": [], "FRD": ["February 27, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01802333?rank=228&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">EFS of 7 + 3 compared to IA [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">A two-sided test of the hazard ratio (HR) of 7:3: IA (versus the null hypothesis of HR =1) will be done using a proportional hazards regression model with the stratification factors included as covariates.</div></li>\n<li style=\"margin:1ex 0.5ex\">EFS rate [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">1-year, 2-year and 3-year EFS rates will be compared between patients who receive standard 7+3 or IA and patients who receive IA + V; between patients who receive standard 7+3 therapy versus IA; and between patients who receive standard 7+3 versus IA.</div></li>\n<li style=\"margin:1ex 0.5ex\">OS rate [\u00a0Time\u00a0Frame:\u00a0Up to 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">1-year, 2-year and 3-year EFS rates will be compared between patients who receive standard 7+3 or IA and patients who receive IA + V; between patients who receive standard 7+3 therapy versus IA; and between patients who receive standard 7+3 versus IA.</div></li>\n</ul></td>"], "BT": ["Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia"], "OOOM": ["Not Provided"], "LUD": ["July 28, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT01802333"], "EPCD": ["June 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA+V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)"], "COOM": [], "SD": ["February 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01893112"], "CPOM": ["Change in stigma scores from baseline to 12 months. [\u00a0Time\u00a0Frame:\u00a0baseline, after intervervention, 4 months, 6 months, 8 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["February 11, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01893112?rank=230&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Location as a moderator variable [\u00a0Time\u00a0Frame:\u00a0baseline, after intervervention, 4 months, 6 months, 8 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">This is a multi-site study (Chicago and Birmingham) and we are interested in seeing if location is a moderating variable</div></li>\n<li style=\"margin:1ex 0.5ex\">Post-Traumatic Stress Disorder Checklist [\u00a0Time\u00a0Frame:\u00a0baseline, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Adherence to HIV Medication [\u00a0Time\u00a0Frame:\u00a0baseline, after intervention, 4 months, 6 months, 8 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adherence to HIV medication will be measured by participants self report of adherence using commonly used set of questions.</div></li>\n<li style=\"margin:1ex 0.5ex\">Patient Health Questionnaire (PHQ-9) [\u00a0Time\u00a0Frame:\u00a0baseline, after intervention, 4 months, 6 months, 8 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">We will look at the correlation between stigma scores and depression scores over time.</div></li>\n<li style=\"margin:1ex 0.5ex\">Medical Outcomes Study Social Support Scale [\u00a0Time\u00a0Frame:\u00a0Study duration\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">We are going to use a validated social support scale, and analyze social support as a correlate.</div></li>\n<li style=\"margin:1ex 0.5ex\">substance abuse [\u00a0Time\u00a0Frame:\u00a0baseline, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">substance use and stigma of substance use will be measured using: Alcohol Use disorders Identification Test (AUDIT) Severity of Dependence Scale (SDS) Substance Abuse Self Stigma (SASS)</div></li>\n<li style=\"margin:1ex 0.5ex\">Engagement in Care (from patient record) [\u00a0Time\u00a0Frame:\u00a0baseline, 4 months, 8 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Research assistants will access participants' medical records to see if patients have missed any HIV related visits (i.e. medical, counseling). Engagement to care will be measured as a proportion (missed visits over total scheduled). Rescheduled visits will not count as missed visits. At baseline, we will look at visits for the past 12 months.</div></li>\n<li style=\"margin:1ex 0.5ex\">HIV viral load (from medical chart) over 1 year study duration [\u00a0Time\u00a0Frame:\u00a0baseline, 4 months, 8 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">We want to examine whether stigma reduction due to the intervention is associated with improved physical health bio-markers such as suppression in HIV viral load in the blood (taken from medical chart/previous clinical blood tests).</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in CD4 count [\u00a0Time\u00a0Frame:\u00a0baseline, 4 months, 8 months, 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">We want to see wither stigma reduction from the intervention associated with improved physical health bio-markers such as CD4+ T cell count.</div></li>\n</ul></td>"], "BT": ["Reducing HIV Stigma for African American Women"], "OOOM": ["Not Provided"], "LUD": ["July 1, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01893112"], "EPCD": ["October 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Reducing HIV Stigma to Improve Health Outcomes for African-American Women"], "COOM": ["Not Provided"], "SD": ["June 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01106833"], "CPOM": [], "FRD": ["April 16, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01106833?rank=233&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Phase II: Avg. daily dose % reduction of prednisone [\u00a0Time\u00a0Frame:\u00a06 and 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Cumulative incidence of treatment failure [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Prevalence of active symptomatic chronic GVHD [\u00a0Time\u00a0Frame:\u00a01 and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Incidence of discontinuation of all systemic immunosuppressive therapy [\u00a0Time\u00a0Frame:\u00a01 and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Overall and cancer progression-free survival [\u00a0Time\u00a0Frame:\u00a01 and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase II: Serum biomarkers of chronic GVHD [\u00a0Time\u00a0Frame:\u00a0baseline, 2 and 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase III: Avg. daily dose % reduction of prednisone [\u00a0Time\u00a0Frame:\u00a06, 12 and 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase III: Cumulative incidence of treatment failure [\u00a0Time\u00a0Frame:\u00a01 and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase III: Prevalence of active symptomatic chronic GVHD [\u00a0Time\u00a0Frame:\u00a01 and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase III: Incidence of discontinuation of all systemic immunosuppressive therapy [\u00a0Time\u00a0Frame:\u00a01 and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phases III: Overall and cancer progression-free survival [\u00a0Time\u00a0Frame:\u00a01 and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Phase III: Serum biomarkers of chronic GVHD [\u00a0Time\u00a0Frame:\u00a0baseline, 1 and 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)"], "OOOM": ["Not Provided"], "LUD": ["May 29, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01106833"], "EPCD": ["March 2019 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN #0801)"], "COOM": ["Not Provided"], "SD": ["April 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01909453"], "CPOM": ["Progression free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["July 24, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01909453?rank=231&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0Up to approximately 4 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS is calculated as the time from date of randomization to date of death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years with update around 3 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PFS is defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, whichever occurs first. PFS will be determined based on tumor assessment (RECIST version 1.1 criteria) as per Blinded Independent Review Committee (BIRC) and survival information. The local Investigator's assessments will be used as supportive analyses.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR calculated as the proportion of patient with a best overall response of complete response (CR) or partial response (PR). ORR will be calculated for confirmed and unconfirmed responses separately.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time To Response (TTR) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">TTR calculated as the time from date of randomization until first documented complete response (CR) or partial response(PR).</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease Control Rate (DCR) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DCR calculated as the proportion of patient with a best overall response of CR, PR or stable disease (SD)</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of objective response (DOR) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DOR calculated as the time from the date of first documented CR or PR to the first documented progression or death due to underlying cancer</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of combination and LGX818 [\u00a0Time\u00a0Frame:\u00a0Up to approximately 4 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Number of patients with adverse events and serious adverse events , changes in laboratory values, vital signs, electrocardiograms (ECGs), MUGA (Multi-Gated Acquisition Scan)/echocardiogram and assessment of physical, dermatological and ocular examinations graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03</div></li>\n<li style=\"margin:1ex 0.5ex\">ECOG Performance status (PS) [\u00a0Time\u00a0Frame:\u00a0Approximatley 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Change from baseline in the ECOG PS</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 1 point deterioration in ECOG performance status [\u00a0Time\u00a0Frame:\u00a0Approximatley 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive 1 point deterioration in the ECOG PS is defined as the time form date of randomization to definitive deterioration, where deterioration is considered as definitive if no improvement in the ECOG PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics of LGX818 and MEK162 [\u00a0Time\u00a0Frame:\u00a0Approximatley 2 years after first pateint randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Plasma concentration-profiles of LGX818 and MEK162 and model based PK parameters</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 10% deterioration in global health status (EORTC QLQC30) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive 10% deterioration in the global health status score of the EORTC QLQ-C30 is the time from the date of randomization to the date of at least 10% relative to baseline worsening with no later improvement above this threshold observed during the course of the study or death due to any cause</div></li>\n<li style=\"margin:1ex 0.5ex\">Global health status (EORTC QLQC30) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Change from baseline in the global health status score of the EORTC QLQ-C30</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 10% deterioration in the FACT-M melanoma subscale [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive 10% deterioration in the FACT-M melanoma (subscale) is the time from the date of randomization to the date of at least 10% relative to baseline worsening with no later improvement above this threshold observed during the course of the study or death due to any cause</div></li>\n<li style=\"margin:1ex 0.5ex\">Global health status (EQ-5D) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Change from baseline in the EQ-5D</div></li>\n</ul></td>"], "BT": ["Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma"], "OOOM": ["Not Provided"], "LUD": ["June 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0Up to approximately 4 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS is calculated as the time from date of randomization to date of death due to any cause.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years with update around 3 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">PFS is defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, whichever occurs first. PFS will be determined based on tumor assessment (RECIST version 1.1 criteria) as per Blinded Independent Review Committee (BIRC) and survival information. The local Investigator's assessments will be used as supportive analyses.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR calculated as the proportion of patient with a best overall response of complete response (CR) or partial response (PR). ORR will be calculated for confirmed and unconfirmed responses separately.</div></li>\n<li style=\"margin:1ex 0.5ex\">Time To Response (TTR) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">TTR calculated as the time from date of randomization until first documented complete response (CR) or partial response(PR).</div></li>\n<li style=\"margin:1ex 0.5ex\">Disease Control Rate (DCR) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DCR calculated as the proportion of patient with a best overall response of CR, PR or stable disease (SD)</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of objective response (DOR) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">DOR calculated as the time from the date of first documented CR or PR to the first documented progression or death due to underlying cancer</div></li>\n<li style=\"margin:1ex 0.5ex\">Safety and tolerability of combination and LGX818 [\u00a0Time\u00a0Frame:\u00a0Up to approximately 4 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Number of patients with adverse events and serious adverse events , changes in laboratory values, vital signs, electrocardiograms (ECGs), MUGA(Multi Gated Acquisition Scan)/echocardiogram and assessment of physical,dermatological and ocular examinations graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03</div></li>\n<li style=\"margin:1ex 0.5ex\">ECOG Performance status (PS) [\u00a0Time\u00a0Frame:\u00a0Approximatley 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Change from baseline in the ECOG PS</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 1 point deterioration in ECOG performance status [\u00a0Time\u00a0Frame:\u00a0Approximatley 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive 1 point deterioration in the ECOG PS is defined as the time form date of randomization to definitive deterioration, where deteriorationis considered as definitive if no improvement in the ECOG PS status is observed at a subsequent time of measurement during the treatment period following the time point where the deterioration is observed.</div></li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetics of LGX818 and MEK162 [\u00a0Time\u00a0Frame:\u00a0Approximatley 2 years after first pateint randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Plasma concentration-profiles of LGX818 and MEK162 and model based PK parameters</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 10% deteriortaion in global health status (EORTC QLQC30) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive 10% deterioration in the global health status score of theEORTC QLQ-C30 is the time from the date of randomization to the date of at least 10% relative to baseline worsening with no later improvement above this threshold observed during the course of the study or death due to any cause</div></li>\n<li style=\"margin:1ex 0.5ex\">Global health status (EORTC QLQC30) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Change from baseline in the global health status score of the EORTC QLQ-C30</div></li>\n<li style=\"margin:1ex 0.5ex\">Time to definitive 10% deterioration in the FACT-M melanoma subscale [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time to definitive 10% deterioration in the FACT-M melanoma (subscale) is the time from the date of randomization to the date of at least 10% relative to baseline worsening with no later improvement above this threshold observed during the course of the study or death due to any cause</div></li>\n<li style=\"margin:1ex 0.5ex\">Global health status (EQ-5D) [\u00a0Time\u00a0Frame:\u00a0Approximately 2 years after first patient randomized\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Change from baseline in the EQ-5D</div></li>\n</ul></td>"], "record_id": ["NCT01909453"], "EPCD": ["June 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized, 3-arm, Open Label, Multicenter Study of LGX818 Plus MEK162 and LGX818 Monotherapy Compared With Vemurafenib in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma"], "COOM": ["Not Provided"], "SD": ["September 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01239797"], "CPOM": [], "FRD": ["November 8, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01239797?rank=232&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival - The period of time from study entry until the date of death or last known date alive [\u00a0Time\u00a0Frame:\u00a0Survival will be assessed every 12 weeks in the Follow Up Phase of the trial (approximate length of the overall survival period is 6.75 years)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change from baseline of the mean score of pain severity and the change from baseline of the mean score of pain interference using the Brief Pain Inventory-Short Form (BPI-SF) of LdE versus Ld [\u00a0Time\u00a0Frame:\u00a0Approximately up to 6.75 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">Lenalidomide, (low-dose) Dexamethasone, Elotuzumab (LdE)</p>\n<p style=\"margin-top:0ex; margin-bottom:1ex;\">Lenalidomide, (low-dose) Dexamethasone (Ld)</p></div></li>\n</ul></td>"], "BT": ["Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma"], "OOOM": ["Not Provided"], "LUD": ["July 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective Response Rate - The percentage of patients who have a partial or complete response to study therapy [\u00a0Time\u00a0Frame:\u00a0All response endpoints assessed every 4 weeks (\u00b1 1 week) (median length of the endpoint assessment period is projected to be approximately 13 months)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival - The period of time from study entry until the date of death or last known date alive [\u00a0Time\u00a0Frame:\u00a0Survival will be assessed every 12 weeks in the Follow Up Phase of the trial (approximate length of the overall survival period is 6.75 years)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01239797"], "EPCD": ["July 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)"], "COOM": ["Not Provided"], "SD": ["March 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01175356"], "CPOM": [], "FRD": ["August 3, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01175356?rank=234&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Incidence of adverse events and SOS, assessed by Common Terminology Criteria (CTC)v.4.0 for toxicity assessment and grading [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</td>"], "BT": ["Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin"], "OOOM": ["Not Provided"], "LUD": ["April 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Response rate [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Tumor burden [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relationship of SOS to dosages of myeloablative consolidation therapy and ASCR, and whole-body radiation or delay of radiation clearance due to 131 I-MIBG [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01175356"], "EPCD": ["December 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma"], "COOM": ["Not Provided"], "SD": ["October 2010"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01351935"], "CPOM": ["Safety, tolerability,and dose limiting toxicities will be determined using AEs,PE,ophthalmologic examinations,clinical laboratory tests,vital signs, ECGs and echocardiograms/MUGA scans. [\u00a0Time\u00a0Frame:\u00a0with in the first 28 days after initiation of once daily oral dosing\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 10, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01351935?rank=239&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Establish recommended Phase 2 dose, after completing dose escalation in Part 1 and evaluating accumulated safety,PK,and PD data from the dose escalation phase (Part1) [\u00a0Time\u00a0Frame:\u00a0Completion of Part 1 dose escalation phase of study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">After completion of observation for dose limiting toxicities in Part 1 of the study, the accumulated safety, PK, and PD data from Part 1 will be evaluated by the investigators and Sponsor to select a preliminary RP2D for administration to additional subjects to be enrolled into 1 of 3 independent and non-randomized diagnosis-specific expansion cohorts in Part 2 of the study</div></li>\n<li style=\"margin:1ex 0.5ex\">Evaluate the Pharmacokinetic parameters of AVL-292 [\u00a0Time\u00a0Frame:\u00a0First 28 days of dosing\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Serial blood sampling to enable PK characterization of AVL-292 will be performed for the Cycle1 Day 1 (C1D1) and Cycle 1Day 15 dose administrations. Additional samples will be obtained on C1D8 and C1D22.A non-compartmental model will be evaluated for all subjects.</div></li>\n<li style=\"margin:1ex 0.5ex\">Evaluate the Pharmacodynamics of AVL-292 by measurement of free Btk [\u00a0Time\u00a0Frame:\u00a0First 28 days of dosing\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The PD activity of AVL-292 will be studied with a quantitative assay using a covalent probe to directly assess free Btk in PBMC lysates.</div></li>\n<li style=\"margin:1ex 0.5ex\">Characterize preliminary anti-tumor efficacy of AVL-292 in relapsed and/or refractory B-NHL, CLL and WM [\u00a0Time\u00a0Frame:\u00a0After completion of 28 day cycle of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Efficacy response assessments will be formally assessed within 7 days preceding C2D1, C3D1, C5D1, C7D1, and EOT</div></li>\n</ul></td>"], "BT": ["Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia"], "OOOM": ["Not Provided"], "LUD": ["February 26, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Establish recommended Phase 2 dose, after completing dose escalation in Part 1 and evaluating accumulated safety,PK,and PD data from the dose escalation phase (Part1) [\u00a0Time\u00a0Frame:\u00a0Completion of Part 1 dose escalation phase of study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">After completion of observation for dose limiting toxicities in Part 1 of the study, the accumulated safety, PK, and PD data from Part 1 will be evaluated by the investigators and Sponsor to select a preliminary RP2D for administration to additional subjects to be enrolled into 1 of 3 independent and non-randomized diagnosis-specific expansion cohorts in Part 2 of the study</div></li>\n<li style=\"margin:1ex 0.5ex\">evaluate the Pharmacokinetic parameters of AVL-292 [\u00a0Time\u00a0Frame:\u00a0First 28 days of dosing\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Serial blood sampling to enable PK characterization of AVL-292 will be performed for the Cycle1 Day 1 (C1D1) and Cycle 1Day 15 dose administrations.  Additional samples will be obtained on C1D8 and C1D22.A non-compartmental model will be evaluated for all subjects.</div></li>\n<li style=\"margin:1ex 0.5ex\">evaluate the Pharmacodynamics of AVL-292 by measurement of free Btk [\u00a0Time\u00a0Frame:\u00a0First 28 days of dosing\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The PD activity of AVL-292 will be studied with a quantitative assay using a covalent probe to directly assess free Btk in PBMC lysates.</div></li>\n<li style=\"margin:1ex 0.5ex\">Characterize preliminary anti-tumor efficacy of AVL-292 in relapsed and/or refractory B-NHL, CLL and WM [\u00a0Time\u00a0Frame:\u00a0After completion of 28 day cycle of treatment\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Efficay response assessments will be formally assessed within 7 days preceding C2D1, C3D1, C5D1, C7D1, and EOT</div></li>\n</ul></td>"], "record_id": ["NCT01351935"], "EPCD": ["December 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia"], "COOM": ["Not Provided"], "SD": ["June 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01387932"], "CPOM": ["Median overall survival [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 11, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01387932?rank=240&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Objective Response Rates (ORR) [\u00a0Time\u00a0Frame:\u00a0Approx 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">ORR in the treated area [\u00a0Time\u00a0Frame:\u00a0Approx 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Adverse Events [\u00a0Time\u00a0Frame:\u00a0Approx 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Resource utilization [\u00a0Time\u00a0Frame:\u00a0Approx 6 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular "], "OOOM": ["Not Provided"], "LUD": ["April 21, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01387932"], "EPCD": ["December 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma"], "COOM": ["Not Provided"], "SD": ["April 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01215136"], "CPOM": ["Response Rate [\u00a0Time\u00a0Frame:\u00a04 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["October 4, 2010"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01215136?rank=237&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Number of Participants with Adverse Events as a Measure of Safety and Tolerability [\u00a0Time\u00a0Frame:\u00a04 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine the safety of everolimus and everolimus plus paclitaxel in this patient population.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression Free Survival [\u00a0Time\u00a0Frame:\u00a04 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine progression free survival</div></li>\n<li style=\"margin:1ex 0.5ex\">Survival - 1 year [\u00a0Time\u00a0Frame:\u00a012 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">To determine survival at 1-year from the initiation of treatment.</div></li>\n</ul></td>"], "BT": ["First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma"], "OOOM": ["Not Provided"], "LUD": ["April 14, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01215136"], "EPCD": ["December 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU10-147"], "COOM": ["Not Provided"], "SD": ["December 2010"]},
{"OPOM": ["Central Nervous System Bioavailability of Sulfasalazine [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01577966"], "CPOM": ["Central Nervous System Bioavailability of Sulfasalazine [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 11, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01577966?rank=236&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Safety will be analyzed for all patients treated in study [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</td>"], "BT": ["Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma"], "OOOM": ["Not Provided"], "LUD": ["January 14, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01577966"], "EPCD": ["January 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Pilot Study to Determine the Effect of Sulfasalazine on Glutamate Levels Detected by Magnetic Resonance Spectroscopy(MRS) in Patients With Glioma"], "COOM": ["Not Provided"], "SD": ["January 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01865747"], "CPOM": ["Progression-free survival (PFS) [\u00a0Time\u00a0Frame:\u00a0up to 17 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 21, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01865747?rank=238&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0up to 36 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">OS is measured from the time of randomization until death due to any cause assessed up to 36 months.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective Response Rate (ORR) [\u00a0Time\u00a0Frame:\u00a0up to 17 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">ORR is the proportion of subjects, assessed up to 17 months, who have measurable disease at baseline and who have complete response (CR) or partial response (PR) at data cut off.</div></li>\n</ul></td>"], "BT": ["A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma"], "OOOM": ["Not Provided"], "LUD": ["July 29, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01865747"], "EPCD": ["September 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy"], "COOM": ["Not Provided"], "SD": ["June 2013"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01660451"], "CPOM": ["Tumor response [\u00a0Time\u00a0Frame:\u00a0Up to 10 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 6, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01660451?rank=241&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of response after 12 months [\u00a0Time\u00a0Frame:\u00a0After 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from first observed tumor response (Complete response, Complete response unconfirmed or Partial Response) until progressive disease or until death caused by progressive disease.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of response after 3 years [\u00a0Time\u00a0Frame:\u00a0After 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from first observed tumor response (Complete response, Complete response unconfirmed or Partial Response) until progressive disease or until death caused by progressive disease.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival after 12 months [\u00a0Time\u00a0Frame:\u00a0After 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from treatment assignment to disease progression or death (if death occurs before a documented progression).</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival after 3 years [\u00a0Time\u00a0Frame:\u00a0After 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from treatment assignment to disease progression or death (if death occurs before a documented progression).</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival after 12 months [\u00a0Time\u00a0Frame:\u00a0After 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from treatment assignment until death from any cause or until the last date the patient is known to be alive.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival after 3 years [\u00a0Time\u00a0Frame:\u00a0After 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from treatment assignment until death from any cause or until the last date the patient is known to be alive.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with adverse events as a measure of safety and tolerability [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of response after study withdrawal [\u00a0Time\u00a0Frame:\u00a0After 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from first observed tumor response (Complete response, complete response unconfirmed or Partial response) until progressive disease or until death caused by progressive disease .</div></li>\n</ul></td>"], "BT": ["Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas"], "OOOM": ["Not Provided"], "LUD": ["July 22, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of response after 12 months [\u00a0Time\u00a0Frame:\u00a0After 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from first observed tumor response (Complete response, Complete response unconfirmed or Partial Response) until progressive disease or until death caused by progressive disease.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of response after 3 years [\u00a0Time\u00a0Frame:\u00a0After 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from first observed tumor response (Complete response, Complete response unconfirmed or Partial Response) until progressive disease or until death caused by progressive disease.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival after 12 months [\u00a0Time\u00a0Frame:\u00a0After 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from treatment assignment to disease progression or death (if death occurs before a documented progression).</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression free survival after 3 years [\u00a0Time\u00a0Frame:\u00a0After 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from treatment assignment to disease progression or death (if death occurs before a documented progression).</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival after 12 months [\u00a0Time\u00a0Frame:\u00a0After 12 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from treatment assignment until death from any cause or until the last date the patient is known to be alive.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall survival after 3 years [\u00a0Time\u00a0Frame:\u00a0After 3 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Defined as the time (in days) from treatment assignment until death from any cause or until the last date the patient is known to be alive.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of participants with adverse events as a measure of safety and tolerability [\u00a0Time\u00a0Frame:\u00a0Up to 4 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01660451"], "EPCD": ["May 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas"], "COOM": ["Not Provided"], "SD": ["November 2012"]},
{"OPOM": ["Adherence rate to 6MP defined as the ratio of MEMS pill container openings to the number of days that 6MP doses were prescribed during each study month [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01503632"], "CPOM": ["Adherence rate to 6MP defined as the ratio of MEMS pill container openings to the number of days that 6MP doses were prescribed during each study month [\u00a0Time\u00a0Frame:\u00a0Length of study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 3, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01503632?rank=242&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Effect of socio-demographic and clinical characteristics as well as health beliefs/knowledge on changes in adherence with the IP [\u00a0Time\u00a0Frame:\u00a0Length of study\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Adherence to prescribed therapy is a complex health behavior determined by a variety of socioeconomic, individual, familial, and cultural factors. Adolescents are more likely to be non-adherent; other risk factors include larger family size, medication side effects, and educational, cultural and socioeconomic factors.  Lack of adherence in pediatric ALL patients is a clinically important problem in 10% to 33% of children.</div></td>"], "BT": ["Study Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission"], "OOOM": ["Not Provided"], "LUD": ["February 17, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Effect of socio-demographic and clinical characteristics as well as health beliefs/knowledge on changes in adherence with the IP [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "record_id": ["NCT01503632"], "EPCD": ["June 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL"], "COOM": ["Not Provided"], "SD": ["February 2012"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01343693"], "CPOM": ["Disc Degeneration [\u00a0Time\u00a0Frame:\u00a024 Months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["April 27, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01343693?rank=243&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Change in Disc Height [\u00a0Time\u00a0Frame:\u00a024 Months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Change in disc height is defined as the change in distance between the anterior-inferior (posterior-inferior) corner of the superior vertebra, and the corresponding corner of the inferior vertebra.  This change is measured perpendicular to the superior endplate of the inferior vertebra.  Change in average disc height is calculated as the simple average of the change in anterior and posterior disc heights. Change in disc height is calculated by subtracting the measured disc height at one time point from a baseline disc height measurement.  The results will be recorded in units of millimeters.</div></li>\n<li style=\"margin:1ex 0.5ex\">Fusion Status [\u00a0Time\u00a0Frame:\u00a024 Months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\"><p style=\"margin-top:0ex; margin-bottom:1ex;\">Fusion will be assessed by an independent radiographer when data collection is complete at each site.  The radiographic report (if available) and the x-rays will be sent to an independent radiologist for review at the end of the study.  X-rays will be evaluated at each visit for fusion determination.  The grading system is as follows:</p>\n<ul style=\"margin-top:1ex; margin-bottom:1ex;\"><li style=\"margin-top:0.7ex;\">Grade 1 - No graft incorporation</li>\n<li style=\"margin-top:0.7ex;\">Grade 2 - Incomplete graft incorporation</li>\n<li style=\"margin-top:0.7ex;\">Grade 3 - Graft Incorporation</li>\n<li style=\"margin-top:0.7ex;\">Grade 4 - Solid fusion with graft incorporation</li>\n</ul></div></li>\n</ul></td>"], "BT": ["MaxAn Post Market Surveillance Validation"], "OOOM": ["Not Provided"], "LUD": ["July 17, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01343693"], "EPCD": ["December 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Post Market Surveillance Validation to Evaluate the Effectiveness of the MaxAn Anterior Cervical Plate"], "COOM": ["Not Provided"], "SD": ["June 2011"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT02047214"], "CPOM": [], "FRD": ["January 24, 2014"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT02047214?rank=244&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Efficacy of TPI 287 + bevacizumab in adults with GBM that progressed following radiation &amp; TMZ &amp; prior bevacizumab as measured by median progression free survival (PFS), overall response rate, &amp; PFS rate at 4 &amp; 6 months (PFS4 &amp; PFS6) [\u00a0Time\u00a0Frame:\u00a0Baseline &amp; on Day 1 of each 42-day treatment cycle starting with Cycle 2, and/or as clinically indicated\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Response Assessment in Neuro-Oncology (RANO) working group recommendations for updated response criteria for high-grade gliomas (Wen et al. 2010) will be used to determine response for this trial.</div></td>"], "BT": ["Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy"], "OOOM": ["Not Provided"], "LUD": ["July 24, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Efficacy of TPI 287 + bevacizumab in adults with GBM that progressed following radiation &amp; TMZ &amp; prior bevacizumab as measured by median progression free survival (PFS), overall response rate, &amp; PFS rate at 4 &amp; 6 months (PFS4 &amp; PFS6) [\u00a0Time\u00a0Frame:\u00a0Baseline &amp; on Day 1 of each 42-day treatment cycle starting with Cycle 2, and/or as clinically indicated\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The Response Assessment in Neuro-Oncology (RANO) working group recommendations for updated response criteria for high-grade gliomas ((Wen et al. 2010) will be used to determine response for this trial.</div></td>"], "record_id": ["NCT02047214"], "EPCD": ["January 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen"], "COOM": ["Not Provided"], "SD": ["January 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01457885"], "CPOM": ["Disease free survival following transplant using a CloBu4 conditioning regimen for patients with non-remission AML [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]"], "FRD": ["October 19, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01457885?rank=248&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival following transplant using a CloBu4 conditioning regimen for patients with non-remission AML [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relapse Rate [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "BT": ["Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen"], "OOOM": ["Not Provided"], "LUD": ["July 18, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival following transplant using a CloBu4 conditioning regimen for patients with non-remission AML [\u00a0Time\u00a0Frame:\u00a01 year\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Regimen related toxicities [\u00a0Time\u00a0Frame:\u00a0100 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to neutrophil and platelet engraftment [\u00a0Time\u00a0Frame:\u00a0100 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence and Severity of acute Graft versus Host Disease [\u00a0Time\u00a0Frame:\u00a0100 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence and Severity of chronic Graft versus Host Disease [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Relapse Rate [\u00a0Time\u00a0Frame:\u00a02 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li s[{"OPOM": ["Progression-Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a036 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01925274"], "CPOM": ["Progression-Free Survival (PFS) [\u00a0Time\u00a0Frame:\u00a036 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["August 15, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01925274?rank=8&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Number of participants with Dose-limiting toxicities (DLT) [\u00a0Time\u00a0Frame:\u00a028 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Determination of unacceptable toxicity in patients enrolled at sites in Japan.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants With Objective Response [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Number of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed CR defined as disappearance of all target lesions. Confirmed PR defined as \u226530% decrease in sum of the longest dimensions (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST. Confirmed responses are those that persist on repeat imaging study \u22654 weeks after initial documentation of response.</div></li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (DR) [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7. DR was calculated for the subgroup of participants with a confirmed objective tumor response.</div></li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.</div></li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants Using Healthcare Resources [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">FACT-C</div></li>\n<li style=\"margin:1ex 0.5ex\">Area under the Concentration-Time Curve (AUC) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.</div></li>\n<li style=\"margin:1ex 0.5ex\">Maximum Observed Plasma Concentration (Cmax) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to Reach Maximum Observed Plasma Concentration (Tmax) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Levels of signaling proteins in paired and single tumor biopsies [\u00a0Time\u00a0Frame:\u00a00, 36, 37\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Gene sequences and/or gene copy numbers in paired tumor biopsies [\u00a0Time\u00a0Frame:\u00a00, 36, 37\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal "], "OOOM": ["Not Provided"], "LUD": ["July 11, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Number of participants with Dose-limiting toxicities (DLT) [\u00a0Time\u00a0Frame:\u00a028 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants With Objective Response [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Duration of Response (DR) [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Number of Participants Using Healthcare Resources [\u00a0Time\u00a0Frame:\u00a0up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Area under the Concentration-Time Curve (AUC) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Maximum Observed Plasma Concentration (Cmax) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Time to Reach Maximum Observed Plasma Concentration (Tmax) [\u00a0Time\u00a0Frame:\u00a00, 1, 2, 4, 6, 24, 72, 120 hours\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01925274"], "EPCD": ["January 2016 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Phase 2 Study Of PF-05212384 Plus Irinotecan Versus Cetuximab Plus Irinotecan In Patients With KRAS and NRAS Wild Type Metastatic Colorectal "], "COOM": ["Not Provided"], "SD": ["April 2014"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT00898365"], "CPOM": [], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00898365?rank=6&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\">Loss of heterozygosity [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "BT": ["Study of Kidney ", " in Young Patients"], "OOOM": ["Not Provided"], "LUD": ["February 5, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\">Loss of heterozygosity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</td>"], "record_id": ["NCT00898365"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Renal ", " Classification, Biology, and Banking Study"], "COOM": ["Not Provided"], "SD": ["February 2006"]},
{"OPOM": [], "CH": ["/ct2/archive/NCT01997333"], "CPOM": [], "FRD": ["November 18, 2013"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01997333?rank=7&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Duration of Response  (DOR) [\u00a0Time\u00a0Frame:\u00a0At least 18 months following treatment initiation\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall Survival (OS) [\u00a0Time\u00a0Frame:\u00a0During treatment and 3 months from end of treatment through end of study or approximately up to 5 years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Adverse Events (AE) [\u00a0Time\u00a0Frame:\u00a0Usually following at least 1 cycle of study treatment (1 dose of CDX-011 or capecitabine and until discontinuation of follow-up)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The percentage of patients experiencing one or more adverse events will be summarized by treatment arm, relationship to study drug, and severity.</div></li>\n<li style=\"margin:1ex 0.5ex\">Pharmacokinetic (PK) [\u00a0Time\u00a0Frame:\u00a0Following 1 dose of CDX-011.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Concentration of the antibody-drug conjugate, total antibody and free MMAE will be determined.</div></li>\n</ul></td>"], "BT": ["Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast "], "OOOM": ["Not Provided"], "LUD": ["June 23, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><i style=\"color:#777777\">Same as current</i></td>"], "record_id": ["NCT01997333"], "EPCD": ["September 2015 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast ", " (The METRIC Study)"], "COOM": ["Not Provided"], "SD": ["November 2013"]},
{"OPOM": ["Overall survival time between 3 treatment arms [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00632853"], "CPOM": ["Overall survival time between 3 treatment arms [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 8, 2008"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00632853?rank=4&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Time\u00a0Frame:\u00a0Up to Interim Analysis\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Complete and partial response rates [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Failure-free survival [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local tumor progression according to RECIST criteria [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates of distant metastases and intracranial metastases [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung ", " Receiving Cisplatin and Etoposide"], "OOOM": ["Not Provided"], "LUD": ["June 14, 2013"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Complete and partial response rates [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Failure-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local tumor progression according to RECIST criteria [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates of distant metastases and intracranial metastases [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00632853"], "EPCD": ["June 2023 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung ", " Also Receiving Cisplatin and Etoposide"], "COOM": ["Not Provided"], "SD": ["March 2008"]},
{"OPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00588770"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0Time from randomization to date of death from any cause, censored at date of last contact, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["December 28, 2007"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00588770?rank=5&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of toxicity as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">One-sided Fisher's exact tests with alpha of 0.05 will be used.</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response rates [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The sum of the longest diameters of all target lesions will be calculated at baseline and reported as the baseline sum longest diameter. The sum longest diameter will be used to characterize the objective tumor response.</div></li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Time\u00a0Frame:\u00a0From the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression, assessed up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Comorbidities [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The impact of comorbidities on endpoints will be assessed.</div></li>\n</ul></td>"], "BT": ["Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck "], "OOOM": ["Not Provided"], "LUD": ["July 18, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Toxicity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Progression-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Impact of comorbidity [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT00588770"], "EPCD": ["December 2017 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck "], "COOM": ["Not Provided"], "SD": ["August 2008"]},
{"OPOM": ["Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01546987"], "CPOM": ["Overall survival [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death due to any cause.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["March 3, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01546987?rank=9&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of unexpected grade \u2265 3 adverse events and/or clinically significant decrement in patient-reported quality of life (PR-QOL) among patients treated with TAK-700 [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented AE \u2265 grade 3 and/or to the date of first clinically significant decrement in patient-reported quality of life (PR-QOL) among patients treated with TAK-700.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates and cumulative incidence of biochemical control - freedom from PSA failure [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented biochemical failure by the Phoenix definition (PSA \u2265 2 ng/ml over the nadir PSA) or the initiation of salvage androgen deprivation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">General clinical treatment failure-free interval [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first documented general clinical treatment failure defined as: PSA &gt; 25 ng/ml or documented local disease progression or regional or distant metastasis or initiation of androgen deprivation therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prostate cancer-specific survival and other-cause survival [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of death due to prostate cancer for prostate cancer-specific survival and to the date of death due to other causes for other-cause survival.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in fatigue from baseline to 1 year, as measured by PROMIS [\u00a0Time\u00a0Frame:\u00a0One year from the date of randomization.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in PR-QOL as measured by EPIC [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the week prior to RT start, to the last week of RT and 1 year and 2.5 years after the initiation of therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Assessment of quality-adjusted survival using the EQ-5D [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the week prior to RT start, to the last week of RT and 1 year and 2.5 years after the initiation of therapy.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Nadir and average serum testosterone at 12 and 24 months during treatment [\u00a0Time\u00a0Frame:\u00a0From baseline to 12 months and 24 months of treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lipid profiles at 12 and 24 months [\u00a0Time\u00a0Frame:\u00a0From baseline to 12 months and 24 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Fasting plasma glucose, fasting plasma insulin, and hemoglobin A1c at 12 and 24 months [\u00a0Time\u00a0Frame:\u00a0From baseline to 12 months and 24 months.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in body mass index (BMI) during 24 months of treatment and during the first three years of follow-up [\u00a0Time\u00a0Frame:\u00a0From baseline to 2 years from the start of treatment and after that every year for 3 more years.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events ascertained via Common Toxicity Criteria for Adverse Effects (CTCAE) version 4 [\u00a0Time\u00a0Frame:\u00a0From the start of therapy to 6 months of follow-up.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of recovery of testosterone to &gt; 230 ng/dL (accepted threshold for supplementation) after 12 and 24 months of follow-up [\u00a0Time\u00a0Frame:\u00a0From the treatment end date to the date when testosterone levels first recovered to &gt; 230 ng/dl within 12 months and 24 months of treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Median time to recovery of testosterone to &gt; 230 ng/dL during the first five years of follow-up [\u00a0Time\u00a0Frame:\u00a0From the date of ranomization to the post-treatment end date when testosterone levels first recovered to &gt; 230 ng/dl within 5 years after treatment.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidence of relevant clinical survivorship endpoints including new diagnosis of type 2 diabetes, coronary artery disease, myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, or osteoporotic fracture [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first reported new incidence of any of the above mentioned clinical endpoints.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates and cumulative incidence of local/regional progression [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of the documented presence of local/regional recurrence.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates and cumulative incidence of distant metastases [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of documented distant recurrence.\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "BT": ["Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate "], "OOOM": ["Not Provided"], "LUD": ["July 9, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Incidence of unexpected grade \u2265 3 adverse events and/or clinically significant decrement in patient-reported quality of life (PR-QOL) among patients treated with TAK-700 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rates and cumulative incidence of biochemical control (freedom from PSA failure), local/regional progression, and distant metastases [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">General clinical treatment failure-free interval [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Prostate cancer-specific survival and other-cause survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Change in fatigue from baseline to 1 year, as measured by PROMIS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in PR-QOL as measured by EPIC [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Assessment of quality-adjusted survival using the EQ-5D [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Nadir and average serum testosterone at 12 and 24 months during treatment [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lipid profiles at 12 and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Fasting plasma glucose, fasting plasma insulin, and hemoglobin A1c at 12 and 24 months [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Changes in body mass index (BMI) during 24 months of treatment and during the first three years of follow-up [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events ascertained via CTCAE version 4 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Rate of recovery of testosterone to &gt; 230 ng/dL (accepted threshold for supplementation) after 12 and 24 months of follow-up [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Median time to recovery of testosterone to &gt; 230 ng/dL during the first five years of follow-up [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Cumulative incidence of relevant clinical survivorship endpoints including new diagnosis of type 2 diabetes, coronary artery disease, myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis, or osteoporotic fracture [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01546987"], "EPCD": ["October 2014 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate "], "COOM": ["Not Provided"], "SD": ["May 2012"]},
{"OPOM": ["CR rate in the brain at 12-weeks post-WBRT measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on MRI scan of the brain [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01622868"], "CPOM": ["CR rate in the brain measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on MRI scan of the brain [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["June 15, 2012"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01622868?rank=3&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">CR rate in the brain measured using revise RECIST version 1.1 based on MRI scan of the brain [\u00a0Time\u00a0Frame:\u00a04 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Response in the brain also will be measured using bidimensional measurements (WHO/modified McDonald's criteria).</div></li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) (CR + PR) measured using RECIST version 1.1 based on MRI scan of the brain [\u00a0Time\u00a0Frame:\u00a0At 4 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">ORR (CR + PR) measured using RECIST version 1.1 based on MRI scan of the brain [\u00a0Time\u00a0Frame:\u00a0At 12 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-specific ORR (CR + PR) [\u00a0Time\u00a0Frame:\u00a0At 4 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-specific ORR (CR + PR) [\u00a0Time\u00a0Frame:\u00a0At 12 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall response (CR, PR, or stable disease [SD]) [\u00a0Time\u00a0Frame:\u00a0Up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Treatment-related toxicity as measured by Common Terminology Criterial for Adverse Events version 4 [\u00a0Time\u00a0Frame:\u00a0Up to 12 weeks post WBRT\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">CNS PFS [\u00a0Time\u00a0Frame:\u00a0From the time of randomization to the date of first failure (CNS progression or death due to any cause), assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated by the Kaplan-Meier method. Compared between arms using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with PFS.</div></li>\n<li style=\"margin:1ex 0.5ex\">PFS [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first failure or last follow-up, assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated by the Kaplan-Meier method. Compared between arms using the log rank test. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with PFS.</div></li>\n<li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0From the date of randomization to the date of first failure, assessed up to 2 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Estimated by the Kaplan-Meier method. The Cox proportional hazard regression model will be used to analyze the effects of factors, in addition to treatment, that may be associated with OS.</div></li>\n</ul></td>"], "BT": ["Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast "], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">CR rate in the brain at 4-weeks post WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Objective response rate (ORR) (CR + PR) at 4 weeks post-WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">ORR at 12 weeks post-WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-specific ORR at 4 weeks post-WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Lesion-specific ORR at 12 weeks post-WBRT [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall response (CR, PR, or stable disease [SD]), assessed up to 12 weeks post-WBRT and then every 12 weeks thereafter [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Treatment-related toxicity as measured by Common Terminology Criterial for Adverse Events (CTCAE) version 4, assessed up to 12 weeks post-WBRT and then every 12 weeks thereafter [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">CNS PFS from the time of randomization to the date of first failure (CNS progression or death due to any cause) [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">OS from the date of randomization to the date of first failure [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01622868"], "EPCD": ["February 2018 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast ", ": A Collaborative Study of RTOG and KROG"], "COOM": ["Not Provided"], "SD": ["July 2012"]},
{"OPOM": ["Invasive disease-free survival (DFS) of women with node-positive breast cancer treated with endocrine therapy with vs without chemotherapy [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01272037"], "CPOM": ["RS, as measured by Oncotype DX [\u00a0Time\u00a0Frame:\u00a0Up to 15 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 6, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01272037?rank=1&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0The time from the second registration (randomization) to death due to any cause, assessed up to 15 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">DDFS [\u00a0Time\u00a0Frame:\u00a0The time from second registration to distant recurrence, new invasive primary, or death due to any cause, assessed up to 15 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local disease-free interval [\u00a0Time\u00a0Frame:\u00a0The time from second registration to local/regional recurrence, assessed up to 15 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicities using standard National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 5 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">Compared between the two arms using logistic regression.</div></li>\n</ul></td>"], "BT": ["Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast "], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Distant DFS [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Local disease-free interval [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Toxicities using standard NCI-CTCAE version 4.0 [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]</li>\n</ul></td>"], "record_id": ["NCT01272037"], "EPCD": ["February 2022 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast ", " With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast "], "COOM": ["Not Provided"], "SD": ["January 2011"]},
{"OPOM": ["Repository of malignant, borderline malignant neoplasms,  and related biological specimens [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT00898079"], "CPOM": ["Repository of malignant, borderline malignant neoplasms, and related biological specimens [\u00a0Time\u00a0Frame:\u00a0Baseline\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["May 9, 2009"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT00898079?rank=10&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"missing_color\">Not Provided</td>"], "BT": ["Collecting and Storing Malignant, Borderline ", ", and Related Samples From Young Patients With "], "OOOM": ["Not Provided"], "LUD": ["February 13, 2014"], "OSOM": ["<td class=\"missing_color\">Not Provided</td>"], "record_id": ["NCT00898079"], "EPCD": ["January 2100 \u00a0 (final data collection date for primary outcome measure)"], "OT": ["A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric "], "COOM": ["Not Provided"], "SD": ["March 2003"]},
{"OPOM": ["Invasive disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "CH": ["/ct2/archive/NCT01275677"], "CPOM": ["IDFS [\u00a0Time\u00a0Frame:\u00a0Time to local, regional, or distant recurrence, second non-breast primary breast cancer, or death from any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]"], "FRD": ["January 11, 2011"], "url": "http://www.clinicaltrials.gov/ct2/show/record/NCT01275677?rank=2&recr=Recruiting&state1=NA%3AUS%3AAL&term=cancer", "CSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">DFS-DCIS [\u00a0Time\u00a0Frame:\u00a0Up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">BCFS [\u00a0Time\u00a0Frame:\u00a0From randomization until local recurrence, or death from any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">RFI [\u00a0Time\u00a0Frame:\u00a0From randomization until invasive local, regional, or distant recurrence, or death from breast cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">DRFI [\u00a0Time\u00a0Frame:\u00a0From randomization until the first diagnosis of distant metastasis or death from breast cancer, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">OS [\u00a0Time\u00a0Frame:\u00a0From randomization to death from any cause, assessed up to 10 years\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Incidence of adverse events using the National Cancer Institute CTCAE v4.0 [\u00a0Time\u00a0Frame:\u00a0Up to 30 days\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The frequency and severity of adverse events will be graded.</div></li>\n<li style=\"margin:1ex 0.5ex\">Change in HER2 mRNA level [\u00a0Time\u00a0Frame:\u00a0From baseline to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The interaction between treatment effect and HER2 mRNA level will be evaluated in the proportional hazards model, which would include an indicator for treatment group and the HER2 mRNA level as a continuous variable, and the corresponding interaction term. The log-hazard ratio plot for the interaction term with 95% confidence intervals will be used to determine the cut-off of the HER2 mRNA level that would determine a subset of the patients who would benefit from the adjuvant trastuzumab therapy.</div></li>\n<li style=\"margin:1ex 0.5ex\">Fcgamma receptor polymorphism [\u00a0Time\u00a0Frame:\u00a0From baseline to up to 24 months\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]<div class=\"indent2\" style=\"margin-top:1ex;\">The polymorphism of the Fcgamma 158 receptor gene will be dichotomized as V/V (valine) vs. other genotypes and the polymorphism of the Fcgamma 131 receptor gene will be dichotomized as H/H (histidine) vs. other genotypes to evaluate an interaction between treatment group and Fcgamma polymorphism. The Kaplan-Meier method105 will be used to estimate the distribution of the primary endpoints stratified by the dichotomized subgroups, and the log-rank test106 will be used to statistically compare the time-to-event distributions.</div></li>\n</ul></td>"], "BT": ["Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast "], "OOOM": ["Not Provided"], "LUD": ["July 30, 2014"], "OSOM": ["<td class=\"body3\" valign=\"top\"><ul style=\"margin:0ex 1em; padding:0ex 0em\"><li style=\"margin:1ex 0.5ex\">Disease-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Breast cancer-free survival [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Recurrence-free interval [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Distant recurrence-free interval [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0]</li>\n<li style=\"margin:1ex 0.5ex\">Overall survival [\u00a0Designated\u0